CA3071959A1 - Enriched alcoholic beverages - Google Patents
Enriched alcoholic beverages Download PDFInfo
- Publication number
- CA3071959A1 CA3071959A1 CA3071959A CA3071959A CA3071959A1 CA 3071959 A1 CA3071959 A1 CA 3071959A1 CA 3071959 A CA3071959 A CA 3071959A CA 3071959 A CA3071959 A CA 3071959A CA 3071959 A1 CA3071959 A1 CA 3071959A1
- Authority
- CA
- Canada
- Prior art keywords
- enriched
- alcoholic
- alcohol
- beer
- wine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013334 alcoholic beverage Nutrition 0.000 title claims abstract description 114
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 206
- 235000013405 beer Nutrition 0.000 claims abstract description 123
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 113
- 239000002243 precursor Substances 0.000 claims abstract description 106
- 230000000694 effects Effects 0.000 claims abstract description 88
- 235000014101 wine Nutrition 0.000 claims abstract description 59
- 235000013361 beverage Nutrition 0.000 claims abstract description 51
- 230000000506 psychotropic effect Effects 0.000 claims abstract description 22
- 206010015535 Euphoric mood Diseases 0.000 claims abstract description 21
- 230000035987 intoxication Effects 0.000 claims abstract description 19
- 231100000566 intoxication Toxicity 0.000 claims abstract description 19
- 230000008450 motivation Effects 0.000 claims abstract description 12
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 188
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 146
- 230000001476 alcoholic effect Effects 0.000 claims description 106
- 229960003638 dopamine Drugs 0.000 claims description 93
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 80
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 73
- 229960001948 caffeine Drugs 0.000 claims description 73
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 73
- 235000013305 food Nutrition 0.000 claims description 71
- 229960004441 tyrosine Drugs 0.000 claims description 63
- 239000000126 substance Substances 0.000 claims description 59
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 57
- 239000003368 psychostimulant agent Substances 0.000 claims description 51
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 39
- 239000000796 flavoring agent Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 23
- 235000019634 flavors Nutrition 0.000 claims description 23
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 23
- 239000013589 supplement Substances 0.000 claims description 22
- 235000019987 cider Nutrition 0.000 claims description 21
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 17
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 16
- 235000015095 lager Nutrition 0.000 claims description 16
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 16
- 229960002748 norepinephrine Drugs 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 16
- 102000009025 Endorphins Human genes 0.000 claims description 15
- 108010049140 Endorphins Proteins 0.000 claims description 15
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 15
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 13
- 235000015107 ale Nutrition 0.000 claims description 13
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 230000001976 improved effect Effects 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 235000013522 vodka Nutrition 0.000 claims description 12
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 11
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 235000012754 curcumin Nutrition 0.000 claims description 11
- 239000004148 curcumin Substances 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 229960005139 epinephrine Drugs 0.000 claims description 11
- 229940109262 curcumin Drugs 0.000 claims description 10
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 10
- 235000019640 taste Nutrition 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 9
- 235000015203 fruit juice Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 229940076279 serotonin Drugs 0.000 claims description 8
- 235000015041 whisky Nutrition 0.000 claims description 8
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims description 7
- 229960004373 acetylcholine Drugs 0.000 claims description 7
- 230000006870 function Effects 0.000 claims description 7
- 229960004502 levodopa Drugs 0.000 claims description 7
- 230000003340 mental effect Effects 0.000 claims description 7
- 229960000249 pregnenolone Drugs 0.000 claims description 7
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims description 7
- 235000015096 spirit Nutrition 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002996 emotional effect Effects 0.000 claims description 6
- 235000020094 liqueur Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000020095 red wine Nutrition 0.000 claims description 6
- 235000020097 white wine Nutrition 0.000 claims description 6
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 5
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 235000020004 porter Nutrition 0.000 claims description 5
- 230000036642 wellbeing Effects 0.000 claims description 5
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 206010062519 Poor quality sleep Diseases 0.000 claims description 4
- 235000003713 Rhodiola rosea Nutrition 0.000 claims description 4
- 244000042430 Rhodiola rosea Species 0.000 claims description 4
- 230000036626 alertness Effects 0.000 claims description 4
- 239000002518 antifoaming agent Substances 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 4
- 235000003373 curcuma longa Nutrition 0.000 claims description 4
- 239000004088 foaming agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 235000020030 perry Nutrition 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000013976 turmeric Nutrition 0.000 claims description 4
- 235000015192 vegetable juice Nutrition 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 239000011726 vitamin B6 Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- 240000004246 Agave americana Species 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 230000037007 arousal Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229940014144 folate Drugs 0.000 claims description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 235000013599 spices Nutrition 0.000 claims description 3
- 235000015106 stout Nutrition 0.000 claims description 3
- 229940026510 theanine Drugs 0.000 claims description 3
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims description 2
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims description 2
- 241001539473 Euphoria Species 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000020053 arrack Nutrition 0.000 claims description 2
- 235000013532 brandy Nutrition 0.000 claims description 2
- 235000020062 cachaça Nutrition 0.000 claims description 2
- 235000014171 carbonated beverage Nutrition 0.000 claims description 2
- 235000019993 champagne Nutrition 0.000 claims description 2
- 235000008504 concentrate Nutrition 0.000 claims description 2
- 235000021185 dessert Nutrition 0.000 claims description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 235000013531 gin Nutrition 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 235000021084 monounsaturated fats Nutrition 0.000 claims description 2
- 235000008486 nectar Nutrition 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 2
- 235000020075 ouzo Nutrition 0.000 claims description 2
- 235000013533 rum Nutrition 0.000 claims description 2
- 235000020081 slivovitz Nutrition 0.000 claims description 2
- 235000015040 sparkling wine Nutrition 0.000 claims description 2
- 235000020354 squash Nutrition 0.000 claims description 2
- 235000013529 tequila Nutrition 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 235000020047 vermouth Nutrition 0.000 claims description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 1
- 244000163122 Curcuma domestica Species 0.000 claims 1
- 240000007673 Origanum vulgare Species 0.000 claims 1
- 229960004205 carbidopa Drugs 0.000 claims 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 235000020043 port wine Nutrition 0.000 claims 1
- 235000020096 rose wine Nutrition 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000002743 euphoric effect Effects 0.000 abstract description 19
- 230000002411 adverse Effects 0.000 abstract description 4
- 208000033618 Elevated mood Diseases 0.000 abstract description 3
- 235000019441 ethanol Nutrition 0.000 description 184
- 210000004556 brain Anatomy 0.000 description 48
- 239000000047 product Substances 0.000 description 43
- 239000002585 base Substances 0.000 description 38
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 20
- 230000001624 sedative effect Effects 0.000 description 19
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- 230000004936 stimulating effect Effects 0.000 description 14
- 230000035622 drinking Effects 0.000 description 13
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- 240000005979 Hordeum vulgare Species 0.000 description 10
- 235000007340 Hordeum vulgare Nutrition 0.000 description 10
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 235000019629 palatability Nutrition 0.000 description 10
- 230000002035 prolonged effect Effects 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 9
- 230000006399 behavior Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- -1 for example Substances 0.000 description 9
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000036651 mood Effects 0.000 description 8
- 230000035807 sensation Effects 0.000 description 8
- 235000019615 sensations Nutrition 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 229940049906 glutamate Drugs 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000035882 stress Effects 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000000994 depressogenic effect Effects 0.000 description 6
- 230000002964 excitative effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000013016 learning Effects 0.000 description 6
- 230000033001 locomotion Effects 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000007848 Alcoholism Diseases 0.000 description 5
- 235000008694 Humulus lupulus Nutrition 0.000 description 5
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 description 5
- 241000220225 Malus Species 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002051 biphasic effect Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000005360 mashing Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000004515 ventral tegmental area Anatomy 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 240000005183 Lantana involucrata Species 0.000 description 4
- 240000003183 Manihot esculenta Species 0.000 description 4
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 4
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 241000219094 Vitaceae Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 235000021021 grapes Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000001009 nucleus accumben Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 244000008991 Curcuma longa Species 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 235000014443 Pyrus communis Nutrition 0.000 description 3
- 240000001987 Pyrus communis Species 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 235000009754 Vitis X bourquina Nutrition 0.000 description 3
- 235000012333 Vitis X labruscana Nutrition 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 206010001584 alcohol abuse Diseases 0.000 description 3
- 208000025746 alcohol use disease Diseases 0.000 description 3
- 208000029650 alcohol withdrawal Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000009924 canning Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000019219 chocolate Nutrition 0.000 description 3
- 235000016213 coffee Nutrition 0.000 description 3
- 235000013353 coffee beverage Nutrition 0.000 description 3
- 230000010485 coping Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 235000012732 erythrosine Nutrition 0.000 description 3
- 239000004174 erythrosine Substances 0.000 description 3
- 235000019240 fast green FCF Nutrition 0.000 description 3
- 235000012738 indigotine Nutrition 0.000 description 3
- 239000004179 indigotine Substances 0.000 description 3
- 235000015122 lemonade Nutrition 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 235000019520 non-alcoholic beverage Nutrition 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 210000002442 prefrontal cortex Anatomy 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 235000020017 wheat beer Nutrition 0.000 description 3
- 235000020019 witbier Nutrition 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 206010053155 Epigastric discomfort Diseases 0.000 description 2
- 239000004214 Fast Green FCF Substances 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 2
- 206010024796 Logorrhoea Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 240000005561 Musa balbisiana Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 241001165494 Rhodiola Species 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 244000263375 Vanilla tahitensis Species 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000012741 allura red AC Nutrition 0.000 description 2
- 239000004191 allura red AC Substances 0.000 description 2
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 2
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- 235000012665 annatto Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000021016 apples Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 235000019998 barley wine Nutrition 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 238000013124 brewing process Methods 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- 239000004161 brilliant blue FCF Substances 0.000 description 2
- 235000015044 brown ale Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 235000012730 carminic acid Nutrition 0.000 description 2
- 235000019999 cask ale Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000003930 cognitive ability Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- SMVRDGHCVNAOIN-UHFFFAOYSA-L disodium;1-dodecoxydodecane;sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O.CCCCCCCCCCCCOCCCCCCCCCCCC SMVRDGHCVNAOIN-UHFFFAOYSA-L 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- GHFGJTVYMNRGBY-UHFFFAOYSA-N m-tyramine Chemical compound NCCC1=CC=CC(O)=C1 GHFGJTVYMNRGBY-UHFFFAOYSA-N 0.000 description 2
- 235000021577 malt beverage Nutrition 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020037 nihamanchï Nutrition 0.000 description 2
- 235000020001 old ale Nutrition 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000020007 pale lager Nutrition 0.000 description 2
- DIJBBUIOWGGQOP-QGVNFLHTSA-N pregnenolone sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DIJBBUIOWGGQOP-QGVNFLHTSA-N 0.000 description 2
- 210000000063 presynaptic terminal Anatomy 0.000 description 2
- 230000004800 psychological effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 235000020071 rectified spirit Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 235000010269 sulphur dioxide Nutrition 0.000 description 2
- 235000012751 sunset yellow FCF Nutrition 0.000 description 2
- 239000004173 sunset yellow FCF Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 229940072690 valium Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000020023 weizenbier Nutrition 0.000 description 2
- 230000003936 working memory Effects 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 241001444063 Aronia Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000002877 Artemisia absinthium Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 235000021537 Beetroot Nutrition 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000040284 Carnegiea gigantea Species 0.000 description 1
- 235000001383 Carnegiea gigantea Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- 102100020802 D(1A) dopamine receptor Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 102000004076 Dopamine D1 Receptors Human genes 0.000 description 1
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- 206010016173 Fall Diseases 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241001456088 Hesperocnide Species 0.000 description 1
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- 108010002822 Phenylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- RINHYCZCUGCZAJ-IPXOVKFZSA-N Rosavin Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC\C=C\C=2C=CC=CC=2)O1 RINHYCZCUGCZAJ-IPXOVKFZSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 1
- 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000013323 absinthe Nutrition 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000001670 anatto Substances 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000019996 baijiu Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004464 cereal grain Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 235000012698 chlorophylls and chlorophyllins Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000004121 copper complexes of chlorophylls and chlorophyllins Substances 0.000 description 1
- 235000012700 copper complexes of chlorophylls and chlorophyllins Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 235000020032 desi daru Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- OPCRGEVPIBLWAY-QNRZBPGKSA-N ethyl (2E,4Z)-deca-2,4-dienoate Chemical compound CCCCC\C=C/C=C/C(=O)OCC OPCRGEVPIBLWAY-QNRZBPGKSA-N 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000015038 fortified wine Nutrition 0.000 description 1
- 235000020400 fruit nectar Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 235000020033 huangjiu Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000021539 instant coffee Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 235000020034 kasiri Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000020035 kilju Nutrition 0.000 description 1
- 235000015138 kumis Nutrition 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000010387 memory retrieval Effects 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020000 mild ale Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000002450 orbitofrontal effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 235000015105 pale ale Nutrition 0.000 description 1
- 235000020076 palinka Nutrition 0.000 description 1
- 235000020038 palm wine Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000019989 pulque Nutrition 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000020050 sangria Nutrition 0.000 description 1
- 229960004617 sapropterin Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000020015 schwarzbier Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000008454 sleep-wake cycle Effects 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 235000020039 sonti Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000020049 table wine Nutrition 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 235000020040 tepache Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000020041 tiswin Nutrition 0.000 description 1
- 235000015149 toffees Nutrition 0.000 description 1
- 235000020042 tonto Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000020048 vinsanto Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940074158 xanax Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C5/00—Other raw materials for the preparation of beer
- C12C5/02—Additives for beer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12C5/00—Other raw materials for the preparation of beer
- C12C5/02—Additives for beer
- C12C5/026—Beer flavouring preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/005—Solid or pasty alcoholic beverage-forming compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
- C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0652—Tyrosine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2108—Caffeine, coffee extract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Alcoholic beverages enriched with a neurotransmitter precursor are provided.
The enriched alcoholic beverages, for example, beer, wine or spirit, afford certain desired psychoactive and psychotropic effects upon consumption thereof, such as enhanced euphoric feeling, elevated mood, motivation, focus and sociability, which exceed similar effects exerted by corresponding non-enriched beverages, yet reduce or avoid the adverse effects associated with alcohol consumption, particularly with intoxication.
The enriched alcoholic beverages, for example, beer, wine or spirit, afford certain desired psychoactive and psychotropic effects upon consumption thereof, such as enhanced euphoric feeling, elevated mood, motivation, focus and sociability, which exceed similar effects exerted by corresponding non-enriched beverages, yet reduce or avoid the adverse effects associated with alcohol consumption, particularly with intoxication.
Description
ENRICHED ALCOHOLIC BEVERAGES
FIELD OF THE INVENTION
The present invention, in some embodiments thereof, relates to alcoholic products, more specifically, but not exclusively to enriched alcoholic beverages.
BACKGROUND
The element which accounts for the psychotropic effect caused by alcoholic beverages is ethanol, a two-carbon chain alcohol molecule that interacts with neurotransmitter systems in the brain, and directly affects brain chemistry by altering the levels of some neurotransmitters. Ethanol has dual properties both of a stimulant and a depressant since it affects both "excitatory" neurotransmitters and "inhibitory" neurotransmitters. As a depressant, it reduces energy levels, and slows down thought, speech and movements, exerts relaxation and drowsiness, mainly by increasing production of the inhibitory neurotransmitter GABA, and suppressing the excitatory neurotransmitter glutamate.
As a stimulant, ethanol indirectly causes release of dopamine in the reward pathway in the nucleus accumbens (NAc) part of the brain, which accounts for euphoric feeling, cheerful mood and incentive to seek pleasure. Dopamine is released to the synapse upon alcohol consumption, and the more dopamine is released the merrier and joyful a person becomes. Re-uptake of dopamine which follows and, thereby, decreased levels of the neurotransmitter in the synapse, leads to a down feelings and depression which often characterize alcohol withdrawal or sobering up.
Excessive and/or prolonged alcohol consumption may have some undesired short-term physiological and psychological effects such as gastric irritation, anxiety disorders and other excitable states, and highly undesired longer-term effects such as cirrhosis, cardiomyopathy and dementia. Alcohol consumption may lead to intoxication, which, in turn, can have serious consequences such as accidents and uncontrolled violent behavior with subsequent medical complications.
The standard way alcohol is consumed is by drinking, usually over a few hours.
In the case of beers/lagers, alcohol (i.e., ethanol) is provided as relatively dilute solution, wines are stronger, and spirits contain the maximum alcohol concentration.
One approach to reduce or abolish the undesired effects of ethanol is to reduce the concentration of alcohol in drinks. Dealcoholized beverages have been known for nearly 100 years, and are disclosed, for example, in U.S. Patent Nos. 1,390,710, 1,256,894, 6,472,009, 1,401,700, 4,999,209, and 4,612,916. While removing alcohol may seem a practical option for beers, in some cases, especially in wine and spirits, there is a marked deterioration in taste, bouquet, and other qualities of the beverage due to processes performed to eliminate or reduce alcohol content, such as boiling or steaming.
Another approach which has been practiced is the safer alcohol approach, which utilizes drugs that act in a similar way to alcohol but are free of some of its immediate adverse effects, such as gastric irritation, and do not produce the longer-term effects such as cirrhosis, cardiomyopathy and dementia. However, all the drugs had limited use due to development of dependence thereon, and/or abuse thereof.
There is an unmet need for "safer" consumption of alcoholic beverages that would not deprive the drinker from the pleasure and psychotropic and psychoactive effects provided by drinking alcohol, yet, would reduce or even be devoid of the adverse effects associated with alcohol consumption, particularly with intoxication.
SUMMARY
In an aspect of the present disclosure, an alcoholic food product is provided comprising an edible base material, which may be a liquid, solid or semi-solid edible substance, for example, liquid, alcohol, and at least one neurotransmitter and/or at least one neurotransmitter precursor. The food product thus provided is an alcoholic food product, namely a food product that essentially contains a certain amount of alcohol for example, from about 0.5% to about 98% by volume or by weight. The inclusion of a neurotransmitter and/or a precursor thereof in the alcoholic food product, enriches the alcoholic food product with certain qualities which impart it the ability to effect certain desired psychotropic and psychoactive effects upon consumption thereof.
In some embodiments, a disclosed enriched alcoholic food product is an enriched alcoholic beverage such as beer, wine, spirit, cider, perry and alcopop.
FIELD OF THE INVENTION
The present invention, in some embodiments thereof, relates to alcoholic products, more specifically, but not exclusively to enriched alcoholic beverages.
BACKGROUND
The element which accounts for the psychotropic effect caused by alcoholic beverages is ethanol, a two-carbon chain alcohol molecule that interacts with neurotransmitter systems in the brain, and directly affects brain chemistry by altering the levels of some neurotransmitters. Ethanol has dual properties both of a stimulant and a depressant since it affects both "excitatory" neurotransmitters and "inhibitory" neurotransmitters. As a depressant, it reduces energy levels, and slows down thought, speech and movements, exerts relaxation and drowsiness, mainly by increasing production of the inhibitory neurotransmitter GABA, and suppressing the excitatory neurotransmitter glutamate.
As a stimulant, ethanol indirectly causes release of dopamine in the reward pathway in the nucleus accumbens (NAc) part of the brain, which accounts for euphoric feeling, cheerful mood and incentive to seek pleasure. Dopamine is released to the synapse upon alcohol consumption, and the more dopamine is released the merrier and joyful a person becomes. Re-uptake of dopamine which follows and, thereby, decreased levels of the neurotransmitter in the synapse, leads to a down feelings and depression which often characterize alcohol withdrawal or sobering up.
Excessive and/or prolonged alcohol consumption may have some undesired short-term physiological and psychological effects such as gastric irritation, anxiety disorders and other excitable states, and highly undesired longer-term effects such as cirrhosis, cardiomyopathy and dementia. Alcohol consumption may lead to intoxication, which, in turn, can have serious consequences such as accidents and uncontrolled violent behavior with subsequent medical complications.
The standard way alcohol is consumed is by drinking, usually over a few hours.
In the case of beers/lagers, alcohol (i.e., ethanol) is provided as relatively dilute solution, wines are stronger, and spirits contain the maximum alcohol concentration.
One approach to reduce or abolish the undesired effects of ethanol is to reduce the concentration of alcohol in drinks. Dealcoholized beverages have been known for nearly 100 years, and are disclosed, for example, in U.S. Patent Nos. 1,390,710, 1,256,894, 6,472,009, 1,401,700, 4,999,209, and 4,612,916. While removing alcohol may seem a practical option for beers, in some cases, especially in wine and spirits, there is a marked deterioration in taste, bouquet, and other qualities of the beverage due to processes performed to eliminate or reduce alcohol content, such as boiling or steaming.
Another approach which has been practiced is the safer alcohol approach, which utilizes drugs that act in a similar way to alcohol but are free of some of its immediate adverse effects, such as gastric irritation, and do not produce the longer-term effects such as cirrhosis, cardiomyopathy and dementia. However, all the drugs had limited use due to development of dependence thereon, and/or abuse thereof.
There is an unmet need for "safer" consumption of alcoholic beverages that would not deprive the drinker from the pleasure and psychotropic and psychoactive effects provided by drinking alcohol, yet, would reduce or even be devoid of the adverse effects associated with alcohol consumption, particularly with intoxication.
SUMMARY
In an aspect of the present disclosure, an alcoholic food product is provided comprising an edible base material, which may be a liquid, solid or semi-solid edible substance, for example, liquid, alcohol, and at least one neurotransmitter and/or at least one neurotransmitter precursor. The food product thus provided is an alcoholic food product, namely a food product that essentially contains a certain amount of alcohol for example, from about 0.5% to about 98% by volume or by weight. The inclusion of a neurotransmitter and/or a precursor thereof in the alcoholic food product, enriches the alcoholic food product with certain qualities which impart it the ability to effect certain desired psychotropic and psychoactive effects upon consumption thereof.
In some embodiments, a disclosed enriched alcoholic food product is an enriched alcoholic beverage such as beer, wine, spirit, cider, perry and alcopop.
2 The neurotransmitter may be, for example, norepinephrine, epinephrine, serotonin, dopamine, endorphin, acetylcholine, gamma-aminobutyric acid (GABA), and any combination thereof. The neurotransmitter precursor may be, for example, a norepinephrine precursor, for example dopamine; an epinephrine precursor; a serotonin precursor, for example, 5-hydroxytriptophan; a dopamine precursor such as L-phanylalanina, L-tyrosine or levodopa; an endorphin precursor; an acetylcholine precursor;
or a gamma-aminobutyric acid (GABA) precursor, and any combination thereof.
In exemplary embodiments, a disclosed enriched alcoholic beverage comprises the dopamine precursor tyrosine, in amounts ranging, e.g., from about 10 mg to about 5000 mg per 1 liter, for example, from about 100 mg/L to about 1000 mg/L.
A contemplated enriched alcoholic food product, for example, enriched alcoholic beverage, may further comprise one or more psychostimulant substances, namely, a substance that is directly or indirectly involved in enhancement of a neurotransmitter synthesis and/or stability, inhibition of degradation of a neurotransmitter and/or inhibition of reuptake of a neurotransmitter. Such a psychostimulant is exemplified in some embodiments, by caffeine, wherein the amount of caffeine in a disclosed enriched alcoholic food product may be from about 10 mg/L to about 750 mg/L.
In exemplary embodiments, an enriched beer is provided, comprising tyrosine and caffeine, for example, ale, stout, porter, or lager.
The alcoholic food product and/or the enriched alcoholic beverage, upon consumption thereof, exerts one or more positive psychoactive effects and/or one or more positive psychotropic effects which may commence 5 minutes and last up to 24 hours, or even up to 48 hours after alcohol consumption. For example, consumption of a disclosed enriched alcoholic beverage such as beer may promote enhanced and prolonged sense of euphoria.
A contemplated enriched beer, wine, spirit, alcopop and/or cider provided herein may exert upon a consumer stimulant effects such as elevated mood (high spirit), energy, excitement, talkativeness, vigorous and vitality which exceed in intensity and duration of similar effects exerted by a corresponding non-enriched beer, wine, spirit, alcopop or cider, while reducing intoxication effects and sedative effects such as difficulty in concentrating,
or a gamma-aminobutyric acid (GABA) precursor, and any combination thereof.
In exemplary embodiments, a disclosed enriched alcoholic beverage comprises the dopamine precursor tyrosine, in amounts ranging, e.g., from about 10 mg to about 5000 mg per 1 liter, for example, from about 100 mg/L to about 1000 mg/L.
A contemplated enriched alcoholic food product, for example, enriched alcoholic beverage, may further comprise one or more psychostimulant substances, namely, a substance that is directly or indirectly involved in enhancement of a neurotransmitter synthesis and/or stability, inhibition of degradation of a neurotransmitter and/or inhibition of reuptake of a neurotransmitter. Such a psychostimulant is exemplified in some embodiments, by caffeine, wherein the amount of caffeine in a disclosed enriched alcoholic food product may be from about 10 mg/L to about 750 mg/L.
In exemplary embodiments, an enriched beer is provided, comprising tyrosine and caffeine, for example, ale, stout, porter, or lager.
The alcoholic food product and/or the enriched alcoholic beverage, upon consumption thereof, exerts one or more positive psychoactive effects and/or one or more positive psychotropic effects which may commence 5 minutes and last up to 24 hours, or even up to 48 hours after alcohol consumption. For example, consumption of a disclosed enriched alcoholic beverage such as beer may promote enhanced and prolonged sense of euphoria.
A contemplated enriched beer, wine, spirit, alcopop and/or cider provided herein may exert upon a consumer stimulant effects such as elevated mood (high spirit), energy, excitement, talkativeness, vigorous and vitality which exceed in intensity and duration of similar effects exerted by a corresponding non-enriched beer, wine, spirit, alcopop or cider, while reducing intoxication effects and sedative effects such as difficulty in concentrating,
3 down feeling, heavy head, heavy body, sedative, slow thinking, and sluggishness compared to corresponding non-enriched alcoholic beverages.
Also provided herein is a process for the preparation of an enriched alcoholic beverage, such as beer, wine, whisky, vodka a liquor, comprising combining a base alcoholic liquid with one or more neurotransmitter precursors, and, optionally, one or more psychostimulant substances.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE FIGURES
[0001] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
[0002] In the drawings:
Figs. 1A-1B are bar graphs showing STIM (short for "stimulant effects") values obtained in an exemplary Biphasic Alcohol Effects Scale (BAES) test conducted with enriched beer of the disclosure (1B) and a corresponding non-enriched beer (1A); and Figs. 2A-2B are bar graphs showing SED (short for "sedative effects") values obtained in an exemplary Biphasic Alcohol Effects Scale (BAES) test conducted with enriched beer of the disclosure (1B) and a corresponding non-enriched beer (1A).
Also provided herein is a process for the preparation of an enriched alcoholic beverage, such as beer, wine, whisky, vodka a liquor, comprising combining a base alcoholic liquid with one or more neurotransmitter precursors, and, optionally, one or more psychostimulant substances.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE FIGURES
[0001] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
[0002] In the drawings:
Figs. 1A-1B are bar graphs showing STIM (short for "stimulant effects") values obtained in an exemplary Biphasic Alcohol Effects Scale (BAES) test conducted with enriched beer of the disclosure (1B) and a corresponding non-enriched beer (1A); and Figs. 2A-2B are bar graphs showing SED (short for "sedative effects") values obtained in an exemplary Biphasic Alcohol Effects Scale (BAES) test conducted with enriched beer of the disclosure (1B) and a corresponding non-enriched beer (1A).
4 DETAILED DESCRIPTION
The present invention, in some embodiments thereof, relates to enriched alcoholic food products, more specifically, but not exclusively to enriched alcoholic beverages.
Alcohol is one of the favorite, commonly used, yet a somehow dangerous psychoactive substance. The prevailing and predominant way alcohol is consumed is by drinking alcoholic beverages, usually over a few hours. People consume alcohol for several reasons such as quenching thirst, heating or cooling the drinker, for the taste of alcohol, the association alcoholic beverages have with other aspects of life such as food and friendship, and mostly due to the psychological and psychotropic effects of alcohol associated with alcohol consumption. Consuming alcohol often confers upon the consumer a euphoric feeling, a cheerful mood, relaxation, and a reduced self-awareness. Part of the pleasure of alcohol - at least for the non-dependent consumer - is the taste and the associated rituals of consumption that may fill primitive appetitive functions.
While seeking for the emotional and psychological benefits when consuming alcoholic products, there are, inherently, short term and long-term undesired consequences of consuming alcohol, more so when consuming excessive amount of alcohol.
Dealcoholized beverages, such as beer and wine, designed in attempt to address the need to reduce the hazardous consequences of alcohol intoxication, are available in reasonably palatable forms. However, while non-alcoholic drinks can fill such use-values of alcoholic beverages as quenching thirst and heating or cooling the drinker, they do not provide the range of psychoactivity and palatability which people are seeking in alcohol.
Unless stated otherwise, "alcohol" as referred to herein is ethanol.
The present disclosure is based on a discovery by the present inventor that the effects associated with consumption of alcoholic food products, for example, alcoholic beverages, that contain a neurotransmitter precursor, particularly the pleasurable effects, may be enhanced and prolonged without the need to increase the amount of alcohol in the product. Moreover, the present inventor envisaged and successfully obtained alcoholic beverages containing at least one neurotransmitter and/or a precursor thereof, and optionally further containing a psychostimulant substances such as caffeine, which provide to the consumer stronger and continuing euphoric feeling while minimizing and even circumventing at least some of the non-pleasurable effects associated with alcohol consumption, particularly the undesired physical and emotional sensations of intoxication.
Disclosed herein is a discovery by the present inventor that consumption of alcoholic food products containing neurotransmitter precursors affects the level of certain neurotransmitters in the brain, for example neurotransmitters that are boosted or released due to alcohol consumption. Alteration, for example, elevation, of certain brain neurotransmitters level, increases or enhances, e.g., the euphoric sensation provided or bestowed by alcohol. This euphoric feeling lasts longer than that induced by consuming alcohol alone, and, furthermore, it is mostly not accompanied by undesired physiological and psychological short-term effects associated with the concomitant and rather intense decrease in neurotransmitters level that follows shortly afterward.
In an aspect of the disclosure, there is provided a food product comprising an edible base material, alcohol and one or more neurotransmitters and/or neurotransmitter precursors.
The term "food product" as used herein refers to a substance that can be used or prepared for use as food by humans or non-humans.
"Alcoholic food product" (or "alcoholic product") is a composition of an edible base material defined herein as any substance composed of carbohydrates, fats, proteins and/or water, and alcohol (e.g., ethanol) in the amount of 0-99%, for example from about 1% to about 20%, from about 1% to about 5%, from about 3% to about 8%, from about
The present invention, in some embodiments thereof, relates to enriched alcoholic food products, more specifically, but not exclusively to enriched alcoholic beverages.
Alcohol is one of the favorite, commonly used, yet a somehow dangerous psychoactive substance. The prevailing and predominant way alcohol is consumed is by drinking alcoholic beverages, usually over a few hours. People consume alcohol for several reasons such as quenching thirst, heating or cooling the drinker, for the taste of alcohol, the association alcoholic beverages have with other aspects of life such as food and friendship, and mostly due to the psychological and psychotropic effects of alcohol associated with alcohol consumption. Consuming alcohol often confers upon the consumer a euphoric feeling, a cheerful mood, relaxation, and a reduced self-awareness. Part of the pleasure of alcohol - at least for the non-dependent consumer - is the taste and the associated rituals of consumption that may fill primitive appetitive functions.
While seeking for the emotional and psychological benefits when consuming alcoholic products, there are, inherently, short term and long-term undesired consequences of consuming alcohol, more so when consuming excessive amount of alcohol.
Dealcoholized beverages, such as beer and wine, designed in attempt to address the need to reduce the hazardous consequences of alcohol intoxication, are available in reasonably palatable forms. However, while non-alcoholic drinks can fill such use-values of alcoholic beverages as quenching thirst and heating or cooling the drinker, they do not provide the range of psychoactivity and palatability which people are seeking in alcohol.
Unless stated otherwise, "alcohol" as referred to herein is ethanol.
The present disclosure is based on a discovery by the present inventor that the effects associated with consumption of alcoholic food products, for example, alcoholic beverages, that contain a neurotransmitter precursor, particularly the pleasurable effects, may be enhanced and prolonged without the need to increase the amount of alcohol in the product. Moreover, the present inventor envisaged and successfully obtained alcoholic beverages containing at least one neurotransmitter and/or a precursor thereof, and optionally further containing a psychostimulant substances such as caffeine, which provide to the consumer stronger and continuing euphoric feeling while minimizing and even circumventing at least some of the non-pleasurable effects associated with alcohol consumption, particularly the undesired physical and emotional sensations of intoxication.
Disclosed herein is a discovery by the present inventor that consumption of alcoholic food products containing neurotransmitter precursors affects the level of certain neurotransmitters in the brain, for example neurotransmitters that are boosted or released due to alcohol consumption. Alteration, for example, elevation, of certain brain neurotransmitters level, increases or enhances, e.g., the euphoric sensation provided or bestowed by alcohol. This euphoric feeling lasts longer than that induced by consuming alcohol alone, and, furthermore, it is mostly not accompanied by undesired physiological and psychological short-term effects associated with the concomitant and rather intense decrease in neurotransmitters level that follows shortly afterward.
In an aspect of the disclosure, there is provided a food product comprising an edible base material, alcohol and one or more neurotransmitters and/or neurotransmitter precursors.
The term "food product" as used herein refers to a substance that can be used or prepared for use as food by humans or non-humans.
"Alcoholic food product" (or "alcoholic product") is a composition of an edible base material defined herein as any substance composed of carbohydrates, fats, proteins and/or water, and alcohol (e.g., ethanol) in the amount of 0-99%, for example from about 1% to about 20%, from about 1% to about 5%, from about 3% to about 8%, from about
5% to about 10%, from about 8% to about 12%, from about 10% to about 15%, from about 15% to about 25%, from about 20% to about 30%, from about 25% to about 40%, from about 30% to about 50%, from about 40% to about 60%, from about 50% to about 65%, or from about 60% to about 80%, ethanol by weight or by volume. It can be eaten or drunk by humans or by animal for nutrition or pleasure.
Non-limiting examples of alcoholic food products include, alcoholic liquids comprising a base material such as water, juice, e.g., fruit or vegetable juice, and milk and alcohol. Alcoholic liquid products include, for example, beverages such as beer, wine, spirit and the like. Solid or semi-solid alcoholic products are edible foods that contain alcohol, for example, foods that have been cooked, combined and/or mixed with alcohol.
Such alcohol-containing solid or semi-solid products are exemplified by meat, fish,
Non-limiting examples of alcoholic food products include, alcoholic liquids comprising a base material such as water, juice, e.g., fruit or vegetable juice, and milk and alcohol. Alcoholic liquid products include, for example, beverages such as beer, wine, spirit and the like. Solid or semi-solid alcoholic products are edible foods that contain alcohol, for example, foods that have been cooked, combined and/or mixed with alcohol.
Such alcohol-containing solid or semi-solid products are exemplified by meat, fish,
6
7 chicken, fruits, breads, soups, stews, sauces, fondues, backed desserts such as cakes, pastries such as cookies and pies, and no-bake desserts such as creams, ice-cream, puddings and mousses, extract flavoring such as pure vanilla extract and pure almond extract, filled candies such as filled chocolate, snacks and food flamed with alcohol.
In some embodiments, a contemplated alcoholic food product is an alcoholic beverage.
The terms "enriched alcoholic food product" and "enriched alcoholic beverage"
as used herein refer to an alcoholic food product or alcoholic beverage, respectively, enriched by the addition thereto, provision thereto, mixing thereof, or combining it with at least one neurotransmitter and/or at least one neurotransmitter precursor. "Enrichment"
of the alcoholic food products or alcoholic beverages contemplated herein is further meant herein enriching the product with desired qualities imparted to it by enriching it with at least one neurotransmitter and/or a precursor thereof.
The term "one or more neurotransmitter precursor" as used herein is interchangeable with the term "at least one neurotransmitter precursor" and means at least one precursor of at least one neurotransmitter.
Neurotransmitters and precursors thereof The action of alcohol is biphasic, when blood alcohol concentration (BAC) levels are rising, the stimulant properties of alcohol are more pronounced; when BAC
levels are falling, the depressant effects of alcohol are more pronounced. Alcohol, for example, ethanol, being a small molecule, can interact with many neurotransmitter systems in the brain. It directly affects brain chemistry by altering levels of neurotransmitters. Alcohol affects both "excitatory" neurotransmitters and "inhibitory" neurotransmitters and, hence, has the properties of both a stimulant and a depressant. This makes the action of alcohol in the brain very different from, and much more complex than, large molecules such as opiates, tetrahydrocannabinol (THC), or amphetamine, which simulate a specific neurotransmitter and interact with a specific neurotransmitter system.
Neurotransmitters play a key role in the function of the central nervous system, being chemical "messengers" that transmit signals throughout the body, signals such as those controlling thinking processes, behavior and emotion. Neurotransmitters are excreted to, and travel through, the synapses, those extremely small gaps between the axon terminal of neurons that release neurotransmitters in response to an impulse, and the membrane of adjacent axons, dendrites, muscle or gland cells having the appropriate receptors for binding the neurotransmitters. Neurotransmitters can either prompt or suppress the further signaling of nearby neurons. The main neurotransmitters include norepinephrine, epinephrine, serotonin, dopamine, endorphin, acetylcholine, gamma-aminobutyric acid (GABA), glycine, glutamic acid, aspartic acid, and taurine, the first six of which are neurotransmitters synthesized from amino acids, and the last three are amino acids per se.
The term "neurotransmitter precursor", as used herein, refers to a substance that can be converted into a neurotransmitter in the body, particularly in the brain, usually through enzymatic reactions such as metabolic processes. For example, 5 -hydroxytryptophane is a serotonin precursor.
Neurotransmitters which may be directly or indirectly affected by alcohol include, for example, GABA, endorphins, glutamate, dopamine, norepinephrine and adrenaline (epinephrine).
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter, which reduces energy levels and calms everything down. Drugs like Xanax and Valium increase GABA production in the brain, resulting in sedation. Alcohol increases the effects of GABA and affects the GABA system in a manner similar to valium leading to relaxation and drowsiness. Alcohol's effect on the GABA system may also be responsible for its depressant effects.
Glutamate is an excitatory neurotransmitter which normally increases brain activity and energy levels. Alcohol suppresses glutamate levels probably by inhibiting the N-methyl-d-aspartate (NMDA) glutamate receptor, resulting in a slowdown along the brain's highways. It is alcohol's effects on the glutamate system which lead to staggering, slurred speech, and memory blackouts.
Alcohol may exert depressant effects because it suppresses the excitatory neurotransmitter glutamate and increases the inhibitory neurotransmitter GABA.
What this means is that the thought, speech and movements of a person consuming alcohol are slowed down, and the more alcohol is consumed the more of these effects will be felt (hence the stumbling around, falling over chairs and other clumsy things drunk people do). Cerebral cortex is this region in the brain where thought processing and consciousness are centered,
In some embodiments, a contemplated alcoholic food product is an alcoholic beverage.
The terms "enriched alcoholic food product" and "enriched alcoholic beverage"
as used herein refer to an alcoholic food product or alcoholic beverage, respectively, enriched by the addition thereto, provision thereto, mixing thereof, or combining it with at least one neurotransmitter and/or at least one neurotransmitter precursor. "Enrichment"
of the alcoholic food products or alcoholic beverages contemplated herein is further meant herein enriching the product with desired qualities imparted to it by enriching it with at least one neurotransmitter and/or a precursor thereof.
The term "one or more neurotransmitter precursor" as used herein is interchangeable with the term "at least one neurotransmitter precursor" and means at least one precursor of at least one neurotransmitter.
Neurotransmitters and precursors thereof The action of alcohol is biphasic, when blood alcohol concentration (BAC) levels are rising, the stimulant properties of alcohol are more pronounced; when BAC
levels are falling, the depressant effects of alcohol are more pronounced. Alcohol, for example, ethanol, being a small molecule, can interact with many neurotransmitter systems in the brain. It directly affects brain chemistry by altering levels of neurotransmitters. Alcohol affects both "excitatory" neurotransmitters and "inhibitory" neurotransmitters and, hence, has the properties of both a stimulant and a depressant. This makes the action of alcohol in the brain very different from, and much more complex than, large molecules such as opiates, tetrahydrocannabinol (THC), or amphetamine, which simulate a specific neurotransmitter and interact with a specific neurotransmitter system.
Neurotransmitters play a key role in the function of the central nervous system, being chemical "messengers" that transmit signals throughout the body, signals such as those controlling thinking processes, behavior and emotion. Neurotransmitters are excreted to, and travel through, the synapses, those extremely small gaps between the axon terminal of neurons that release neurotransmitters in response to an impulse, and the membrane of adjacent axons, dendrites, muscle or gland cells having the appropriate receptors for binding the neurotransmitters. Neurotransmitters can either prompt or suppress the further signaling of nearby neurons. The main neurotransmitters include norepinephrine, epinephrine, serotonin, dopamine, endorphin, acetylcholine, gamma-aminobutyric acid (GABA), glycine, glutamic acid, aspartic acid, and taurine, the first six of which are neurotransmitters synthesized from amino acids, and the last three are amino acids per se.
The term "neurotransmitter precursor", as used herein, refers to a substance that can be converted into a neurotransmitter in the body, particularly in the brain, usually through enzymatic reactions such as metabolic processes. For example, 5 -hydroxytryptophane is a serotonin precursor.
Neurotransmitters which may be directly or indirectly affected by alcohol include, for example, GABA, endorphins, glutamate, dopamine, norepinephrine and adrenaline (epinephrine).
Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter, which reduces energy levels and calms everything down. Drugs like Xanax and Valium increase GABA production in the brain, resulting in sedation. Alcohol increases the effects of GABA and affects the GABA system in a manner similar to valium leading to relaxation and drowsiness. Alcohol's effect on the GABA system may also be responsible for its depressant effects.
Glutamate is an excitatory neurotransmitter which normally increases brain activity and energy levels. Alcohol suppresses glutamate levels probably by inhibiting the N-methyl-d-aspartate (NMDA) glutamate receptor, resulting in a slowdown along the brain's highways. It is alcohol's effects on the glutamate system which lead to staggering, slurred speech, and memory blackouts.
Alcohol may exert depressant effects because it suppresses the excitatory neurotransmitter glutamate and increases the inhibitory neurotransmitter GABA.
What this means is that the thought, speech and movements of a person consuming alcohol are slowed down, and the more alcohol is consumed the more of these effects will be felt (hence the stumbling around, falling over chairs and other clumsy things drunk people do). Cerebral cortex is this region in the brain where thought processing and consciousness are centered,
8 alcohol depresses the behavioral inhibitory centers, making the person less inhibited; it slows down the processing of information from the eyes, ears, mouth and other senses; and it inhibits the thought processes, making it difficult to think clearly.
Alcohol also affects the cerebellum, the center of movement and balance in the brain, resulting in the staggering, off-balance swagger often associated with the so-called "falling-down drunk."
Endorphins are produced in response to certain stimuli, especially stress, fear or pain. They originate in various parts of the body such as the pituitary gland, spinal cord and throughout other parts of the brain and nervous system and interact mainly with receptors in cells found in regions of the brain responsible for blocking pain and controlling emotion. Alcohol affects the endorphin system in a manner similar to opiates, acting as a pain-killer and giving an endorphin "high".
Alcohol increases the release of dopamine (interchangeable herein with "DA"), adrenaline and norepinephrine.
Adrenaline (epinephrine) and its precursor norepinephrine (noradrenalin), are important hormones produced by the adrenal gland. They increase the heart rate, blood pressure, and blood glucose levels, open up the airways in the lungs and, like cortisol, help inhibit non-essential bodily functions. Alcohol causes the adrenal glands to release adrenaline and norepinephrine which ultimately enter the brain and promote alertness and "fight response". This is one reason why alcohol acts as stimulant.
Dopamine, 3,4-dihydroxyphenethylamine, is an organic chemical of the catecholamine and phenethylamine families having the chemical structure:
H 0,,,,,.,;.,,,,,,,-,,,,, NH 2 HO
This amine is synthesized by removing a carboxyl group from its precursor levodopa (L-dopa; dihydroxyphenylalanine), which is synthesized in the brain and kidneys during the metabolism of the amino acid tyrosine. It is a neurotransmitter in itself, and a precursor of the hormone neurotransmitters epinephrine and norepinephrine.
Two main brain areas produce dopamine that relays signals that travel throughout the brain:
the substantia nigra, a tiny strip of tissue on either side of the base of the human brain (situated in a region known as the midbrain), and the close by ventral tegmental area.
Dopamine from the substantia nigra helps in movements and speech. Dopamine, thus,
Alcohol also affects the cerebellum, the center of movement and balance in the brain, resulting in the staggering, off-balance swagger often associated with the so-called "falling-down drunk."
Endorphins are produced in response to certain stimuli, especially stress, fear or pain. They originate in various parts of the body such as the pituitary gland, spinal cord and throughout other parts of the brain and nervous system and interact mainly with receptors in cells found in regions of the brain responsible for blocking pain and controlling emotion. Alcohol affects the endorphin system in a manner similar to opiates, acting as a pain-killer and giving an endorphin "high".
Alcohol increases the release of dopamine (interchangeable herein with "DA"), adrenaline and norepinephrine.
Adrenaline (epinephrine) and its precursor norepinephrine (noradrenalin), are important hormones produced by the adrenal gland. They increase the heart rate, blood pressure, and blood glucose levels, open up the airways in the lungs and, like cortisol, help inhibit non-essential bodily functions. Alcohol causes the adrenal glands to release adrenaline and norepinephrine which ultimately enter the brain and promote alertness and "fight response". This is one reason why alcohol acts as stimulant.
Dopamine, 3,4-dihydroxyphenethylamine, is an organic chemical of the catecholamine and phenethylamine families having the chemical structure:
H 0,,,,,.,;.,,,,,,,-,,,,, NH 2 HO
This amine is synthesized by removing a carboxyl group from its precursor levodopa (L-dopa; dihydroxyphenylalanine), which is synthesized in the brain and kidneys during the metabolism of the amino acid tyrosine. It is a neurotransmitter in itself, and a precursor of the hormone neurotransmitters epinephrine and norepinephrine.
Two main brain areas produce dopamine that relays signals that travel throughout the brain:
the substantia nigra, a tiny strip of tissue on either side of the base of the human brain (situated in a region known as the midbrain), and the close by ventral tegmental area.
Dopamine from the substantia nigra helps in movements and speech. Dopamine, thus,
9 helps regulate movement and emotional responses. When the brain cells that make dopamine in this area start to die off, a person can have trouble initiating movement.
The ventral tegmental area usually sends dopamine into the brain when animals or human expect or receive a reward, and helps control the brain's reward and pleasure centers. The reward center (also known as the "reward pathway") is comprised primarily of the nucleus accumbens (NAc), the ventral tegmental area (VTA), and a part of the prefrontal cortex. This combination of brain areas which form the reward center is affected by virtually all pleasurable activity, including everything from hanging out with friends, going on vacation, ingesting drugs (e.g., cocaine), listening to music, eating and drinking, having sexual activity, and consuming alcohol. All things which give us pleasure, cause a release of dopamine in the reward pathway as well as trigger a number of other events in the brain including endorphin release and activation of the orbitofrontal region of the prefrontal cortex. Dopamine is known as the "motivation molecule" or the "reinforcement molecule" as it is responsible for reward-seeking behavior and helps provide the drive, focus and concentration needed to get things done. This dopamine release tells the brain that whatever it just experienced is worth getting more of, and that helps animals and humans change their behaviors in ways that will help them attain more of the rewarding item or experience. This brain reward system is associated with "feeling good"
and promotes survival of the species by rewarding behaviors necessary for continued survival.
Dopamine is also involved in many other functions of the brain including motor activity, motivation, learning, pain processing, mood, attention span and regulation of sleep. It regulates stress relief.
Lowering dopamine can make animals and humans lose pleasure in activities like eating and drinking. This joyless state, where animals or human no longer find pleasure in activities they used to enjoy and are no longer motivated to do those activities, is called anhedonia. People with some mental illnesses, such as depression and schizophrenia, may experience anhedonia as part of their disease.
Dopamine deficiency results in Parkinson's Disease, and people with low dopamine activity may be more prone to addiction. Alcohol as well as all drugs which lead to dependence appear to affect the dopamine system. Stimulants like amphetamine and cocaine affect dopamine directly whereas alcohol and other drugs appear to affect it indirectly.
Alcohol consumption triggers a boost of dopamine release. Alcohol does not lead to an increase of dopamine throughout the brain; it only causes an increase in dopamine in the reward center, leading to the relaxing and carefree experience of the alcohol "buzz".
Consumption of even small amounts of alcohol increases the amount of dopamine in the NAc in a dose-response manner. Alcohol increases DA via the promotion of synaptic terminal DA release rather than via the inhibition of DA transporters. Alcohol can also indirectly increase DA levels by affecting the GABA system and the endorphin system.
Neurons from the GABA system extend into the reward pathway and when alcohol affects the GABA system these neurons release dopamine into the reward pathway.
Likewise, neurons extend from the endorphin system into the reward pathway and these also release dopamine into the reward pathway when alcohol directly stimulates the endorphin system.
It is unlikely that the increase in dopamine alone is responsible for the stimulant properties of alcohol. It is most likely that the stimulating effects of alcohol are due to its effects on adrenaline, norepinephrine, and the prefrontal cortex as well.
A boost in the activation of Dopaminergic pathways eventually causes a depletion of the dopamine reserves within the brain cells, leaving the brain in an imbalanced state.
As Dopamine itself is impenetrable to the blood-brain barrier, it must synthesized in situ from its precursors. Over time, with more drinking, the dopamine effect diminishes until its almost nonexistent.
It has been postulated by the present inventor that kicking-off brain DA
release via alcohol consumption, and simultaneously providing means to sustain elevated brain DA
level by providing DA building blocks, may enhance the euphoric feeling and afford qualities such as increased motivation, focus and concentration to pursue rewarding actions such as working and learning, increased sociability, and attention, while at the same time alleviating alcohol withdrawal symptoms and, moreover, substantially decreasing addiction disposition.
The present inventors envisaged, and successfully practiced enriched alcoholic food products, for example, enriched alcoholic beverages, containing a precursor of DA, for example, tyrosine, and, optionally, a psychostimulant substance such as caffeine, based on their strong affiliations to the metabolism of DA within the brain, thereby promoting DA synthesis within the central nervous system and establishing a long lasting steady state of readily available DA. This sustained supply of DA building blocks from the very first moment of alcohol intake, may increase the positive and enjoyable effects of alcohol consumption, while neutralizing negative effects associated with DA depletion followed by it.
Furthermore, enhancement of the positive effects of alcohol may help reduce the risk of alcohol abuse. Motives of alcohol consumption are classically "enhancing motives"
(drinking to enhance positive and social mood) and "coping motives" (drinking to cope with negative mood). While enhancing drinkers enjoy the positive effects of alcohol consumption, coping drinkers rely on its sedative effects, and are strongly exposed to risks of alcohol abuse and alcoholism. Through the enhancement of alcohol's positive effects and the negation of its sedative effects, provided herein is a method to reduce risks of alcohol abuse amongst coping drinkers.
In some embodiments, the alcoholic products described herein are designed to promote at least the levels of dopamine, endorphin norepinephrine and/or epinephrine in the brain. To this end, the alcoholic products are enriched with one or more neurotransmitters and/or neurotransmitters precursors.
For example, L-phenylalanine (Phe), L-tyrosine (Tyr) and/or levodopa (L-dopa) are the precursors of dopamine and other catecholamines such as norepinephrine and epinephrine.
The terms "dopamine precursor" and "dopamine immediate metabolic precursor"
as used herein are interchangeable and refer to a substance that can be converted into dopamine in the body through a series of one or more metabolic reactions.
The primary and minor metabolic pathways for obtaining DA from its precursors are:
Primary: Phe ¨> Tyr ¨> levodopa ¨> DA
Minor: Phe ¨> Tyr ¨> p-Tyramine ¨> DA
Minor: Phe ¨> m-Tyrosine ¨> m-Tyramine ¨> DA
The direct or immediate metabolic precursor of dopamine, L-dopa, can be synthesized indirectly from the essential amino acid Phe or directly from the non-essential amino acid Tyr. Additionally or alternatively in can be supplemented form plants (e.g.
legumes) and animals. Most of the levodopa is immediately broken down (e.g., in the intestine) before it enters the brain primarily by decarboxylase enzymes and catecholamine-0-methyltransferase (COMT).
L-Phenylalanine is converted into Tyr by the enzyme phenylalanine hydroxylase, with molecular oxygen (02) and tetrahydrobiopterin (THB) as cofactors. L-Tyrosine is converted into L-dopa by the enzyme tyrosine hydroxylase, with tetrahydrobiopterin, 02, and iron (Fe2 ) as cofactors. L-dopa is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase (also known as dopa decarboxylase), with pyridoxal phosphate (the active form of vitamin B6) as the cofactor.
Dopamine is converted into norepinephrine by the enzyme dopamine 0-hydroxylase, with 02 and L-ascorbic acid (vitamin C) as cofactors.
Norepinephrine is converted into epinephrine by the enzyme phenylethanolamine N-methyltransferase with S-adenosyl-L-methionine (SAMe) as the cofactor.
In some embodiments, the enriched alcoholic food product provided herein may increase DA brain level. In some embodiments, the enriched alcoholic product may afford continued elevated DA levels in the brain initiated by alcohol consumption, to thereby provide at least some of the desired benefits exerted by dopamine release, for example joyful and euphoric feeling, and relaxation. In the context of any of these embodiments, a disclosed enriched alcoholic food product may comprise or may be supplemented with DA
and/or one or more DA precursors.
Without wishing to be bound by theory, it is assumed that when the enriched alcoholic food product, e.g. an alcoholic beverage, is consumed, the alcohol in the product causes an immediate release of dopamine. A dopamine precursor contained in the product, reinforces the neurotransmitter supply in the brain, thereby maintaining or even amplifying its level for a prolonged period of time. This prolonged and sustained level of neurotransmitters in the brain, which last long after the alcohol level in the blood has gown down to zero, affords not only a prolonged euphoric feeling but, moreover, quenches or circumvent the unpleasant psychological and physiological sensations associated with alcohol withdrawal such as headache, nausea and depression. These effects outgo the psychotropic effects associated with consumption of high amounts of alcohol alone.
In some embodiments, supplementing an alcoholic food product, for example, alcoholic beverage such as beer or wine, with precursors of neurotransmitters as provided herein, enriches the alcoholic food product and imparts to it at least the following positive psychoactive effects: blissful, joyful and euphoric sensation. The term "psychoactive" as used herein means affecting the mood, and "positive psychoactive effect"
herein means affect the mood is a positive, desired manner.
Positive psychoactive effects exerted by the enrich alcoholic food product provided herein may sustain long after consumption of the product, and it may not be accompanied by drunkenness or intoxication. In some embodiments, the euphoric feeling lasts from about 5 minutes up to 24 hours post consumption, with almost no accompanying feeling of intoxication. For example, a euphoric state of mind may last about 5-10 min, about 10-15 mm, about 10-20 mm, about 20-30 min, about 30-40 min, about 40-50 min, 0-1 hours, about 1-3 hours, about 1-4 hours, about 2-5 hours, about 3-5 hours, about 4-6 hours, about 5-8 hours, about 5-9 hours, about 6-10 hours, about 7-10 hours, about 8-11 hours, about 9-hours, about 9-11 hours, about 9-15 hours, about 10-12 hours, about 12-15 hours, about 15-18 hours, about 15-20 hours, about 18-22, about 20-24 hours, or even longer, after blood alcohol level has already dropped to zero.
One of the unique and unexpected properties of the enriched alcoholic food product provided herein, e.g., an alcoholic beverage, is that it does not dim the consumer's sense of alertness as often happens upon alcohol consumption, but to contrary: the enriched alcoholic food product provided herein keeps the consumer well and sharply focused, fully conscious, in-control and with the ability to remain concentrated for extended periods, contrary to the psychotropic effects exerted by regular alcoholic products particularly alcoholic beverages. In fact, the enriched alcoholic product provided herein affords to the consumer a better, higher and prolonged focusing and concentration abilities in spite the alcohol it contains.
The term "psychotropic", as used herein, means the ability to influences the mind or cognitive abilities of a person, and/or to affect mental processes (e.g., emotions, perception) and mental activity (e.g., behavior). The term "positive psychotropic effects"
herein means affect the mind, mental and/or the cognitive abilities is a positive, desired manner.
In some embodiments, supplementing an alcoholic food product, for example, alcoholic beverage such as beer or wine, with one or more neurotransmitters and/or one or more precursors of neurotransmitters as described herein, enriches the alcoholic food product by imparting to it the ability to exert at least the following positive psychotropic effects: (i) higher motivation e.g., to work, learn and take part in rewarded activities; (ii) improved concentration and focus; (iii) higher self-confidence; (iv) arousal;
(v) wakefulness; (vi) elevated alertness; (vii) improved creativity and creative thinking (viii) curiosity and openness to new experiences; (ix) sense of self-fulfillment, self-contempt; (x) relaxation; (xi) improved capacity to switch attention efficiently between tasks; (xii) improved sociability and extroversion behavior (xiii) better cognitive and/or mental function; and (xiv) emotional and physical sense of well-being.
The positive psychotropic effects exerted by an enriched alcoholic food product may last hours and even days after consumption thereof. In some embodiments, a positive psychotropic effect, for example, higher motivation, or improved ability e.g., to concentrate and maintain focused, alert, awaken, self-confident and/or improved sociability lasts from minutes to about 72 hours after consuming the enriched alcoholic food product.
For example, a person consuming e.g., an enriched alcoholic beverage such as beer or wine may experience higher motivation to conduct rewarding activities, improved sociability, better cognitive and/or mental or emotional function, and/or physical sense of well-being, from about 5 min to about 10 min, from about 8 mm to about 15 mm, from about 10 min to about 20 min, from about 25 min to about 40 min, from about 0.5 hour to about 2 hours, from about 1.5 hours to about 4 hours, from about 2 hours to about 5 hours, from about 3 hours to about 6 hours, from about 4 hours to about 7 hours, from about 4 hours to about 8 hours, from about 5 hours to about 8 hours, from about 6 hours to about 9 hours, from about 6 hours to about 10 hours, from about 7 hours to about 12 hours, from about 9 hours to about 15 hours, from about 8 hours to about 16 hours, from about 10 hours to about 15 hours, from about 15 hours to about 20 hours, from about 18 hours to about 22 hours, from about 20 hours to about 25 hours, from about 25 hours to about 35 hours, or even from about 35 hours to about 48 hours, after consuming the beer or wine enriched with one or more neurotransmitter and/or precursors thereof.
In some embodiments, a person consuming e.g., an enriched alcoholic beverage such as beer, wine or spirit may experience higher motivation, better or improved creative thinking, concentration, wakefulness, self-confident and/or joyful self-contentment that lasts from about 0.25 day to about 0.5 day, from about 0.5 day to about 0.75 day, from about 0.5 day to about 1.0 day, from about 0.5 day to about 1.25 days, from about 0.75 day to about 1.0 day, from about 1.0 day to about 1.5 days, from about 1.5 days to about 2.0 days, from about 1.5 days to about 2.5 days, from about 2.0 days to about 2.5 days, or from about 2.5 days to about 3.0 days, and even longer, after consuming the beer, wine or spirit enriched with one or more neurotransmitter and/or precursors thereof.
In some embodiment, a disclosed enriched alcoholic food product comprises dopamine and/or one or more dopamine precursors.
In some embodiments, a disclosed enriched alcoholic food product comprises at least one dopamine precursor.
For example, elevated levels of DA conferred or induced by a contemplated enriched alcoholic food product may enhance the expectation of pleasure in a person consuming the product.
A contemplated alcoholic food product enriched, for example, with one or more DA precursors, for example Tyr, may positively affect memory and learning, as dopamine activity in the brain plays a substantial part in memory and learning. It is essential for long-term memory storage and retrieval. Dopamine further signals important events:
it helps remembering events that have motivational significance. This ensures that memories are relevant and accessible for future behavior. Dopamine also plays an essential role in working memory. Working memory is the capacity to use information from short-term memory for guiding one's own actions.
For example, a contemplated alcoholic food product enriched with one or more DA
precursors may positively affect focus and attention. Moderate levels of dopamine (not too high or too low) improve the capacity of individuals to switch attention efficiently between tasks. Furthermore, moderate levels of dopamine direct attention more efficiently to stimuli that are relevant to ongoing tasks.
For example, a contemplated alcoholic food product enriched with one or more DA
precursors may positively affect pathways associated with social and extroversion behavior and/or with forming romantic attachments. Intense romantic love is associated with the dopamine reward system, and the crosstalk between oxytocin, the "love molecule", and dopamine.
A contemplated alcoholic product enriched with one or more DA precursors may further confer or bestow to the consumer one or more of the following benefits or effects:
(a) controlled sleep-wake cycle. Dopamine D1 receptor (DRD1) activation induces arousal and wakefulness;
(b) increased creativity. Dopamine is involved in cognitive flexibility - one of the main components of creativity and creative thinking. Dopamine is also responsible for openness to new experiences, another factor associated with creativity;
(c) stimulated sexual drive. A person's response to sex, just like other rewards, is largely dependent on DA. Erections are dependent upon activation of both dopaminergic neurons (ventral tegmental area) and dopamine receptors (NAc); and (d) depression amelioration. Elevated DA levels exerted by a disclosed product may ameliorate mental conditions related to low DA levels, such as hopelessness, worthlessness, stress handling, lack of interest in life, decreased motivation, procrastination, inability to feel pleasure, altered sleep patterns, mood swings, and impulsive or self-destructive behaviors.
In exemplary embodiments the neurotransmitter precursor or the DA precursor of a contemplated enriched alcoholic food product is L-tyrosine (Tyr).
In some embodiments, the enriched alcoholic product is an alcoholic beverage supplemented with at least one neurotransmitter precursors which is a DA
precursor selected from Phe, Tyr or L-dopa.
In exemplary embodiments, the dopamine precursor supplemented to the beverage is Tyr.
The amounts of tyrosine provided to the alcoholic beverages described herein is determined depending on some variables, for example, the amount of alcohol in the beverage, the amount and type of other supplements in the alcoholic beverage that may cross react with tyrosine, and the amount and type of other supplements provided to the beverages that may further promote elevated levels of dopamine. Usually, the amount of Tyr is in the range of 10 mg to 5000 mg per 1 liter of beverage, for example, from about mg to about 30 mg, from about 20 mg to about 50 mg, from about 30 mg to about mg, from about 50 mg to about 70 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 100 mg to about 250 mg, from about 200 mg to about 400 mg, from about 200 mg to about 300 mg, from about 200 mg to about 500 mg, from about 300 mg to about 400 mg, from about 300 mg to about 700 mg, from about 400 mg to about 800 mg, from about 500 mg to about 900 mg, from about 500 mg to about 1000 mg, from about 800 mg to about 1000 mg, from about 900 mg to about 1100 mg, from about 1000 mg to about 1200 mg, from about 1000 mg to about 1500 mg, from about 1000 mg to about 1600 mg, from about 1500 mg to about 2000 mg, from about 2000 mg to about 3000 mg, from about 3000 mg to about 4000 mg, or from about 4000 mg to about 5000 mg per liter, and any intermediate ranges therebetween.
In exemplary embodiments, the amount of tyrosine is about 350 mg/L, about 500 mg/L, about 750 mg/L or from about 100 mg/L to about 1000 mg/L.
Psychostimulant substances The enriched alcoholic food products described herein may further comprise supplements that promote or support increased level of a neurotransmitter such as, but not limited to, norepinephrine, serotonin, dopamine, endorphin, acetylcholine, GABA, glycine, glutamic acid, aspartic acid, and/or taurine.
The terms "psychostimulant supplement" and "psychostimulant substance", herein used interchangeably, refer to an edible substance that has a direct or indirect effect in increasing the levels of one or more neurotransmitters in the body, particularly in the brain, or in maintaining elevated neurotransmitter levels brought about, for example, by in situ conversion of a neurotransmitter precursor into a neurotransmitter, and/or by consuming alcohol. A psychostimulant substance may be directly or indirectly involved in enhancement of neurotransmitter synthesis and/or neurotransmitter stability, or upregulation of a neurotransmitter, for example, by upregulating enzymes that synthesize the neurotransmitter or protect the neurotransmitter from metabolic degradation. A
psychostimulant substance may, additionally or alternatively, be directly or indirectly involved in inhibition of neurotransmitter reuptake and/or neurotransmitter degradation, for example, by inhibiting or down regulating a neurotransmitter metabolic enzyme.
RECTIFIED SHEET (RULE 91) Psychostimulant substances may further foods which supply building blocks for production of a neurotransmitter or a precursor thereof.
In some embodiments, a psychostimulant substance increases metabolism rate in the body, thereby increasing metabolic conversion of a neurotransmitter precursor into a neurotransmitter.
In some embodiments, a psychostimulant substance inhibits or blocks metabolic enzymes that degrade a neurotransmitter precursor in the blood stream or in the digestive system.
Non-limiting examples of psychostimulant substances include caffeine, omega-3, fatty acids such as docosahexaenoic acid (DHA), magnesium, soluble fibers, folate, olive oil or monounsaturated fats extracted therefrom, green tea or theanine extracted therefrom, pregnenolone and any derivative thereof, uridine, iron, spices such as turmeric or curcumin extracted therefrom, Rhodiola rosea or an extract thereof, oregano or an extract thereof, co-factors, vitamins such as vitamin C and vitamin B6, minerals and the like.
Caffeine is the most widely consumed psychostimulant substance. It is known to highly effects the metabolism within the central nervous system via the blockade of adenosine receptors, which modulate the neurotransmission of glutamate, serotonin, acetylcholine and dopamine. Caffeine itself has a wide variety of effects on the dopaminergic system, which is crucial for the expression of caffeine's stimulating properties. Furthermore, caffeine promotes tyrosine hydroxylase activation via cellular Ca2+ entry stimulation mechanism, and it has been shown that chronic caffeine intake increases tyrosine hydroxylase mRNA expression. As tyrosine hydroxylase is the rate-limiting enzyme in the biosynthesis of DA and other catecholamines, caffeine may accelerates DA synthesis through upregulation of this enzyme. Caffeine may provide an energy boost just like sugar and alcohol. However, caffeine alone indirectly promotes DA
level elevation only temporarily.
Without being limited by theory, it is assumed that providing caffeine and alcohol together with a supply of DA precursors such as tyrosine, phenylalanine and/or any other DA precursor, may enable enhanced and continued conversion of immediate metabolic DA
precursors to DA, thus affording stable elevated levels of DA in the brain for a prolonged time, hence a prolonged duration of desired psychotropic and/or psychoactive effects such as euphoric and bliss feelings, high motivation and energy, that would last long after consumption of alcohol ceased.
In an enrich alcoholic food product, for example, a liquid product, the amount of caffeine may range from about 0 mg to about 2 gr per 1 liter of beverage. For example, from about 5 mg/L to about 10 mg/L, from about 10 mg/L to about 20 mg/L, from about mg/L to about 50 mg/L, from about 50 mg/L to about 80 mg/L, from about 60 mg/L
to about 100 mg/L, from about 200 mg/L to about 300 mg/L g, from about 200 mg/L
to about 400 mg/L, from about 300 mg/L to about 500 mg/L, from about 500 mg/L to about mg/L, from about 600 mg/L to 900 mg/L, from about 700 mg/L to 750 mg/L, from about 800 mg/L to about 1000 mg/L, from about 800 mg/L to about 1200 mg/L, from about 900 mg/L to about 1200 mg/L, from about 1100 mg/L to about 1400 mg/L, from about mg/L to about 1500 mg/L, from about 1500 mg/L to about 1700 mg/L, from about mg/L to about 2000 mg/L, or from about 1700 mg/L to about 2000 mg/L.
In certain embodiments, liquid alcoholic food products described herein contain from about 10 mg/L to about 1200 mg/L, for example, about 35 mg/L about 50 mg/L, about 100 mg/L or 350 mg/L of caffeine.
In exemplary embodiment an enriched beer is provided comprising a DA precursor such as tyrosine and a psychostimulant substance such as caffeine.
A contemplated enriched beer, for example, can contain Tyr and about 0.75 mg/ml caffeine and yet maintain the original taste, aroma, palatability and gas content of a beer with no hint for caffeine's dominant bitter taste.
Enriched beers as well as other enriched alcoholic beverages provided herein, provide the exact combination of alcohol, DA precursor such as tyrosine and psychostimulant substance such as caffeine, that affords an optimal rate of brain dopamine level increase, as well as optimal, stable DA level that provide to the consumer intensified, long lasting pleasure and a pleasant drinking experience, while circumventing the "down"
feeling often associated with alcohol consumption.
Certain minerals and B-vitamins, especially zinc, vitamin B6, and folate, are necessary for dopamine synthesis and neurotransmission. These nutrients are often depleted in individuals due to medications, inadequate diets, excessive stress, and toxic environmental exposures, compromising the ability to properly synthesize RECTIFIED SHEET (RULE 91) neurotransmitters like dopamine. Dopamine is easily oxidized, thus antioxidants such as vitamins C and E may assist in maintaining desired levels of DA.
Magnesium deficiency can cause decreased levels of dopamine, which might lead to depression.
Pregnenolone is the main steroid produced from cholesterol mainly in the brain, gonads and adrenal glands. Pregnenolone and its sulfate (pregnenolone sulfate) are excitatory neurosteroids, i.e., they stimulate the brain, and can increase DA.
Pregnenolone and/or its derivatives have anti-stress and mood-elevating effect, they enhance learning and memory and increase the amount of deep sleep, improve energy, vision, clarity of thinking, wellbeing, and often sexual enjoyment or libido.
The amount of pregnenolone and derivatives thereof, particularly pregnenolone sulfate, in, e.g., a liquid alcoholic product described herein is in the range of from about 0 mg to 3.0 mg per liter, for example 0.1-0.5 mg/L, or about 1 mg/L.
Curcumin is known to be the most active phytochemical in yellow dietary spice turmeric. Curcumin has been proven to have anti-oxidant, anti-inflammatory, anti-microbial, hypoglycemic, anti-rheumatic, wound healing and anti-cancer activities.
Curcumin further possesses antidepressant properties by way of interacting with dopamine receptors and increasing brain dopamine levels. For example, curcumin increases DA
concentration in the brain by inhibiting monoamine oxidase (MAO)-mediated DA
break down. Curcumin may be taken daily in large amounts, even up to 8 gr/day.
The amount of curcumin in, e.g., liquid alcoholic product described herein is in the range of from about 0.1 mg/ml to 2.0 g/ml, for example about 0.2-0.5 g/ml.
L-theanine is an amino acid uniquely found in green tea that creates an alert state of relaxation without drowsiness. L-theanine is known to be able to cross the blood-brain barrier and increase dopamine levels in the brain. As such, it may have anti-depressant and anti-anxiety effects, it may reduce mental and physical stress, and lead to improvements in learning and memory in humans and animals. Even just a single, small dose of L-theanine (100 mg) significantly improves the ability to pay attention and maintain focus.
The amount L-theanine e.g., in a liquid alcoholic product in accordance with some embodiments, is in the range of from about 0 mg to about 2000 mg per 1 liter of beverage, for example, from about 10 mg/L to about 30 mg/L, 20 mg/L to about 50 mg/L, 50 mg/L
RECTIFIED SHEET (RULE 91) to about 100 mg/L, 80 mg/L to about 150 mg/L, 100 mg/L to about 150 mg/L, 150 mg/L
to about 200 mg/L, 150 mg/L to about 400 mg/L, 300 mg/L to about 500 mg/L, 550 mg/L
to about 750 mg/L, 500 mg/L to about 1000 mg/L, 700 mg/L to about 1200 mg/L, mg/L to about 1250 mg/L, 1200 mg/L to about 1500 mg/L, 1550 mg/L to about 1850 mg/L, or 1700 mg/L to about 1000 mg/L.
In certain embodiments, enriched alcoholic beverages described herein contain mg/L, 1200 mg/L or 1800 mg/L of L-theanine.
Rhodiola rosea, or "golden root," is a popular plant in traditional medicine in Eastern Europe and Asia, with a reputation for improving depression, enhancing work performance, eliminating fatigue and treating symptoms resulting from intense physical and psychological stress. Rhodiola exerts its benefits via multiple effects on the central nervous system, including enhancing the stability of dopamine and supporting its reuptake.
This leads to notable decreases in depression, anxiety, and fatigue, as well as an increased ability to handle stress.
Rhodiola extract derived from Rhodiola rosea root and standardized to contain 3%
total rosavins and a minimum 1% salidrosides may be included in, e.g., enriched liquid alcoholic product described herein in amounts which range from about 300 mg to about 2000 mg per liter, for example, 510 mg/L, 800 mg/L or 1100 mg/L.
Other psychostimulant substances contemplated herein include, for example, nutritional or brewer's yeasts which is rich in uridine-5w-monophosphate that may increase DA levels in the brain; oregano, which increases DA levels by decreasing DA
break down and reuptake; and resistant starch, a type of soluble fiber that increases butyrate, which may increase dopamine levels.
In some embodiment, a disclosed enriched alcoholic food product comprises one or more psychostimulant substances that directly or indirectly affect DA brain level, for example, caffeine, theanine, curcumin, uridine, pregnenolone, and/or oregano.
The amounts of psychostimulant substance provided to the enrich alcoholic products described herein vary and depend on the psychostimulant substance itself as well an on the other ingredients provided to the enriched alcoholic product, particularly to the amount of alcohol, the amount and type of DA precursor(s), the presence of other neurotransmitter or precursors thereof, and/or the amount and type of other supplements that may cross react or enhance the effect of a particular psychostimulant substance. Excess dopamine is dangerous and needs to be avoided, and a skilled person would appreciate that the amount and number of psychostimulant substances provided to the alcoholic beverages are to be adjusted so as to avoid secretion, production and/or otherwise promotion of excess DA.
The amount of one or more psychostimulant substances in a contemplated enriched alcoholic food product may be in a range of from 0 to about 10% by weight. For example, from about 0.01% to about 1.00%, from about 0.01% to about 1.00%, from about 0.05%
to about 1.00%, from about 0.1% to about 0.3%, from about 0.2% to about 0.5%, from about 0.5% to about 1.0%, from about 1.0% to about 3.0%, from about 1.0% to about 5.0%, from about 5.0% to about 10.0%, from about 8% to about 10.0%, by weight or by volume of total enriched alcoholic product, and any sub-ranges and/or individual values therebetween.
The amount of psychostimulant substances in a contemplated product are adjusted such that the original texture, smell and palatability of the product is maintained.
Alcoholic beverages In an aspect of the disclosure, there is provided an enriched alcoholic beverage comprising a base liquid, alcohol, one or more neurotransmitter and/or one or more neurotransmitter precursors as defined herein.
In some embodiments, a contemplated enriched alcoholic beverage optionally further comprises one or more psychostimulant substances as defined herein.
In some embodiments, provided herein is enriched alcoholic beverage comprising a base liquid, alcohol, dopamine and/or at least one dopamine precursor and, optionally, one or more psychostimulant substances as described herein, for example, caffeine.
Herein throughout, the term "base liquid" describes a liquid form of a substance or a mixture of substances which either alone or when mixed with other additives can form a beverage. In some embodiments, the base liquid is a base beverage.
In some embodiments, the base beverage is an alcohol-free base beverage.
The phrase "alcohol-free base beverage", as used herein, is a beverage having alcohol percentage that is no more than 50% of the alcohol content in a corresponding alcoholic beverage, preferably no more than 40%, no more than 30%, no more than 20%, no more than 15%, no more than 10%, no more than 5%, no more than 1%, no more than 0.5%, no more than 0.1%, no more than 0.05%, or no more than 0.01%, of the alcohol content acceptable for a certain beverage, including any subranges and any intermediate values there between. This phrase is used herein as encompassing both base beverages that are typically used for forming alcoholic beverages, and base beverages which are typically used as non-alcoholic beverages, for example, juices.
In some embodiments, the alcohol-free base beverage is devoid of alcohol.
By "devoid of alcohol" is meant herein less than 0.01% or less than 0.005%, or less than 0.001%, of alcohol by volumes, or even null.
Exemplary alcohol-free base beverages which form the liquid base for the enriched alcoholic beverages described herein include, but are not limited to, natural or artificially flavored fruit juice (such as grape, mango, elder, apple, orange juice, and the like), vegetable juice, fruit syrup, concentrate or nectar from fruits, plant materials such as agave, jello, carbonated beverages such as cola, optionally with addition of roasted malt beer, caffeinated beverages, specialized flavor formulations emulating the taste of existing wines and spirits, non-alcoholic cocktails ("mocktails"), malt beer, dealcoholized ciders, dealcoholized wines, dealcoholized beers, dealcoholized spirits, tonic water and water.
When the liquid base comprises alcohol, it is termed herein a "base alcoholic liquid". In some embodiments, the base alcoholic liquid is an alcoholic beverage. The term "alcoholic beverage" as used herein encompasses any beverage having an alcohol (ethanol) content of at least 2% by volume, whether distilled, fortified, brewed, or produced by fermentation, and includes, but is not limited to, wine, beer, fermented liquids derived in whole or in part from fruit juices, such as cider and perry (pear cider), spirits, flavored alcoholic beverages collectively termed herein and in the art as "alcopops", and the like.
In some embodiments, the base alcoholic liquid is an alcoholic beverage substitute that has residual alcohol content of 0-20% by volume, depending on the alcoholic beverage being substituted.
Embodiments described herein provide an enriched alcoholic beverage comprising a base alcoholic liquid, one or more neurotransmitter and/or one or more neurotransmitter precursors as defined herein.
In some embodiments, a contemplated enriched alcoholic beverage optionally further comprises one or more psychostimulant substances as defined herein.
In some embodiments, provided herein is enriched alcoholic beverage comprising a base alcoholic liquid, dopamine and/or at least one dopamine precursor as described herein and, optionally, one or more psychostimulant substances as described herein.
Any combination of the base liquid, base alcohol-free liquid and base alcoholic liquid as described herein is contemplated for the enriched alcoholic beverages described herein.
The contemplated enriched alcoholic beverages provided herein provide the drinker with the palatability effect of common alcoholic beverages, and further provide the drinker with a sustained euphoric feeling, pleasure and overall sensation of wellbeing and vitality which far exceed the effects provided by corresponding alcoholic beverages which do not contain these enriching supplements and additives. Moreover, unlike common alcoholic beverages, the enriched alcoholic beverages provided herein provide a substantial relief of the adverse effects associated with alcohol consumption, particularly the "down" feeling or depression associated with intoxication and sobering up.
A unique and surprising feature of the enriched alcoholic beverage provided herein is that they provide the drinker with intensified and prolonged pleasurable, joyful, and euphoric feelings accompanied with a boost of energy and motivation, while affording a substantial reduction in drunkenness symptoms.
Contemplated enriched alcoholic beverages provide substantial reduction of intoxication effects, namely, they substantially minimize intoxication effects. For example, these beverages reduce intoxication by 10-95%, or minimize intoxication effects to at least 5% of the effect associated with consuming a corresponding non-enriched alcoholic beverage having the same alcohol content.
In some embodiments, intoxication and/or other negative physical and emotional feelings accompanying sobering up may be relieved, eased or alleviated by about 0 to 100%. For example, alleviation of undesired effects exerted by a contemplated enriched alcoholic beverage may be up to 10%, up to 20%, up to 30%, up to 40 %, up to 50%, up to 60% up to 70%, up to 80%, up to 90%, up to 95%, or up to 100% as compared to a corresponding non-enriched alcoholic beverage. The extent of intoxication relief or moderation changes form one person to another and depends on a collective of variable such as the person's tolerance to alcohol, the amount of alcohol in the beverage or the amount of beverage consumed. In some embodiments, the drinker does not experience any insobriety at all even though relatively high amount of alcohol is consumed, for example, at least 1 liter of enriched beer or at least 3 glasses of enriched wine.
Any combination of neurotransmitter precursors and psychostimulant substances as described herein is contemplated herein.
Because the enriched alcoholic beverage of the present disclosure affords palatability and psychotropic effect which outgo the effects of a corresponding non-enriched alcoholic beverages, these enriched beverages may be provided with reduced amounts of alcohol as compared to the corresponding non-enriched alcoholic beverages.
For example, the alcohol amount in a contemplated enriched alcoholic beverages may be about 100%, about 95%, about 90%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 20%, about 15%, about 10%, about 5%, about 3%, about 1% or about 0.5%, of the amount of alcohol in a corresponding non-enriched alcoholic beverage.
In some embodiments, the enriched alcoholic beverage is selected from enriched beer, wine, cider, spirit and/or enriched alcopop beverage. In some embodiments, these enriched alcoholic beverages comprise one or more neurotransmitter precursors.
In exemplary embodiments, the neurotransmitter precursor is a precursor of dopamine, for example, L-tyrosine.
The term "beer" as used herein and in the art means an alcoholic beverage obtained by malting and fermenting one or more of the cereal grains, and includes ale, stout, porter and lager. Typical alcoholic beer beverages include an alcoholic content of 3-8%. Some high-alcohol content beers comprise 8-12% alcohol, for example 10% alcohol.
In some embodiments, the beer is a "reduced alcohol beer", namely a beer as defined herein comprising up to 3.5% alcohol, for example, up to 3.0%, up to 2.2%, up to 2.0%, up to 1.5%, up to 1.0%, up to 0.5%, up to 0.3%, up to 0.1%, up to 0.05%, up to 0.01%, alcohol, or the beer may be devoid of alcohol.
Non-limiting examples of enriched beers provided in embodiments described herein include:
(i) Ale. A type of beer brewed using a warm fermentation method, resulting in a sweet, full-bodied and fruity taste. As with most beers, ale typically can have a bittering agent to balance the sweetness of the malt and act as a preservative. Ale is usually bittered with hops, the dried, cone-shaped flowers of the Mulberry plant used in the beer-brewing process to give a beer a bitter taste. Ale is typically fermented at temperatures between 15 and 24 C (60 and 75 F). At temperatures above 24 C (75 F) the yeasts can produce significant amounts of esters and other secondary flavour and aroma products, and the result is often a beer with slightly "fruity" compounds resembling those found in fruits such as apple, pear, pineapple, banana, plum, cherry, or prune.
Contemplated enriched Ale beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) Brown Ale, a lightly hopped beer, fairly mildly flavoured, often with a nutty taste. Brown ales range from dark brown beers containing around 3-3.5% alcohol and quite sweet, to red-brown containing 4.5-5% alcohol, and drier beers; (b) Pale Ale, also known as "Bitter Ale", a beer made from malt dried with coke; (c) India Pale Ale (IPA), a Pale Ale containing extra hops, a beer appreciated for its light and refreshing character; (d) Golden Ale, similar to pale ale but paler, having from 3.5% to 5.3% alcohol; (e) Scotch Ale, a malty, strong ale, amber-to-dark red in color.
The malt may be slightly caramelized to impart toffee notes; (f) Barley wine, range from
The ventral tegmental area usually sends dopamine into the brain when animals or human expect or receive a reward, and helps control the brain's reward and pleasure centers. The reward center (also known as the "reward pathway") is comprised primarily of the nucleus accumbens (NAc), the ventral tegmental area (VTA), and a part of the prefrontal cortex. This combination of brain areas which form the reward center is affected by virtually all pleasurable activity, including everything from hanging out with friends, going on vacation, ingesting drugs (e.g., cocaine), listening to music, eating and drinking, having sexual activity, and consuming alcohol. All things which give us pleasure, cause a release of dopamine in the reward pathway as well as trigger a number of other events in the brain including endorphin release and activation of the orbitofrontal region of the prefrontal cortex. Dopamine is known as the "motivation molecule" or the "reinforcement molecule" as it is responsible for reward-seeking behavior and helps provide the drive, focus and concentration needed to get things done. This dopamine release tells the brain that whatever it just experienced is worth getting more of, and that helps animals and humans change their behaviors in ways that will help them attain more of the rewarding item or experience. This brain reward system is associated with "feeling good"
and promotes survival of the species by rewarding behaviors necessary for continued survival.
Dopamine is also involved in many other functions of the brain including motor activity, motivation, learning, pain processing, mood, attention span and regulation of sleep. It regulates stress relief.
Lowering dopamine can make animals and humans lose pleasure in activities like eating and drinking. This joyless state, where animals or human no longer find pleasure in activities they used to enjoy and are no longer motivated to do those activities, is called anhedonia. People with some mental illnesses, such as depression and schizophrenia, may experience anhedonia as part of their disease.
Dopamine deficiency results in Parkinson's Disease, and people with low dopamine activity may be more prone to addiction. Alcohol as well as all drugs which lead to dependence appear to affect the dopamine system. Stimulants like amphetamine and cocaine affect dopamine directly whereas alcohol and other drugs appear to affect it indirectly.
Alcohol consumption triggers a boost of dopamine release. Alcohol does not lead to an increase of dopamine throughout the brain; it only causes an increase in dopamine in the reward center, leading to the relaxing and carefree experience of the alcohol "buzz".
Consumption of even small amounts of alcohol increases the amount of dopamine in the NAc in a dose-response manner. Alcohol increases DA via the promotion of synaptic terminal DA release rather than via the inhibition of DA transporters. Alcohol can also indirectly increase DA levels by affecting the GABA system and the endorphin system.
Neurons from the GABA system extend into the reward pathway and when alcohol affects the GABA system these neurons release dopamine into the reward pathway.
Likewise, neurons extend from the endorphin system into the reward pathway and these also release dopamine into the reward pathway when alcohol directly stimulates the endorphin system.
It is unlikely that the increase in dopamine alone is responsible for the stimulant properties of alcohol. It is most likely that the stimulating effects of alcohol are due to its effects on adrenaline, norepinephrine, and the prefrontal cortex as well.
A boost in the activation of Dopaminergic pathways eventually causes a depletion of the dopamine reserves within the brain cells, leaving the brain in an imbalanced state.
As Dopamine itself is impenetrable to the blood-brain barrier, it must synthesized in situ from its precursors. Over time, with more drinking, the dopamine effect diminishes until its almost nonexistent.
It has been postulated by the present inventor that kicking-off brain DA
release via alcohol consumption, and simultaneously providing means to sustain elevated brain DA
level by providing DA building blocks, may enhance the euphoric feeling and afford qualities such as increased motivation, focus and concentration to pursue rewarding actions such as working and learning, increased sociability, and attention, while at the same time alleviating alcohol withdrawal symptoms and, moreover, substantially decreasing addiction disposition.
The present inventors envisaged, and successfully practiced enriched alcoholic food products, for example, enriched alcoholic beverages, containing a precursor of DA, for example, tyrosine, and, optionally, a psychostimulant substance such as caffeine, based on their strong affiliations to the metabolism of DA within the brain, thereby promoting DA synthesis within the central nervous system and establishing a long lasting steady state of readily available DA. This sustained supply of DA building blocks from the very first moment of alcohol intake, may increase the positive and enjoyable effects of alcohol consumption, while neutralizing negative effects associated with DA depletion followed by it.
Furthermore, enhancement of the positive effects of alcohol may help reduce the risk of alcohol abuse. Motives of alcohol consumption are classically "enhancing motives"
(drinking to enhance positive and social mood) and "coping motives" (drinking to cope with negative mood). While enhancing drinkers enjoy the positive effects of alcohol consumption, coping drinkers rely on its sedative effects, and are strongly exposed to risks of alcohol abuse and alcoholism. Through the enhancement of alcohol's positive effects and the negation of its sedative effects, provided herein is a method to reduce risks of alcohol abuse amongst coping drinkers.
In some embodiments, the alcoholic products described herein are designed to promote at least the levels of dopamine, endorphin norepinephrine and/or epinephrine in the brain. To this end, the alcoholic products are enriched with one or more neurotransmitters and/or neurotransmitters precursors.
For example, L-phenylalanine (Phe), L-tyrosine (Tyr) and/or levodopa (L-dopa) are the precursors of dopamine and other catecholamines such as norepinephrine and epinephrine.
The terms "dopamine precursor" and "dopamine immediate metabolic precursor"
as used herein are interchangeable and refer to a substance that can be converted into dopamine in the body through a series of one or more metabolic reactions.
The primary and minor metabolic pathways for obtaining DA from its precursors are:
Primary: Phe ¨> Tyr ¨> levodopa ¨> DA
Minor: Phe ¨> Tyr ¨> p-Tyramine ¨> DA
Minor: Phe ¨> m-Tyrosine ¨> m-Tyramine ¨> DA
The direct or immediate metabolic precursor of dopamine, L-dopa, can be synthesized indirectly from the essential amino acid Phe or directly from the non-essential amino acid Tyr. Additionally or alternatively in can be supplemented form plants (e.g.
legumes) and animals. Most of the levodopa is immediately broken down (e.g., in the intestine) before it enters the brain primarily by decarboxylase enzymes and catecholamine-0-methyltransferase (COMT).
L-Phenylalanine is converted into Tyr by the enzyme phenylalanine hydroxylase, with molecular oxygen (02) and tetrahydrobiopterin (THB) as cofactors. L-Tyrosine is converted into L-dopa by the enzyme tyrosine hydroxylase, with tetrahydrobiopterin, 02, and iron (Fe2 ) as cofactors. L-dopa is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase (also known as dopa decarboxylase), with pyridoxal phosphate (the active form of vitamin B6) as the cofactor.
Dopamine is converted into norepinephrine by the enzyme dopamine 0-hydroxylase, with 02 and L-ascorbic acid (vitamin C) as cofactors.
Norepinephrine is converted into epinephrine by the enzyme phenylethanolamine N-methyltransferase with S-adenosyl-L-methionine (SAMe) as the cofactor.
In some embodiments, the enriched alcoholic food product provided herein may increase DA brain level. In some embodiments, the enriched alcoholic product may afford continued elevated DA levels in the brain initiated by alcohol consumption, to thereby provide at least some of the desired benefits exerted by dopamine release, for example joyful and euphoric feeling, and relaxation. In the context of any of these embodiments, a disclosed enriched alcoholic food product may comprise or may be supplemented with DA
and/or one or more DA precursors.
Without wishing to be bound by theory, it is assumed that when the enriched alcoholic food product, e.g. an alcoholic beverage, is consumed, the alcohol in the product causes an immediate release of dopamine. A dopamine precursor contained in the product, reinforces the neurotransmitter supply in the brain, thereby maintaining or even amplifying its level for a prolonged period of time. This prolonged and sustained level of neurotransmitters in the brain, which last long after the alcohol level in the blood has gown down to zero, affords not only a prolonged euphoric feeling but, moreover, quenches or circumvent the unpleasant psychological and physiological sensations associated with alcohol withdrawal such as headache, nausea and depression. These effects outgo the psychotropic effects associated with consumption of high amounts of alcohol alone.
In some embodiments, supplementing an alcoholic food product, for example, alcoholic beverage such as beer or wine, with precursors of neurotransmitters as provided herein, enriches the alcoholic food product and imparts to it at least the following positive psychoactive effects: blissful, joyful and euphoric sensation. The term "psychoactive" as used herein means affecting the mood, and "positive psychoactive effect"
herein means affect the mood is a positive, desired manner.
Positive psychoactive effects exerted by the enrich alcoholic food product provided herein may sustain long after consumption of the product, and it may not be accompanied by drunkenness or intoxication. In some embodiments, the euphoric feeling lasts from about 5 minutes up to 24 hours post consumption, with almost no accompanying feeling of intoxication. For example, a euphoric state of mind may last about 5-10 min, about 10-15 mm, about 10-20 mm, about 20-30 min, about 30-40 min, about 40-50 min, 0-1 hours, about 1-3 hours, about 1-4 hours, about 2-5 hours, about 3-5 hours, about 4-6 hours, about 5-8 hours, about 5-9 hours, about 6-10 hours, about 7-10 hours, about 8-11 hours, about 9-hours, about 9-11 hours, about 9-15 hours, about 10-12 hours, about 12-15 hours, about 15-18 hours, about 15-20 hours, about 18-22, about 20-24 hours, or even longer, after blood alcohol level has already dropped to zero.
One of the unique and unexpected properties of the enriched alcoholic food product provided herein, e.g., an alcoholic beverage, is that it does not dim the consumer's sense of alertness as often happens upon alcohol consumption, but to contrary: the enriched alcoholic food product provided herein keeps the consumer well and sharply focused, fully conscious, in-control and with the ability to remain concentrated for extended periods, contrary to the psychotropic effects exerted by regular alcoholic products particularly alcoholic beverages. In fact, the enriched alcoholic product provided herein affords to the consumer a better, higher and prolonged focusing and concentration abilities in spite the alcohol it contains.
The term "psychotropic", as used herein, means the ability to influences the mind or cognitive abilities of a person, and/or to affect mental processes (e.g., emotions, perception) and mental activity (e.g., behavior). The term "positive psychotropic effects"
herein means affect the mind, mental and/or the cognitive abilities is a positive, desired manner.
In some embodiments, supplementing an alcoholic food product, for example, alcoholic beverage such as beer or wine, with one or more neurotransmitters and/or one or more precursors of neurotransmitters as described herein, enriches the alcoholic food product by imparting to it the ability to exert at least the following positive psychotropic effects: (i) higher motivation e.g., to work, learn and take part in rewarded activities; (ii) improved concentration and focus; (iii) higher self-confidence; (iv) arousal;
(v) wakefulness; (vi) elevated alertness; (vii) improved creativity and creative thinking (viii) curiosity and openness to new experiences; (ix) sense of self-fulfillment, self-contempt; (x) relaxation; (xi) improved capacity to switch attention efficiently between tasks; (xii) improved sociability and extroversion behavior (xiii) better cognitive and/or mental function; and (xiv) emotional and physical sense of well-being.
The positive psychotropic effects exerted by an enriched alcoholic food product may last hours and even days after consumption thereof. In some embodiments, a positive psychotropic effect, for example, higher motivation, or improved ability e.g., to concentrate and maintain focused, alert, awaken, self-confident and/or improved sociability lasts from minutes to about 72 hours after consuming the enriched alcoholic food product.
For example, a person consuming e.g., an enriched alcoholic beverage such as beer or wine may experience higher motivation to conduct rewarding activities, improved sociability, better cognitive and/or mental or emotional function, and/or physical sense of well-being, from about 5 min to about 10 min, from about 8 mm to about 15 mm, from about 10 min to about 20 min, from about 25 min to about 40 min, from about 0.5 hour to about 2 hours, from about 1.5 hours to about 4 hours, from about 2 hours to about 5 hours, from about 3 hours to about 6 hours, from about 4 hours to about 7 hours, from about 4 hours to about 8 hours, from about 5 hours to about 8 hours, from about 6 hours to about 9 hours, from about 6 hours to about 10 hours, from about 7 hours to about 12 hours, from about 9 hours to about 15 hours, from about 8 hours to about 16 hours, from about 10 hours to about 15 hours, from about 15 hours to about 20 hours, from about 18 hours to about 22 hours, from about 20 hours to about 25 hours, from about 25 hours to about 35 hours, or even from about 35 hours to about 48 hours, after consuming the beer or wine enriched with one or more neurotransmitter and/or precursors thereof.
In some embodiments, a person consuming e.g., an enriched alcoholic beverage such as beer, wine or spirit may experience higher motivation, better or improved creative thinking, concentration, wakefulness, self-confident and/or joyful self-contentment that lasts from about 0.25 day to about 0.5 day, from about 0.5 day to about 0.75 day, from about 0.5 day to about 1.0 day, from about 0.5 day to about 1.25 days, from about 0.75 day to about 1.0 day, from about 1.0 day to about 1.5 days, from about 1.5 days to about 2.0 days, from about 1.5 days to about 2.5 days, from about 2.0 days to about 2.5 days, or from about 2.5 days to about 3.0 days, and even longer, after consuming the beer, wine or spirit enriched with one or more neurotransmitter and/or precursors thereof.
In some embodiment, a disclosed enriched alcoholic food product comprises dopamine and/or one or more dopamine precursors.
In some embodiments, a disclosed enriched alcoholic food product comprises at least one dopamine precursor.
For example, elevated levels of DA conferred or induced by a contemplated enriched alcoholic food product may enhance the expectation of pleasure in a person consuming the product.
A contemplated alcoholic food product enriched, for example, with one or more DA precursors, for example Tyr, may positively affect memory and learning, as dopamine activity in the brain plays a substantial part in memory and learning. It is essential for long-term memory storage and retrieval. Dopamine further signals important events:
it helps remembering events that have motivational significance. This ensures that memories are relevant and accessible for future behavior. Dopamine also plays an essential role in working memory. Working memory is the capacity to use information from short-term memory for guiding one's own actions.
For example, a contemplated alcoholic food product enriched with one or more DA
precursors may positively affect focus and attention. Moderate levels of dopamine (not too high or too low) improve the capacity of individuals to switch attention efficiently between tasks. Furthermore, moderate levels of dopamine direct attention more efficiently to stimuli that are relevant to ongoing tasks.
For example, a contemplated alcoholic food product enriched with one or more DA
precursors may positively affect pathways associated with social and extroversion behavior and/or with forming romantic attachments. Intense romantic love is associated with the dopamine reward system, and the crosstalk between oxytocin, the "love molecule", and dopamine.
A contemplated alcoholic product enriched with one or more DA precursors may further confer or bestow to the consumer one or more of the following benefits or effects:
(a) controlled sleep-wake cycle. Dopamine D1 receptor (DRD1) activation induces arousal and wakefulness;
(b) increased creativity. Dopamine is involved in cognitive flexibility - one of the main components of creativity and creative thinking. Dopamine is also responsible for openness to new experiences, another factor associated with creativity;
(c) stimulated sexual drive. A person's response to sex, just like other rewards, is largely dependent on DA. Erections are dependent upon activation of both dopaminergic neurons (ventral tegmental area) and dopamine receptors (NAc); and (d) depression amelioration. Elevated DA levels exerted by a disclosed product may ameliorate mental conditions related to low DA levels, such as hopelessness, worthlessness, stress handling, lack of interest in life, decreased motivation, procrastination, inability to feel pleasure, altered sleep patterns, mood swings, and impulsive or self-destructive behaviors.
In exemplary embodiments the neurotransmitter precursor or the DA precursor of a contemplated enriched alcoholic food product is L-tyrosine (Tyr).
In some embodiments, the enriched alcoholic product is an alcoholic beverage supplemented with at least one neurotransmitter precursors which is a DA
precursor selected from Phe, Tyr or L-dopa.
In exemplary embodiments, the dopamine precursor supplemented to the beverage is Tyr.
The amounts of tyrosine provided to the alcoholic beverages described herein is determined depending on some variables, for example, the amount of alcohol in the beverage, the amount and type of other supplements in the alcoholic beverage that may cross react with tyrosine, and the amount and type of other supplements provided to the beverages that may further promote elevated levels of dopamine. Usually, the amount of Tyr is in the range of 10 mg to 5000 mg per 1 liter of beverage, for example, from about mg to about 30 mg, from about 20 mg to about 50 mg, from about 30 mg to about mg, from about 50 mg to about 70 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 100 mg to about 250 mg, from about 200 mg to about 400 mg, from about 200 mg to about 300 mg, from about 200 mg to about 500 mg, from about 300 mg to about 400 mg, from about 300 mg to about 700 mg, from about 400 mg to about 800 mg, from about 500 mg to about 900 mg, from about 500 mg to about 1000 mg, from about 800 mg to about 1000 mg, from about 900 mg to about 1100 mg, from about 1000 mg to about 1200 mg, from about 1000 mg to about 1500 mg, from about 1000 mg to about 1600 mg, from about 1500 mg to about 2000 mg, from about 2000 mg to about 3000 mg, from about 3000 mg to about 4000 mg, or from about 4000 mg to about 5000 mg per liter, and any intermediate ranges therebetween.
In exemplary embodiments, the amount of tyrosine is about 350 mg/L, about 500 mg/L, about 750 mg/L or from about 100 mg/L to about 1000 mg/L.
Psychostimulant substances The enriched alcoholic food products described herein may further comprise supplements that promote or support increased level of a neurotransmitter such as, but not limited to, norepinephrine, serotonin, dopamine, endorphin, acetylcholine, GABA, glycine, glutamic acid, aspartic acid, and/or taurine.
The terms "psychostimulant supplement" and "psychostimulant substance", herein used interchangeably, refer to an edible substance that has a direct or indirect effect in increasing the levels of one or more neurotransmitters in the body, particularly in the brain, or in maintaining elevated neurotransmitter levels brought about, for example, by in situ conversion of a neurotransmitter precursor into a neurotransmitter, and/or by consuming alcohol. A psychostimulant substance may be directly or indirectly involved in enhancement of neurotransmitter synthesis and/or neurotransmitter stability, or upregulation of a neurotransmitter, for example, by upregulating enzymes that synthesize the neurotransmitter or protect the neurotransmitter from metabolic degradation. A
psychostimulant substance may, additionally or alternatively, be directly or indirectly involved in inhibition of neurotransmitter reuptake and/or neurotransmitter degradation, for example, by inhibiting or down regulating a neurotransmitter metabolic enzyme.
RECTIFIED SHEET (RULE 91) Psychostimulant substances may further foods which supply building blocks for production of a neurotransmitter or a precursor thereof.
In some embodiments, a psychostimulant substance increases metabolism rate in the body, thereby increasing metabolic conversion of a neurotransmitter precursor into a neurotransmitter.
In some embodiments, a psychostimulant substance inhibits or blocks metabolic enzymes that degrade a neurotransmitter precursor in the blood stream or in the digestive system.
Non-limiting examples of psychostimulant substances include caffeine, omega-3, fatty acids such as docosahexaenoic acid (DHA), magnesium, soluble fibers, folate, olive oil or monounsaturated fats extracted therefrom, green tea or theanine extracted therefrom, pregnenolone and any derivative thereof, uridine, iron, spices such as turmeric or curcumin extracted therefrom, Rhodiola rosea or an extract thereof, oregano or an extract thereof, co-factors, vitamins such as vitamin C and vitamin B6, minerals and the like.
Caffeine is the most widely consumed psychostimulant substance. It is known to highly effects the metabolism within the central nervous system via the blockade of adenosine receptors, which modulate the neurotransmission of glutamate, serotonin, acetylcholine and dopamine. Caffeine itself has a wide variety of effects on the dopaminergic system, which is crucial for the expression of caffeine's stimulating properties. Furthermore, caffeine promotes tyrosine hydroxylase activation via cellular Ca2+ entry stimulation mechanism, and it has been shown that chronic caffeine intake increases tyrosine hydroxylase mRNA expression. As tyrosine hydroxylase is the rate-limiting enzyme in the biosynthesis of DA and other catecholamines, caffeine may accelerates DA synthesis through upregulation of this enzyme. Caffeine may provide an energy boost just like sugar and alcohol. However, caffeine alone indirectly promotes DA
level elevation only temporarily.
Without being limited by theory, it is assumed that providing caffeine and alcohol together with a supply of DA precursors such as tyrosine, phenylalanine and/or any other DA precursor, may enable enhanced and continued conversion of immediate metabolic DA
precursors to DA, thus affording stable elevated levels of DA in the brain for a prolonged time, hence a prolonged duration of desired psychotropic and/or psychoactive effects such as euphoric and bliss feelings, high motivation and energy, that would last long after consumption of alcohol ceased.
In an enrich alcoholic food product, for example, a liquid product, the amount of caffeine may range from about 0 mg to about 2 gr per 1 liter of beverage. For example, from about 5 mg/L to about 10 mg/L, from about 10 mg/L to about 20 mg/L, from about mg/L to about 50 mg/L, from about 50 mg/L to about 80 mg/L, from about 60 mg/L
to about 100 mg/L, from about 200 mg/L to about 300 mg/L g, from about 200 mg/L
to about 400 mg/L, from about 300 mg/L to about 500 mg/L, from about 500 mg/L to about mg/L, from about 600 mg/L to 900 mg/L, from about 700 mg/L to 750 mg/L, from about 800 mg/L to about 1000 mg/L, from about 800 mg/L to about 1200 mg/L, from about 900 mg/L to about 1200 mg/L, from about 1100 mg/L to about 1400 mg/L, from about mg/L to about 1500 mg/L, from about 1500 mg/L to about 1700 mg/L, from about mg/L to about 2000 mg/L, or from about 1700 mg/L to about 2000 mg/L.
In certain embodiments, liquid alcoholic food products described herein contain from about 10 mg/L to about 1200 mg/L, for example, about 35 mg/L about 50 mg/L, about 100 mg/L or 350 mg/L of caffeine.
In exemplary embodiment an enriched beer is provided comprising a DA precursor such as tyrosine and a psychostimulant substance such as caffeine.
A contemplated enriched beer, for example, can contain Tyr and about 0.75 mg/ml caffeine and yet maintain the original taste, aroma, palatability and gas content of a beer with no hint for caffeine's dominant bitter taste.
Enriched beers as well as other enriched alcoholic beverages provided herein, provide the exact combination of alcohol, DA precursor such as tyrosine and psychostimulant substance such as caffeine, that affords an optimal rate of brain dopamine level increase, as well as optimal, stable DA level that provide to the consumer intensified, long lasting pleasure and a pleasant drinking experience, while circumventing the "down"
feeling often associated with alcohol consumption.
Certain minerals and B-vitamins, especially zinc, vitamin B6, and folate, are necessary for dopamine synthesis and neurotransmission. These nutrients are often depleted in individuals due to medications, inadequate diets, excessive stress, and toxic environmental exposures, compromising the ability to properly synthesize RECTIFIED SHEET (RULE 91) neurotransmitters like dopamine. Dopamine is easily oxidized, thus antioxidants such as vitamins C and E may assist in maintaining desired levels of DA.
Magnesium deficiency can cause decreased levels of dopamine, which might lead to depression.
Pregnenolone is the main steroid produced from cholesterol mainly in the brain, gonads and adrenal glands. Pregnenolone and its sulfate (pregnenolone sulfate) are excitatory neurosteroids, i.e., they stimulate the brain, and can increase DA.
Pregnenolone and/or its derivatives have anti-stress and mood-elevating effect, they enhance learning and memory and increase the amount of deep sleep, improve energy, vision, clarity of thinking, wellbeing, and often sexual enjoyment or libido.
The amount of pregnenolone and derivatives thereof, particularly pregnenolone sulfate, in, e.g., a liquid alcoholic product described herein is in the range of from about 0 mg to 3.0 mg per liter, for example 0.1-0.5 mg/L, or about 1 mg/L.
Curcumin is known to be the most active phytochemical in yellow dietary spice turmeric. Curcumin has been proven to have anti-oxidant, anti-inflammatory, anti-microbial, hypoglycemic, anti-rheumatic, wound healing and anti-cancer activities.
Curcumin further possesses antidepressant properties by way of interacting with dopamine receptors and increasing brain dopamine levels. For example, curcumin increases DA
concentration in the brain by inhibiting monoamine oxidase (MAO)-mediated DA
break down. Curcumin may be taken daily in large amounts, even up to 8 gr/day.
The amount of curcumin in, e.g., liquid alcoholic product described herein is in the range of from about 0.1 mg/ml to 2.0 g/ml, for example about 0.2-0.5 g/ml.
L-theanine is an amino acid uniquely found in green tea that creates an alert state of relaxation without drowsiness. L-theanine is known to be able to cross the blood-brain barrier and increase dopamine levels in the brain. As such, it may have anti-depressant and anti-anxiety effects, it may reduce mental and physical stress, and lead to improvements in learning and memory in humans and animals. Even just a single, small dose of L-theanine (100 mg) significantly improves the ability to pay attention and maintain focus.
The amount L-theanine e.g., in a liquid alcoholic product in accordance with some embodiments, is in the range of from about 0 mg to about 2000 mg per 1 liter of beverage, for example, from about 10 mg/L to about 30 mg/L, 20 mg/L to about 50 mg/L, 50 mg/L
RECTIFIED SHEET (RULE 91) to about 100 mg/L, 80 mg/L to about 150 mg/L, 100 mg/L to about 150 mg/L, 150 mg/L
to about 200 mg/L, 150 mg/L to about 400 mg/L, 300 mg/L to about 500 mg/L, 550 mg/L
to about 750 mg/L, 500 mg/L to about 1000 mg/L, 700 mg/L to about 1200 mg/L, mg/L to about 1250 mg/L, 1200 mg/L to about 1500 mg/L, 1550 mg/L to about 1850 mg/L, or 1700 mg/L to about 1000 mg/L.
In certain embodiments, enriched alcoholic beverages described herein contain mg/L, 1200 mg/L or 1800 mg/L of L-theanine.
Rhodiola rosea, or "golden root," is a popular plant in traditional medicine in Eastern Europe and Asia, with a reputation for improving depression, enhancing work performance, eliminating fatigue and treating symptoms resulting from intense physical and psychological stress. Rhodiola exerts its benefits via multiple effects on the central nervous system, including enhancing the stability of dopamine and supporting its reuptake.
This leads to notable decreases in depression, anxiety, and fatigue, as well as an increased ability to handle stress.
Rhodiola extract derived from Rhodiola rosea root and standardized to contain 3%
total rosavins and a minimum 1% salidrosides may be included in, e.g., enriched liquid alcoholic product described herein in amounts which range from about 300 mg to about 2000 mg per liter, for example, 510 mg/L, 800 mg/L or 1100 mg/L.
Other psychostimulant substances contemplated herein include, for example, nutritional or brewer's yeasts which is rich in uridine-5w-monophosphate that may increase DA levels in the brain; oregano, which increases DA levels by decreasing DA
break down and reuptake; and resistant starch, a type of soluble fiber that increases butyrate, which may increase dopamine levels.
In some embodiment, a disclosed enriched alcoholic food product comprises one or more psychostimulant substances that directly or indirectly affect DA brain level, for example, caffeine, theanine, curcumin, uridine, pregnenolone, and/or oregano.
The amounts of psychostimulant substance provided to the enrich alcoholic products described herein vary and depend on the psychostimulant substance itself as well an on the other ingredients provided to the enriched alcoholic product, particularly to the amount of alcohol, the amount and type of DA precursor(s), the presence of other neurotransmitter or precursors thereof, and/or the amount and type of other supplements that may cross react or enhance the effect of a particular psychostimulant substance. Excess dopamine is dangerous and needs to be avoided, and a skilled person would appreciate that the amount and number of psychostimulant substances provided to the alcoholic beverages are to be adjusted so as to avoid secretion, production and/or otherwise promotion of excess DA.
The amount of one or more psychostimulant substances in a contemplated enriched alcoholic food product may be in a range of from 0 to about 10% by weight. For example, from about 0.01% to about 1.00%, from about 0.01% to about 1.00%, from about 0.05%
to about 1.00%, from about 0.1% to about 0.3%, from about 0.2% to about 0.5%, from about 0.5% to about 1.0%, from about 1.0% to about 3.0%, from about 1.0% to about 5.0%, from about 5.0% to about 10.0%, from about 8% to about 10.0%, by weight or by volume of total enriched alcoholic product, and any sub-ranges and/or individual values therebetween.
The amount of psychostimulant substances in a contemplated product are adjusted such that the original texture, smell and palatability of the product is maintained.
Alcoholic beverages In an aspect of the disclosure, there is provided an enriched alcoholic beverage comprising a base liquid, alcohol, one or more neurotransmitter and/or one or more neurotransmitter precursors as defined herein.
In some embodiments, a contemplated enriched alcoholic beverage optionally further comprises one or more psychostimulant substances as defined herein.
In some embodiments, provided herein is enriched alcoholic beverage comprising a base liquid, alcohol, dopamine and/or at least one dopamine precursor and, optionally, one or more psychostimulant substances as described herein, for example, caffeine.
Herein throughout, the term "base liquid" describes a liquid form of a substance or a mixture of substances which either alone or when mixed with other additives can form a beverage. In some embodiments, the base liquid is a base beverage.
In some embodiments, the base beverage is an alcohol-free base beverage.
The phrase "alcohol-free base beverage", as used herein, is a beverage having alcohol percentage that is no more than 50% of the alcohol content in a corresponding alcoholic beverage, preferably no more than 40%, no more than 30%, no more than 20%, no more than 15%, no more than 10%, no more than 5%, no more than 1%, no more than 0.5%, no more than 0.1%, no more than 0.05%, or no more than 0.01%, of the alcohol content acceptable for a certain beverage, including any subranges and any intermediate values there between. This phrase is used herein as encompassing both base beverages that are typically used for forming alcoholic beverages, and base beverages which are typically used as non-alcoholic beverages, for example, juices.
In some embodiments, the alcohol-free base beverage is devoid of alcohol.
By "devoid of alcohol" is meant herein less than 0.01% or less than 0.005%, or less than 0.001%, of alcohol by volumes, or even null.
Exemplary alcohol-free base beverages which form the liquid base for the enriched alcoholic beverages described herein include, but are not limited to, natural or artificially flavored fruit juice (such as grape, mango, elder, apple, orange juice, and the like), vegetable juice, fruit syrup, concentrate or nectar from fruits, plant materials such as agave, jello, carbonated beverages such as cola, optionally with addition of roasted malt beer, caffeinated beverages, specialized flavor formulations emulating the taste of existing wines and spirits, non-alcoholic cocktails ("mocktails"), malt beer, dealcoholized ciders, dealcoholized wines, dealcoholized beers, dealcoholized spirits, tonic water and water.
When the liquid base comprises alcohol, it is termed herein a "base alcoholic liquid". In some embodiments, the base alcoholic liquid is an alcoholic beverage. The term "alcoholic beverage" as used herein encompasses any beverage having an alcohol (ethanol) content of at least 2% by volume, whether distilled, fortified, brewed, or produced by fermentation, and includes, but is not limited to, wine, beer, fermented liquids derived in whole or in part from fruit juices, such as cider and perry (pear cider), spirits, flavored alcoholic beverages collectively termed herein and in the art as "alcopops", and the like.
In some embodiments, the base alcoholic liquid is an alcoholic beverage substitute that has residual alcohol content of 0-20% by volume, depending on the alcoholic beverage being substituted.
Embodiments described herein provide an enriched alcoholic beverage comprising a base alcoholic liquid, one or more neurotransmitter and/or one or more neurotransmitter precursors as defined herein.
In some embodiments, a contemplated enriched alcoholic beverage optionally further comprises one or more psychostimulant substances as defined herein.
In some embodiments, provided herein is enriched alcoholic beverage comprising a base alcoholic liquid, dopamine and/or at least one dopamine precursor as described herein and, optionally, one or more psychostimulant substances as described herein.
Any combination of the base liquid, base alcohol-free liquid and base alcoholic liquid as described herein is contemplated for the enriched alcoholic beverages described herein.
The contemplated enriched alcoholic beverages provided herein provide the drinker with the palatability effect of common alcoholic beverages, and further provide the drinker with a sustained euphoric feeling, pleasure and overall sensation of wellbeing and vitality which far exceed the effects provided by corresponding alcoholic beverages which do not contain these enriching supplements and additives. Moreover, unlike common alcoholic beverages, the enriched alcoholic beverages provided herein provide a substantial relief of the adverse effects associated with alcohol consumption, particularly the "down" feeling or depression associated with intoxication and sobering up.
A unique and surprising feature of the enriched alcoholic beverage provided herein is that they provide the drinker with intensified and prolonged pleasurable, joyful, and euphoric feelings accompanied with a boost of energy and motivation, while affording a substantial reduction in drunkenness symptoms.
Contemplated enriched alcoholic beverages provide substantial reduction of intoxication effects, namely, they substantially minimize intoxication effects. For example, these beverages reduce intoxication by 10-95%, or minimize intoxication effects to at least 5% of the effect associated with consuming a corresponding non-enriched alcoholic beverage having the same alcohol content.
In some embodiments, intoxication and/or other negative physical and emotional feelings accompanying sobering up may be relieved, eased or alleviated by about 0 to 100%. For example, alleviation of undesired effects exerted by a contemplated enriched alcoholic beverage may be up to 10%, up to 20%, up to 30%, up to 40 %, up to 50%, up to 60% up to 70%, up to 80%, up to 90%, up to 95%, or up to 100% as compared to a corresponding non-enriched alcoholic beverage. The extent of intoxication relief or moderation changes form one person to another and depends on a collective of variable such as the person's tolerance to alcohol, the amount of alcohol in the beverage or the amount of beverage consumed. In some embodiments, the drinker does not experience any insobriety at all even though relatively high amount of alcohol is consumed, for example, at least 1 liter of enriched beer or at least 3 glasses of enriched wine.
Any combination of neurotransmitter precursors and psychostimulant substances as described herein is contemplated herein.
Because the enriched alcoholic beverage of the present disclosure affords palatability and psychotropic effect which outgo the effects of a corresponding non-enriched alcoholic beverages, these enriched beverages may be provided with reduced amounts of alcohol as compared to the corresponding non-enriched alcoholic beverages.
For example, the alcohol amount in a contemplated enriched alcoholic beverages may be about 100%, about 95%, about 90%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 20%, about 15%, about 10%, about 5%, about 3%, about 1% or about 0.5%, of the amount of alcohol in a corresponding non-enriched alcoholic beverage.
In some embodiments, the enriched alcoholic beverage is selected from enriched beer, wine, cider, spirit and/or enriched alcopop beverage. In some embodiments, these enriched alcoholic beverages comprise one or more neurotransmitter precursors.
In exemplary embodiments, the neurotransmitter precursor is a precursor of dopamine, for example, L-tyrosine.
The term "beer" as used herein and in the art means an alcoholic beverage obtained by malting and fermenting one or more of the cereal grains, and includes ale, stout, porter and lager. Typical alcoholic beer beverages include an alcoholic content of 3-8%. Some high-alcohol content beers comprise 8-12% alcohol, for example 10% alcohol.
In some embodiments, the beer is a "reduced alcohol beer", namely a beer as defined herein comprising up to 3.5% alcohol, for example, up to 3.0%, up to 2.2%, up to 2.0%, up to 1.5%, up to 1.0%, up to 0.5%, up to 0.3%, up to 0.1%, up to 0.05%, up to 0.01%, alcohol, or the beer may be devoid of alcohol.
Non-limiting examples of enriched beers provided in embodiments described herein include:
(i) Ale. A type of beer brewed using a warm fermentation method, resulting in a sweet, full-bodied and fruity taste. As with most beers, ale typically can have a bittering agent to balance the sweetness of the malt and act as a preservative. Ale is usually bittered with hops, the dried, cone-shaped flowers of the Mulberry plant used in the beer-brewing process to give a beer a bitter taste. Ale is typically fermented at temperatures between 15 and 24 C (60 and 75 F). At temperatures above 24 C (75 F) the yeasts can produce significant amounts of esters and other secondary flavour and aroma products, and the result is often a beer with slightly "fruity" compounds resembling those found in fruits such as apple, pear, pineapple, banana, plum, cherry, or prune.
Contemplated enriched Ale beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) Brown Ale, a lightly hopped beer, fairly mildly flavoured, often with a nutty taste. Brown ales range from dark brown beers containing around 3-3.5% alcohol and quite sweet, to red-brown containing 4.5-5% alcohol, and drier beers; (b) Pale Ale, also known as "Bitter Ale", a beer made from malt dried with coke; (c) India Pale Ale (IPA), a Pale Ale containing extra hops, a beer appreciated for its light and refreshing character; (d) Golden Ale, similar to pale ale but paler, having from 3.5% to 5.3% alcohol; (e) Scotch Ale, a malty, strong ale, amber-to-dark red in color.
The malt may be slightly caramelized to impart toffee notes; (f) Barley wine, range from
10% to 12%
alcohol, optionally stored for long periods of time, e.g., about 18 to 24 months. Barley wine may taste like massive sweet malt and ripe fruit of pear, orange and lemon, or like darker fruits, chocolate and coffee if darker malts are used; (g) Mild Ale, or unaged ale, having dark brown color and low strength, typically between 3.0 and 3.5% alcohol; (h) Burton Ale, a strong, dark, somewhat sweet ale; (i) Old ale, a malty, medium-strong dark beer (generally above 5% alcohol), may be treated to resemble the traditional English old ales;
(j) Belgian Ale, ale high in alcoholic content but relatively light in body due to the substitution of part of the grist for sucrose, which provides an alcohol boost without adding unfermentable material to the finished product. This process often makes a beer more digestible; and (k) Cask Ale, or cask-conditioned beer, an unfiltered and unpasteurized beer, which is conditioned (including secondary fermentation) and is served from a cask without additional nitrogen or carbon dioxide pressure;
(ii) Porter or Stout. Porter is a dark style of beer made from brown (roasted) malt or roasted barley, hops, water and yeast;
(iii) Lager. Lager (from German: storeroom or warehouse) a beer that is conditioned at low temperatures. It may be pale, golden, amber, or dark.
Lager beer uses a process of cool fermentation, followed by maturation in cold storage.
Specific yeast (Saccharomyces pastorianus) is used for brewing Lager.
Contemplated enriched lager beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) Pale Lager, such as any one of the common lager beers in worldwide production, for example, Pilsner beer. The flavor of these lighter lagers is usually mild, and it is preferably served refrigerated. Pale lager is a very pale to golden-colored lager with a well attenuated body and noble hop bitterness; (b) Vienna Lager, a reddish-brown or copper-colored beer with medium body and slight malt sweetness. The malt aroma and flavor may have a toasted character; (c) Dark lager, typically ranging in color from amber to dark reddish brown and even black such as a Schwarzbier having a chocolate or liquorice-like flavour similar to stout. Alcohol concentrations of 4.5% to 6% by volume; and (d) Bock, a sweet, relatively strong (6.3%-7.2% alcohol by volume) lager. This beer is clear, ranging in color from light copper to brown, with a bountiful and persistent off-white head.
(iv) Wheat beer. Wheat beer is a beer, usually top-fermented, which is brewed with a large proportion of wheat relative to the amount of malted barley.
Contemplated enriched wheat beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) a German style beer such as WeiBbier (German ¨
"white beer"), based on the German tradition of mixing at least 50% wheat to barley malt to make a light colored top-fermenting beer; and (b) a Belgian style beer such as Witbier, based on the Belgian tradition of using flavorings such as coriander and orange peel.
Belgian style white beers are often made with raw unmalted wheat, as opposed to the malted wheat used in other varieties.
In some embodiments, an enriched beer is provided, comprising one or more dopamine precursors and, optionally, one or more psychostimulant substances as described herein in an amount that imparts to the beer palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched and/or any known beer containing 3.8-10% alcohol by volume.
In certain embodiments, the enriched beer provided herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched beer containing 3.8-10% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched beer described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 mg/ml to about 0.20 mg/ml, from about 0.10 mg/ml to about 0.30 mg/ml, from about 0.25 mg/ml to about 0.45 mg/ml, from about 0.30 mg/ml to about 0.50 mg/ml, from about 0.30 mg/ml to about 0.60 mg/ml, from about 0.45 mg/ml to about 0.65 mg/ml, from about 0.50 mg/ml to about 0.70 mg/ml, from about 0.50 mg/ml to about 0.80 mg/ml, from about 0.60 mg/ml to about 0.90 mg/ml, from about 0.80 mg/ml to about 1.00 mg/ml, from about 0.90 mg/ml to about 1.10 mg/ml, from about 0.95 mg/ml to about 1.25 mg/ml, from about 1.00 mg/ml to about 1.30 mg/ml, from about 1.20 mg/ml to about 1.50 mg/ml, from about 1.45 mg/ml to about 1.75 mg/ml, from about 1.75 mg/ml to about 2.10 mg/ml, from about 2.00 mg/ml to about 2.50 mg/ml, from about 2.45 mg/ml to about 3.00 mg/ml, from about 2.50 mg/ml to about 3.50 mg/ml, from about 3.00 mg/ml to about 4.00 mg/ml, from about 3.75 mg/ml to about 4.50 mg/ml, or from about 4.35 mg/ml to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiment, the enriched beer provided herein comprises from about 0.1 mg/ml to about 0.45 mg/ml of tyrosine.
When the enriched beer described herein comprises a psychostimulant substance, the amount of the psychostimulant substance, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 mg/ml to 0.05 mg/ml, 0.05 mg/ml to 0.08 mg/ml, 0.05 to 0.09 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, 1.50 to 2.00 mg/ml, 2.00 to 3.00 mg/ml, 3.00 to 5.00 mg/ml, 3.50 to 5.00 mg/ml, 4.50 to 6.00 mg/ml, or 6.00 to 9.00 mg/ml, including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched beer herein comprises from about 0.01 mg/ml to about 0.9 mg/ml (or 10 mg/L to about 900 mg/L) of caffeine.
In an exemplary embodiment, an enriched beer is provided, comprising a lager beer, about 0.1 mg/ml to about 0.6 mg/ml of tyrosine and about 0.01 mg/ml to about 0.75 mg/ml caffeine.
In some embodiments, the base liquid of the enriched alcoholic beverages described herein is wine. The wine may have an alcohol content of 10-14%. The term "wine" as used herein and in the art includes the fermented juice of grapes, made in many varieties, such as red, white, sweet, dry, still, and sparkling. Exemplary wine beverages include, but are not limited to, dry red or white wine; semi-dray red or white wine; rosé wine;
dessert wine such as Muscato wine; fruit wine; fortified wine such as Marsala, Port, Madeira, Sherry, vinsanto, and vermouth; sparkling wine such as Champagne, sangria, table wine.
In some embodiments, the wine is a "reduced alcohol wine", namely a wine as defined herein comprising up to 8% alcohol, for example, up to 7%, up to 6%, up to 5%, up to 4.5%, up to 4%, up to 3.5%, up to 3%, up to 1%, up to 0.5%, up to 0.1%, up to 0.05%, or the wine may be devoid of alcohol.
In some embodiments, an enriched wine is contemplated, comprising a dopamine precursor and, optionally, a psychostimulant substance as described herein in an amount that imparts to the wine palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as defined herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched or any known wine containing 10-14%
alcohol by volume.
In certain embodiments, the enriched wine contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched wine containing 7.5-14% alcohol by volume, while substantially minimizing intoxication effects.
In a contemplated enriched wine, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.50 mg/ml, from about 1.50 to about 1.80 mg/ml, from about 1.55 to about 1.95 mg/ml, from about 1.70 to about 2.00 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched wine contemplated herein comprises from about 0.1 mg/ml to about 1.80 mg/ml of tyrosine.
When the enriched wine described herein comprises a dopamine supplement, the amount of dopamine supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, or 1.50 to 2.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched wine contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
The term "spirit" as used herein and in the art refers to a distilled alcohol beverage obtained, for example, by distilling starchy material, and includes, but not limited to, variety of raw grain alcohols, brandies, liquors, saki, Ouzo, arrack, rum, vodka, tequila, schnapps, whiskey, gin, cordial, Cachaca, absinthe, baijiu, eau de vie, soju, aguardiente, palinka, fernet and slivovitz.
In some embodiments, the spirit is a "reduced alcohol spirit", namely a spirit as defined herein comprising up to 80% alcohol, for example, up to 60%, up to 50%, up to 45%, up to 40%, up to 35%, up to 30%, up to 25%, up to 20%, up to 15%, up to 10%, up to 8%, up to 7%, up to 6%, up to 5%, up to 4%, up to 3.5%, up to 3%, up to 2%, up to 1%, up to 0. 5%, or the spirit may be devoid of alcohol.
In some embodiments, an enriched spirit is contemplated, comprising one or more dopamine precursors and, optionally, one or more psychostimulant supplements as described herein in an amount that imparts to the spirit palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by any known corresponding non-enriched spirit containing 50-98% alcohol by volume.
In certain embodiments, the enriched spirit contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched spirit containing 50-98% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched spirit described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.50 mg/ml, from about 1.50 to about 1.80 mg/ml, from about 1.55 to about 1.95 mg/ml, from about 1.70 to about 2.00 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched spirit contemplated herein comprises from about 0.1 mg/ml to about 2.5 mg/ml of tyrosine.
When the enriched spirit described herein comprises a psychostimulant supplement, the amount of psychostimulant supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml 0.10 to 0.17 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.23 to 0.35 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.70 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, 1.50 to 2.00 mg/ml, 1.60 to 2.30 mg/ml, or 2.30 to 2.60 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched spirit contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
Other known alcoholic beverages which can be made enriched alcoholic beverages in accordance with embodiments described herein, include, but are not limited to, Desi daru, made by fermenting molasses or high sugar containing fruits; Huangjiu (Chinese, made from rice, millet, or wheat using a special starter culture of yeast, mold, and bacteria);
Icariine Liquor; Kasiri (made from cassava); Kilju (Finnish, made from sugar);
Kumis (central asia, traditionally made from horse milk but now primarily cow milk);
Mead (made from honey); Nihamanchi (South America) a.k.a. nijimanche (Ecuador and Peru) (made from cassava); Palm wine (made from the sap of various palm trees); Parakari (made from cassava); Pulque (originally made by the natives of Mexico, made from the sap of the maguey plant); Sakura (made from cassava); Sake (made from rice);
Sonti;
Tepache; Tiswin (made from corn or saguaro, a large cactus); and Tonto.
Herein throughout, whenever a percentage (%) is indicated, volume % of the total volume of the beverage is meant, unless otherwise indicated.
Alcopop beverages, also termed herein and in the art "coolers" or "spirit coolers", are flavored alcoholic beverages or flavored malt beverages based on fruit juice or nectar, and/or a variety of naturally and/or artificially flavored syrups. Exemplary alcopop beverages include, but are not limited to (i) a malt beverage, designate herein "a beer cooler", containing a malt base or beer and at least 5% by volume of added natural or artificial blending material, such as fruit juice, flavors, flavorings, colorings, and, optionally, preservatives; (ii) a wine cooler which is a beverage containing wine and more than 15% by volume of added natural or artificial blending material, such as fruit juices, flavors, flavorings, adjuncts, water (plain, carbonated, or sparkling), colorings, and, optionally, preservatives; and (iii) a beverage designated herein "a spirit cooler", containing distilled alcohol, and added natural or artificial blending material, such as fruit juices, flavors, flavorings, colorings, and, optionally, preservatives.
Alcopop brands are numerous and their alcoholic base vary greatly. Most alcopop beverages contain 3.8-7% alcohol by volume, and some may even contain as much as 12.5% alcohol by volume. Some notable brands include, but are not limited to, Smirnoff Ice, Mike's Hard Lemonade, Bacardi Breezer, Skyy Blue, Jack Daniel's Hard Cola, WKD
Original Vodka, Six Degrees and MG Spirits.
In some embodiments, an enriched cider and/or enriched alcopop beverage is contemplated, comprising one or more dopamine precursors and, optionally, one or more psychostimulant supplements as described herein in an amount that imparts to the beer palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched or any known alcopop or cider containing 3.8-10% alcohol by volume.
In certain embodiments, the enriched alcopop or enriched cider contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched alcopop or non-enriched cider containing 3.8-10% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched alcopop described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 mg/ml to about 0.20 mg/ml, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.45 to about 0.70 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.30 mg/ml, from about 1.20 to about 1.50 mg/ml, from about 1.55 to about 1.75 mg/ml, from about 1.75 to about 2.10 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched alcopop contemplated herein comprises from about 0.1 mg/ml to about 0.45 mg/ml of tyrosine.
When the enriched alcopop described herein comprises a psychostimulant supplement, the amount of psychostimulant supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, or 1.50 to 2.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched alcopop contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
Herein throughout, whenever a percentage (%) is indicated, % volume of the total volume (% v/v) of the beverage is meant, unless otherwise indicated.
In some of any one of the embodiments of the present invention, optionally or additionally, the base material of the enriched alcoholic food product, for example, base liquid or base alcoholic liquid, is formulated to include additives, such as flavoring agents, colorants, odoriferous agents, enzymes, CO2 and/or other additives such as viscosity modifying agents, foaming agents, antifoaming agents, and preservatives that account for the taste and texture of e.g., wine or beer or spirit, such that the enriched alcoholic product will contain at least part or all the ingredients used to form the corresponding non-enriched alcoholic product. Preferably, additives used in the enriched alcohol products described herein are FDA-approved, and/or edible. In some embodiments, the additives are selected as soluble in the base material, e.g. base alcoholic beverage or base liquid.
The phrases "flavoring agent" and "odoriferous agent", as used herein, describe a class of substances which are added to edible products in order to induce a certain flavor or smell in the product, respectively, and are commonly referred to also as "flavorants".
Flavorants, also termed herein "taste-improving additives", can be synthetic or natural extracts, which are extracted from a source substance. Typical flavorants are specific and often complex mixtures of singular naturally occurring or synthetic flavor compounds combined together to either imitate or enhance a natural flavor. Many flavorants are esters, which can be characterized by a typical flavor, such as diacetyl which gives a buttery flavor, isoamyl acetate that is perceived as banana, cinnamic aldehyde which is the basis for the typical flavor of cinnamon, ethyl propionate is perceived as fruity, limonene is perceived as orange, ethyl-(E, Z)-2,4-decadienoate is perceived as pear, allyl hexanoate is perceived as pineapple, ethyl maltol, is perceived as sugar or cotton candy, methyl salicylate is known as the wintergreen flavor, and benzaldehyde is perceived as bitter almond. Further synthetic flavorant are exemplified by amaretto, cola and ice cream flavors Flavoring agent of a natural source can be, for example, an extract of a fruit, a vegetable, a herb or of any other edible substance, a fruit juice or a vegetable juice, or any combination thereof. Non-limiting examples of fruit flavorants include elder, grape, orange, ginger, red apple, anise, or lemon grass. These additives are added in addition to or instead of those found in the alcoholic beverage, if indeed present therein.
The term "colorant", as used herein, refers to any natural or synthetic coloring substance, and describes any substance that is added to food or drink in order to alter its color. Exemplary usable colorants include, but are not limited to, synthetic colorants such as FD&C Blue No. 1 - Brilliant Blue FCF (E133), FD&C Blue No. 2 ¨ Indigotine (E132), FD&C Green No. 3 - Fast Green FCF (E143), FD&C Red No. 40 - Allura Red AC
(E129), FD&C Red No. 3 ¨ erythrosine (E127), FD&C Yellow No. 5 ¨ tartrazine (E102), and FD&C Yellow No. 6 - Sunset Yellow FCF (E110), and natural food colorants such as carmine (E120), enocianin (E163), black carrot (E163), paprika (E160c), annatto (E160b), beta carotene (E160a), lutein (E161b), riboflavin (E101), curcumin (E100), copper chlorophyllin (E141), chlorophyll (E140), caramel (E150), and extracts of foodstuffs such as elderberry, aronia, grape, beetroot, carrot, turmeric (tumeric) root, spinach, stinging nettle and burnt sugar (caramelized sugar).
The term "preservative", as used herein, describes a synthetic or natural additive substance that is added to edible products in order to prevent or retard chemical and biochemical decomposition of the product by oxygen, moisture and/or microbes.
Exemplary anti-microbial preservatives include, but are not limited to, calcium propionate, sodium nitrate, sodium nitrite, sulfites (sulfur dioxide, sodium bisulfite, potassium hydrogen sulfite, etc.), disodium EDTA, sodium benzoate, potassium sorbate.
Natural substances that retard microorganisms growth include lactic acid, salt, sugar and vinegar.
Exemplary antioxidant preservatives include, but are not limited to, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Natural antioxidants include, but are not limited to, herbal extracts such as rosemary and oregano, and vitamins such as Vitamin E and Vitamin C (ascorbic acid).
The phrase "foaming agent", as used herein, describes an edible surfactant, which when present in small amounts, facilitates the formation of a foam, or enhances its colloidal stability by inhibiting the coalescence of bubbles. Exemplary foaming agents include, without limitation, sodium laureth/lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES) and ammonium lauryl sulfate (ALS).
The phrase "antifoaming agent", as used herein, describes an edible substance that inhibits the formation of foam and curbs effusion or effervescence in edible products. An exemplary antifoaming agent is polydimethylsiloxane.
The phrases "viscosity modifying agent" or "thickener" as used herein are interchangeable and describe agents that enable to control the viscosity of the enriched alcoholic products described herein. Exemplary thickeners include, but are not limited to, starch-based thickeners such as maltodextrin and gum-based thickeners such as xanthan or cellulose gum.
The enriched alcoholic products described herein may be contained in any of the known containers applied for alcoholic products in general. For example, when the enriched alcoholic product is a beverage, for example a beer, it may be contained and marketed in a 330 ml, 500 ml, 750 ml and 1-liter bottle or tin, or in a barrel. The stability of the enriched alcoholic product obtained according to any of the embodiments described herein is preferably more than 365 days at room temperature, and it may be stored for up to 999 days at 10 C.
In an aspect of some embodiments of the present invention there is provided a process for the preparation of an enriched alcoholic beverage. The process comprises mixing a base liquid as defined herein with an amount of one or more neurotransmitter precursors and/or one or more neurotransmitter precursors as described herein.
In some embodiments, the process further comprises the addition of one or more psychostimulant supplements as described herein. In some embodiments, the base liquid is an alcoholic beverage such as beer, wine, spirit, cider or alcopop.
In some embodiments, the base liquid is a non-alcoholic beverage (e.g, juice, water and the like), and one or more neurotransmitter precursors and/or one or more neurotransmitter precursors and, optionally one or more psychostimulant supplements may be added to the non-alcoholic base beverage together with a desired amount of alcohol.
In some embodiments, the enriched alcoholic beverage, for example beer, is prepared by brewing the beer together with neurotransmitter precursor(s) and the psychostimulant supplement(s). Likewise, wine and spirit may be fermented or distilled, respectively, in processes that are adjusted to includes steps of addition of neurotransmitter precursor(s) and psychostimulant supplement(s), as long as the fermentation, distillation or brewing processes maintain the neurotransmitter precursor(s) and the psychostimulant supplement(s) intact and bioavailable, and further provided that the palatability, texture and appearance of the beverage in not substantially affected by including neurotransmitter precursor(s) and/or the psychostimulant supplement(s) in the process of preparation thereof.
In exemplary embodiments, the process described herein is for the preparation of enriched beers comprising one or more dopamine precursors and, optionally further comprising one or more psychostimulant supplements in the amounts described herein.
In exemplar embodiments, in the process provided herein, tyrosine and caffeine are provided to a base alcoholic beer. In alternative embodiments, an enriched beer is brewed together with tyrosine and caffeine in the brewery.
It is to be understood that the invention as described and discussed in the foregoing and in following sections of the description is not necessarily limited in its application to the details set forth in the present description.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from"
a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "10 pm"
is intended to mean "about 10 pm".
The term "about" as used herein means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean a range of up to 10%, more preferably up to 5%, and still more preferably up to 1% of a given value.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".
The term "consisting of' means "including and limited to".
The term "consisting essentially of" means that the compositions, for example, enriched alcoholic beverages, may include additional ingredients but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed composition.
As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention.
Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Preparation of beer enriched with tyrosine and caffeine Beer enriched with tyrosine and caffeine was prepared using a protocol comprising the following steps:
(i) grinding barley;
(ii) immersing the grinded barley in water at a temperature of 50-75 C for about an hour;
(iii) adding caffeine;
(iv) transferring the mixture of grinded barley and caffeine to a boiler;
(v) adding hops to the mixture in the boiler, and boiling the mixture for about an hour;
(vi) transferring the boiling mass (herein referred to as the "must") into a fermentation tank via a heat exchanger apparatus that cools the must form 100 C to about 20 C;
(v) adding yeasts to the cooled must;
(vi) fermenting the must for a period of 14 to 16 days so as to obtain a beer;
(vii) transferring the fermented mass into a second tank (herein also termed "intermediate tank");
(viii) adding tyrosine and, optionally, glucose and to the fermented beer; and (ix) transferring the beer to bottles, cans or barrels and storing for a second fermentation for a period of 12-40 days at 18 C.
The enriched beer was unfiltered and contained 5.5% alcohol by volume, and 40 mg tyrosine and 35 mg caffeine, per 100 ml.
Beer enriched with tyrosine and caffeine A further recipe for brewing beer enriched with tyrosine and caffeine comprises the following steps:
(i) milling malted barley;
(ii) mashing: transferring milled malted barley into mash tun, adding water and heating to a temperature of from about 50 C to about 75 C for about 1 - 2 hour;
(iii) lautering: separating the wort (the malty liquid that was extracted during mashing) from the grains;
(iv) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(v) boiling the wort;
(vi) adding hops and boiling the mixture for about 45 - 90 minutes;
(vii) separating hopped wort from solid particles;
(viii) cooling the wort to fermentation temperature (about 4 ¨ 25 C) and aerating it;
(ix) adding brewer's yeasts and fermenting the wort for several weeks;
(x) conditioning/maturing: separating fermented beer from dead yeasts and other debris and transferring it into a conditioning tank for a period of several weeks to several months;
(xi) filtering the beer;
(xii) adding caffeine (from about 10 mg/L to about 700 mg/L);
(xiii) heating the beer to 70 C for pasteurization (elimination of harmful bacteria) and to fully dissolve added tyrosine and caffeine; and (xiv) packaging the enriched beer (i.e., bottling, canning and/or transferring to a barrel), and cooling for storage.
Akopop ("hard lemonade") enriched with tyrosine and caffeine Hard lemonade, an alcopop, enriched with tyrosine and caffeine is prepared according to the following steps:
(i) grinding mint leaves with brown sugar;
(ii) adding boiling water;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L), and stirring the tyrosine-containing mixture;
(iv) adding the following ingredients to the above mixture: water (at room temperature), a spirit with at least 40% alcohol (e.g., vodka), and freshly squeezed lemon juice with pulp, in a ratio mixture:water:vodka:lemon juice of about 1:5:4:2;
(v) adding caffeine (from about 10 mg/L to about 700 mg/L); and (vi) bottling and/or canning the enriched alcopop and cooling for storage.
White wine enriched with tyrosine and caffeine White wine enriched with tyrosine and caffeine is prepared according to the following steps:
(i) crushing, pressing and extracting the grape juice (wort) of white-flesh grapes (so as to separate it from skins, seeds and other solids);
(ii) clearing the wort to remove lees, for example, by settling or by other methods;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(iv) optionally, adding wine yeasts to the wort in addition to the existing natural yeasts;
(v) fermenting the wort in fermentation tanks for several weeks at a temperature of 12 ¨ 37 C;
(vi) eliminating fermentation, if desired.
(vii) clearing and refining: separating the fermented wine from dead yeasts and other debris, for example, by filtration or by other methods;
(viii) adding caffeine (from about 10 mg/L to about 700 mg/L; and (ix) bottling the enriched wine.
Red wine enriched with tyrosine and caffeine Red wine enriched with tyrosine and caffeine is prepared according to the following steps:
(i) destemming and crushing grapes to create a must (i.e., a mixture of grapes, skins, juice and seeds);
(ii) settling the must for pre-fermentation maceration at a temperature of about 10 C for a period of 1 to 4 days;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(iv) optionally, adding wine yeasts to the wort in addition to the existing natural yeasts;
(v) fermenting the must in fermentation tanks for several weeks at a temperature of 12 ¨ 37 C. During fermentation, the contact between skins and liquid phase can be maximized by a desired mixing method;
(vi) extracting the juice from the must by pressing and separating it from remaining solids;
(vii) allowing for malolactic fermentation;
(viii) racking: decanting off lees (dead yeasts and other solids) and providing sulfur dioxide preservative to avoid oxidation and bacterial spoilage;
(ix) aging/maturing the wine for a desired period;
(x) clearing and refining, for example, by filtration or by other methods;
(xi) adding caffeine (from about 10 mg/L to about 750 mg/L; and (xii) bottling the enriched wine.
Cider enriched with tyrosine and caffeine "Hard cider" enriched with tyrosine and caffeine is prepared according to the following steps:
(i) crushing and pressing apples to acquire must (apple juice) from pomace (mixture of solid remains of pressed apples, skins, juice and seeds);
cii) adding tyrosine to concentrations of 100 mg/L ¨ 5 gr/L;
(iii) optionally, adding cider yeasts to the must, in addition to existing natural yeasts;
(iv) fermenting the must in fermentation tanks for several weeks at a temperature of 4 ¨ 16 C;
(v) racking: siphoning the liquor into new vats, separating it from dead yeasts and undesirable materials;
(vi) aging/maturing the cider for a desired period;
(vii) adding caffeine to concentrations of 10 mg/L to about 750 mg/L; and (viii) packaging the enriched cider (i.e., bottling, canning and/or transferring to a barrel), and cooling for storage.
Single Malt whisky enriched with tyrosine and caffeine Single Malt whisky enriched with tyrosine and caffeine is prepared according to the following steps:
(i) milling malted barley;
(ii) mashing: transferring milled malted barley into mash tun, adding hot water in three stages and exceeding temperatures (beginning with approx. 60 C, then approx. 75 C and, finally, approx. 90 C). Wort (the malty liquid that is extracted during mashing) is transferred into a washback;
(iii) cooling the wort to fermentation temperature (about 4-25 C);
(iv) adding whisky yeasts;
(v) fermenting the cooled wort for up to several days to receive the "wash";
(vi) distilling the wash twice using stills: first using wash stills to obtain "low wine", and a second time using spirit stills to obtain the final "new-make" spirit (unaged whisky).
During the second distillation, the more volatile compounds which distil off first (foreshots), and the final stage where more oily compounds are vaporized, are both channeled off so that only the pure center cut is collected;
(vii) optionally, diluting the new-make prior to aging;
(viii) transferring new-make to wooden casks and aging for several years;
(ix) chill filtrating: precipitating and filtering to remove fatty acid esters;
(x) adding tyrosine (final concentration 100 mg/L ¨ 5 gr/L);
(xi) adding caffeine (final concentrations 10 mg/L to about 750 mg/L); and (xii) bottling the enriched whisky.
Vodka enriched with tyrosine and caffeine Vodka enriched with tyrosine and caffeine is prepared according to the following steps:
(i) mashing desired starchy ingredient (potatoes, milled grains, etc.), adding water and boiling;
(ii) cooling the mash to enzyme activity temperatures;
(iii) adding starch-breaking enzymes, such as amylase;
(iv) allowing enzyme activity to break down starch within mash to small sugars;
(v) adding vodka yeasts;
(vi) fermenting the starch-broken mash for several days in yeast-activity temperatures (about 4 ¨ 25 C) to obtain the "wash" (i.e., insipid beverage);
(vii) distilling the wash using standard methods to obtain raw spirit of ¨60%
alcohol by volume (ABV). Separating and discarding products of the first and last distillation stages (i.e., first 5% and final 35% of the whole distillation process);
(viii) rectifying the raw spirit to neutral spirit of ¨96% ABV;
(ix) preparing demineralized water solution containing tyrosine (80 - 585 mg/L) and caffeine (15-670 mg/L), heating to ¨80 C until homogenous, and then cooling to ambient temperature;
(x) adding the demineralized water solution to the neutral spirit to reduce ABV to ¨40%;
(xi) filtering the obtained enriched vodka using standard methods; and (xii) bottling the enriched vodka.
Coffee liqueur enriched with tyrosine and caffeine Coffee liqueur enriched with tyrosine and caffeine is prepared according to the following steps:
(i) combining 3 cups of sugar, 2 cups of water and a tablespoon of vanilla extract in a saucepan;
(ii) boiling and stiffing for approx. 30 minutes until volume is reduced by half;
(iii) adding 100 - 400 mg tyrosine and about 100 gr instant coffee, stiffing until homogenous and allowing the syrup mixture to cool;
(iv) combining the syrup with 750 ml 40% ABV vodka in a closed 1-liter bottle, and shaking well;
(v) optionally, adding up to 180 mg caffeine;
(vi) settling for 10 days in a cool, dark place;
(vii) Straining/filtering the enriched liqueur; and (viii) bottling the enriched liqueur.
Biphasic Alcohol Effects Scale (BAES) study The stimulant and sedative effects caused by consuming a beer enriched with a neurotransmitter precursor such as Tyr and, optionally, a psychostimulant substance such as caffeine, versus the stimulant and sedative effects exerted by a corresponding non-enriched beer was assessed in self-reporting participants using a Biphasic Alcohol Effects Scale (BAES)-based questionnaire. The BAES is a reliable and valid systematic 14-item self-report scale designed to measure stimulant and sedative effects of alcohol as separate and distinct constructs. BAES and a brief version thereof (B-BAES) comprising only 6 items are described, for example, in Rueger and King, 2013 (Alcohol Chn Exp Res. 37(3):
470-476; and references cited therein).
Seven items comprise the stimulant subscale of the BAES (elated, energized, excited, stimulated, talkative, up, vigorous), and another seven items comprise the sedative subscale (difficulty in concentrating, down, heavy head, inactive, sedated, slow thoughts, sluggish). The BAES test demonstrates strong psychometric properties, including high internal consistency, reliability and a four-factor structure reflecting the distinctness of the stimulant and sedative constructs during both the ascending and descending limbs of the breath alcohol concentration (BrAC) curve. With use of a conversion factor, called the blood:breath ratio (BBR), the blood alcohol concentration (BAC) can be estimated from BrAC. This four-factor structure is invariant to dose, drinking history, and sex, and demonstrates robustness to an instructional set that does not disclose the content of the alcoholic beverage (see, for example, Rueger et al., 2009, Alcohol Clin Exp Res. 33:916-924).
The BAES study of alcohol effects in accordance with the disclosed study had multiple assessments in one session. For example, the BAES questionnaire was administered before alcohol was consumed and then the assessment was repeated 3-4 more times after consumption to capture rising and declining BrAC limb effects.
In the BAES questionnaire exemplified herein, each participant was presented with 14 items in alphabetical order, 7 of which describe sensations (feelings, perception) associated with stimulant effects (elevated mood (high spirit), energy, excitement, stimulated, talkativeness, vigorous and vitality), and 7 items describing sensations (feelings, perception) associated with sedative effects (difficulty in concentrating, down feeling, heavy head, heavy body, sedative, slow thinking, sluggishness). Each participant had to assign, next to each of these 14 items, a number in the range from 0 to 10 indicating how closely or how well a certain item expresses, corresponds or describes his/her current feeling/sensation, where "0" indicates "not at all describing" or "irrelevant", and "10"
indicates "exactly (or very much) describing".
The numerical indications of the stimulant and sedative effects were averaged to obtain two numerical values designated STIM and SED, respectively.
Participants Healthy nonalcoholic 198 social drinkers participated in the study.
Participants were recruited from the wider community via advertising placed, for example, in web sites.
Each participant's eligibility was subject to the following criteria: (i) aged 18-60 years; (ii) no history of alcohol addiction; (iii) not taking medication having a stimulative or sedative action; (iv) moderate to low regular consumption of alcohol.
Participants were randomly supplied with either one of: (i) an alcoholic beverage, e.g., beer, enriched with tyrosine and caffeine; or (ii) a corresponding non-enriched alcoholic beverage. The study was double-blind, and the participants did not know whether they were supplied with alcoholic beverage (i) or (ii). The gender split was equal across both groups. All participants were requested to refrain from alcohol consumption at least 24 hours before the study.
Study design The study was a 2-sesssion (2 days) study, wherein the second session (day) was at least a week apart from the first session. Participants were either given an enriched (i.e., comprising Tyr and caffeine) or non-enriched beer having 5.2% alcohol.
In each session, participants first filled a BAES questionnaire to set up a baseline assessment, followed (about 5 minutes later) by the consumption of either enriched beer (i) or non-enriched beer (ii). For each participant, the amount of beer provided was calculated so as to reach blood alcohol level of 0.35 gr per kg body weight.
For example, for a participant weighting 75 kg, 26.25 gr of alcohol are required in order to reach the predetermined blood alcohol concentration, thus this participant was supplied with 504.8 ml beer having 5.2% alcohol.
The total amount of alcohol for a participant was divided into 5 equal portions, and the participant was requested to consume each portion within 2 minutes (overall, 10 min for consuming the whole amount of alcoholic beverage). Immediately after the last portion of beverage was fully consumed, time point zero (T=0) was set. Participant were requested to fill a BAES questionnaire at T= 30 min, T= 60 mm and at T=120 min.
Answers obtained from all BAES questionnaires were gathered, averaged (standard deviation was calculated) to obtain the STIM and SED values, and presented graphically.
The results are shown in Figures 1A-1B and 2A-2B, and presented in Tables 1 and 2.
Table 1. BAES study for non-enriched (regular) beer Regular (non-enriched) Beer STIM SD SED SD
Baseline 3.20 0.76 1.51 0.39 30 min 3.54 0.69 1.90 0.50 60 min 2.49 0.52 2.78 0.53 120 min 2.15 0.45 3.33 0.64 Table 2. BAES study for beer enriched with tyrosine and caffeine Enriched Beer STIM SD SED SD
Baseline 3.08 0.77 1.30 0.40 30 min 5.32 0.83 1.10 0.38 60 min 5.04 0.79 1.07 0.38 120 min 4.05 0.61 1.10 0.35 As seen in Table 1, and Figures 1A and 2A, 30 minutes after the regular (non-enriched beer) was consumed, participants experienced slight stimulant and sedative effects. Sixty minutes (T=60) and 120 minutes after consumption, the sedative effects increase while stimulant effects decreased even below baseline levels.
On the other hand, as seen in Table 2, and Figures 1B and 2B, 30 minutes after the enriched beer was consumed, significant elevation of stimulant effects was demonstrated, along with a slight rise in sedative effects. Sixty minutes (T=60) and 120 minutes after consumption of the enriched beer, the stimulant effects gradually regress or decrease, but they were still higher compared to consumption of non-enriched beer. No significant change was seen in the sedative effects, namely, they remained low even after 120 min.
It is shown herein that the beer enriched with Tyr and caffeine significantly strengthens and prolongs the stimulant and mood elevating effects associated with alcohol consumption as compared to a corresponding non-enriched beer, while significantly reducing, nearly nulling, the sedative effects, and for much longer time compared to non-enriched beer.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
alcohol, optionally stored for long periods of time, e.g., about 18 to 24 months. Barley wine may taste like massive sweet malt and ripe fruit of pear, orange and lemon, or like darker fruits, chocolate and coffee if darker malts are used; (g) Mild Ale, or unaged ale, having dark brown color and low strength, typically between 3.0 and 3.5% alcohol; (h) Burton Ale, a strong, dark, somewhat sweet ale; (i) Old ale, a malty, medium-strong dark beer (generally above 5% alcohol), may be treated to resemble the traditional English old ales;
(j) Belgian Ale, ale high in alcoholic content but relatively light in body due to the substitution of part of the grist for sucrose, which provides an alcohol boost without adding unfermentable material to the finished product. This process often makes a beer more digestible; and (k) Cask Ale, or cask-conditioned beer, an unfiltered and unpasteurized beer, which is conditioned (including secondary fermentation) and is served from a cask without additional nitrogen or carbon dioxide pressure;
(ii) Porter or Stout. Porter is a dark style of beer made from brown (roasted) malt or roasted barley, hops, water and yeast;
(iii) Lager. Lager (from German: storeroom or warehouse) a beer that is conditioned at low temperatures. It may be pale, golden, amber, or dark.
Lager beer uses a process of cool fermentation, followed by maturation in cold storage.
Specific yeast (Saccharomyces pastorianus) is used for brewing Lager.
Contemplated enriched lager beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) Pale Lager, such as any one of the common lager beers in worldwide production, for example, Pilsner beer. The flavor of these lighter lagers is usually mild, and it is preferably served refrigerated. Pale lager is a very pale to golden-colored lager with a well attenuated body and noble hop bitterness; (b) Vienna Lager, a reddish-brown or copper-colored beer with medium body and slight malt sweetness. The malt aroma and flavor may have a toasted character; (c) Dark lager, typically ranging in color from amber to dark reddish brown and even black such as a Schwarzbier having a chocolate or liquorice-like flavour similar to stout. Alcohol concentrations of 4.5% to 6% by volume; and (d) Bock, a sweet, relatively strong (6.3%-7.2% alcohol by volume) lager. This beer is clear, ranging in color from light copper to brown, with a bountiful and persistent off-white head.
(iv) Wheat beer. Wheat beer is a beer, usually top-fermented, which is brewed with a large proportion of wheat relative to the amount of malted barley.
Contemplated enriched wheat beers may be based on, or correspond to known (non-enriched) varieties, for example: (a) a German style beer such as WeiBbier (German ¨
"white beer"), based on the German tradition of mixing at least 50% wheat to barley malt to make a light colored top-fermenting beer; and (b) a Belgian style beer such as Witbier, based on the Belgian tradition of using flavorings such as coriander and orange peel.
Belgian style white beers are often made with raw unmalted wheat, as opposed to the malted wheat used in other varieties.
In some embodiments, an enriched beer is provided, comprising one or more dopamine precursors and, optionally, one or more psychostimulant substances as described herein in an amount that imparts to the beer palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched and/or any known beer containing 3.8-10% alcohol by volume.
In certain embodiments, the enriched beer provided herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched beer containing 3.8-10% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched beer described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 mg/ml to about 0.20 mg/ml, from about 0.10 mg/ml to about 0.30 mg/ml, from about 0.25 mg/ml to about 0.45 mg/ml, from about 0.30 mg/ml to about 0.50 mg/ml, from about 0.30 mg/ml to about 0.60 mg/ml, from about 0.45 mg/ml to about 0.65 mg/ml, from about 0.50 mg/ml to about 0.70 mg/ml, from about 0.50 mg/ml to about 0.80 mg/ml, from about 0.60 mg/ml to about 0.90 mg/ml, from about 0.80 mg/ml to about 1.00 mg/ml, from about 0.90 mg/ml to about 1.10 mg/ml, from about 0.95 mg/ml to about 1.25 mg/ml, from about 1.00 mg/ml to about 1.30 mg/ml, from about 1.20 mg/ml to about 1.50 mg/ml, from about 1.45 mg/ml to about 1.75 mg/ml, from about 1.75 mg/ml to about 2.10 mg/ml, from about 2.00 mg/ml to about 2.50 mg/ml, from about 2.45 mg/ml to about 3.00 mg/ml, from about 2.50 mg/ml to about 3.50 mg/ml, from about 3.00 mg/ml to about 4.00 mg/ml, from about 3.75 mg/ml to about 4.50 mg/ml, or from about 4.35 mg/ml to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiment, the enriched beer provided herein comprises from about 0.1 mg/ml to about 0.45 mg/ml of tyrosine.
When the enriched beer described herein comprises a psychostimulant substance, the amount of the psychostimulant substance, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 mg/ml to 0.05 mg/ml, 0.05 mg/ml to 0.08 mg/ml, 0.05 to 0.09 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, 1.50 to 2.00 mg/ml, 2.00 to 3.00 mg/ml, 3.00 to 5.00 mg/ml, 3.50 to 5.00 mg/ml, 4.50 to 6.00 mg/ml, or 6.00 to 9.00 mg/ml, including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched beer herein comprises from about 0.01 mg/ml to about 0.9 mg/ml (or 10 mg/L to about 900 mg/L) of caffeine.
In an exemplary embodiment, an enriched beer is provided, comprising a lager beer, about 0.1 mg/ml to about 0.6 mg/ml of tyrosine and about 0.01 mg/ml to about 0.75 mg/ml caffeine.
In some embodiments, the base liquid of the enriched alcoholic beverages described herein is wine. The wine may have an alcohol content of 10-14%. The term "wine" as used herein and in the art includes the fermented juice of grapes, made in many varieties, such as red, white, sweet, dry, still, and sparkling. Exemplary wine beverages include, but are not limited to, dry red or white wine; semi-dray red or white wine; rosé wine;
dessert wine such as Muscato wine; fruit wine; fortified wine such as Marsala, Port, Madeira, Sherry, vinsanto, and vermouth; sparkling wine such as Champagne, sangria, table wine.
In some embodiments, the wine is a "reduced alcohol wine", namely a wine as defined herein comprising up to 8% alcohol, for example, up to 7%, up to 6%, up to 5%, up to 4.5%, up to 4%, up to 3.5%, up to 3%, up to 1%, up to 0.5%, up to 0.1%, up to 0.05%, or the wine may be devoid of alcohol.
In some embodiments, an enriched wine is contemplated, comprising a dopamine precursor and, optionally, a psychostimulant substance as described herein in an amount that imparts to the wine palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as defined herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched or any known wine containing 10-14%
alcohol by volume.
In certain embodiments, the enriched wine contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched wine containing 7.5-14% alcohol by volume, while substantially minimizing intoxication effects.
In a contemplated enriched wine, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.50 mg/ml, from about 1.50 to about 1.80 mg/ml, from about 1.55 to about 1.95 mg/ml, from about 1.70 to about 2.00 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched wine contemplated herein comprises from about 0.1 mg/ml to about 1.80 mg/ml of tyrosine.
When the enriched wine described herein comprises a dopamine supplement, the amount of dopamine supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, or 1.50 to 2.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched wine contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
The term "spirit" as used herein and in the art refers to a distilled alcohol beverage obtained, for example, by distilling starchy material, and includes, but not limited to, variety of raw grain alcohols, brandies, liquors, saki, Ouzo, arrack, rum, vodka, tequila, schnapps, whiskey, gin, cordial, Cachaca, absinthe, baijiu, eau de vie, soju, aguardiente, palinka, fernet and slivovitz.
In some embodiments, the spirit is a "reduced alcohol spirit", namely a spirit as defined herein comprising up to 80% alcohol, for example, up to 60%, up to 50%, up to 45%, up to 40%, up to 35%, up to 30%, up to 25%, up to 20%, up to 15%, up to 10%, up to 8%, up to 7%, up to 6%, up to 5%, up to 4%, up to 3.5%, up to 3%, up to 2%, up to 1%, up to 0. 5%, or the spirit may be devoid of alcohol.
In some embodiments, an enriched spirit is contemplated, comprising one or more dopamine precursors and, optionally, one or more psychostimulant supplements as described herein in an amount that imparts to the spirit palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by any known corresponding non-enriched spirit containing 50-98% alcohol by volume.
In certain embodiments, the enriched spirit contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched spirit containing 50-98% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched spirit described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.50 mg/ml, from about 1.50 to about 1.80 mg/ml, from about 1.55 to about 1.95 mg/ml, from about 1.70 to about 2.00 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched spirit contemplated herein comprises from about 0.1 mg/ml to about 2.5 mg/ml of tyrosine.
When the enriched spirit described herein comprises a psychostimulant supplement, the amount of psychostimulant supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml 0.10 to 0.17 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.23 to 0.35 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.70 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, 1.50 to 2.00 mg/ml, 1.60 to 2.30 mg/ml, or 2.30 to 2.60 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched spirit contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
Other known alcoholic beverages which can be made enriched alcoholic beverages in accordance with embodiments described herein, include, but are not limited to, Desi daru, made by fermenting molasses or high sugar containing fruits; Huangjiu (Chinese, made from rice, millet, or wheat using a special starter culture of yeast, mold, and bacteria);
Icariine Liquor; Kasiri (made from cassava); Kilju (Finnish, made from sugar);
Kumis (central asia, traditionally made from horse milk but now primarily cow milk);
Mead (made from honey); Nihamanchi (South America) a.k.a. nijimanche (Ecuador and Peru) (made from cassava); Palm wine (made from the sap of various palm trees); Parakari (made from cassava); Pulque (originally made by the natives of Mexico, made from the sap of the maguey plant); Sakura (made from cassava); Sake (made from rice);
Sonti;
Tepache; Tiswin (made from corn or saguaro, a large cactus); and Tonto.
Herein throughout, whenever a percentage (%) is indicated, volume % of the total volume of the beverage is meant, unless otherwise indicated.
Alcopop beverages, also termed herein and in the art "coolers" or "spirit coolers", are flavored alcoholic beverages or flavored malt beverages based on fruit juice or nectar, and/or a variety of naturally and/or artificially flavored syrups. Exemplary alcopop beverages include, but are not limited to (i) a malt beverage, designate herein "a beer cooler", containing a malt base or beer and at least 5% by volume of added natural or artificial blending material, such as fruit juice, flavors, flavorings, colorings, and, optionally, preservatives; (ii) a wine cooler which is a beverage containing wine and more than 15% by volume of added natural or artificial blending material, such as fruit juices, flavors, flavorings, adjuncts, water (plain, carbonated, or sparkling), colorings, and, optionally, preservatives; and (iii) a beverage designated herein "a spirit cooler", containing distilled alcohol, and added natural or artificial blending material, such as fruit juices, flavors, flavorings, colorings, and, optionally, preservatives.
Alcopop brands are numerous and their alcoholic base vary greatly. Most alcopop beverages contain 3.8-7% alcohol by volume, and some may even contain as much as 12.5% alcohol by volume. Some notable brands include, but are not limited to, Smirnoff Ice, Mike's Hard Lemonade, Bacardi Breezer, Skyy Blue, Jack Daniel's Hard Cola, WKD
Original Vodka, Six Degrees and MG Spirits.
In some embodiments, an enriched cider and/or enriched alcopop beverage is contemplated, comprising one or more dopamine precursors and, optionally, one or more psychostimulant supplements as described herein in an amount that imparts to the beer palatability and/or positive psychotropic effects as defined herein and/or positive psychoactive effects as described herein, and/or pleasure of drinking, at least as those provided by a corresponding non-enriched or any known alcopop or cider containing 3.8-10% alcohol by volume.
In certain embodiments, the enriched alcopop or enriched cider contemplated herein affords positive psychoactive effects such as euphoric and joyful feeling, which exceed the effects exerted by a corresponding non-enriched alcopop or non-enriched cider containing 3.8-10% alcohol by volume, while substantially minimizing intoxication effects.
In the enriched alcopop described herein, the amount of dopamine precursor, for example, tyrosine, is within a range of from about 0.10 mg/ml to 5.0 mg/ml, for example, from about 0.10 mg/ml to about 0.20 mg/ml, from about 0.10 to about 0.30 mg/ml, from about 0.25 to about 0.45 mg/ml, from about 0.30 to about 0.50 mg/ml, from about 0.30 to about 0.60 mg/ml, from about 0.35 to about 0.65 mg/ml, from about 0.45 to about 0.65 mg/ml, from about 0.45 to about 0.70 mg/ml, from about 0.50 to about 0.70 mg/ml, from about 0.50 to about 0.80 mg/ml, from about 0.60 to about 0.90 mg/ml, from about 0.80 to about 0.95 mg/ml, from about 0.80 to about 1.00 mg/ml, from about 0.90 to about 1.10 mg/ml, from about 0.95 to about 1.25 mg/ml, from about 1.00 to about 1.30 mg/ml, from about 1.10 to about 1.30 mg/ml, from about 1.20 to about 1.50 mg/ml, from about 1.55 to about 1.75 mg/ml, from about 1.75 to about 2.10 mg/ml, from about 1.95 to about 2.50 mg/ml, from about 2.55 to about 2.95 mg/ml, from about 2.80 to about 3.50 mg/ml, from about 3.50 to about 4.00 mg/ml, from about 3.80 to about 4.50 mg/ml, or from about 4.50 to about 5.00 mg/ml including any subranges and any intermediate values therebetween.
In certain embodiment, the enriched alcopop contemplated herein comprises from about 0.1 mg/ml to about 0.45 mg/ml of tyrosine.
When the enriched alcopop described herein comprises a psychostimulant supplement, the amount of psychostimulant supplement, for example, caffeine, may be within a range selected from 0.01 mg/ml to 0.04 mg/ml, 0.02 to 0.05 mg/ml, 0.05 to 0.10 mg/ml, 0.08 to 0.10 mg/ml, 0.08 to 0.12 mg/ml, 0.09 to 0.15 mg/ml, 0.10 to 0.15 mg/ml, 0.12 to 0.18 mg/ml, 0.12 to 0.20 mg/ml, 0.15 to 0.25 mg/ml, 0.20 to 0.25 mg/ml, 0.25 to 0.45 mg/ml, 0.25 to 0.50 mg/ml, 0.45 to 0.60 mg/ml, 0.50 to 0.75 mg/ml, 0.65 to 0.85 mg/ml, 0.85 to 0.95 mg/ml, 0.95 to 1.00 mg/ml, 0.95 to 1.30 mg/ml, 1.00 to 1.30 mg/ml, 1.00 to 1.50 mg/ml, 1.25 to 1.75 mg/ml, or 1.50 to 2.00 mg/ml, including any subranges and any intermediate values therebetween.
In exemplary embodiments, the enriched alcopop contemplated herein comprises from about 0.01 mg/ml to about 0.75 mg/ml (or 10 mg/L to about 750 mg/L) caffeine.
Herein throughout, whenever a percentage (%) is indicated, % volume of the total volume (% v/v) of the beverage is meant, unless otherwise indicated.
In some of any one of the embodiments of the present invention, optionally or additionally, the base material of the enriched alcoholic food product, for example, base liquid or base alcoholic liquid, is formulated to include additives, such as flavoring agents, colorants, odoriferous agents, enzymes, CO2 and/or other additives such as viscosity modifying agents, foaming agents, antifoaming agents, and preservatives that account for the taste and texture of e.g., wine or beer or spirit, such that the enriched alcoholic product will contain at least part or all the ingredients used to form the corresponding non-enriched alcoholic product. Preferably, additives used in the enriched alcohol products described herein are FDA-approved, and/or edible. In some embodiments, the additives are selected as soluble in the base material, e.g. base alcoholic beverage or base liquid.
The phrases "flavoring agent" and "odoriferous agent", as used herein, describe a class of substances which are added to edible products in order to induce a certain flavor or smell in the product, respectively, and are commonly referred to also as "flavorants".
Flavorants, also termed herein "taste-improving additives", can be synthetic or natural extracts, which are extracted from a source substance. Typical flavorants are specific and often complex mixtures of singular naturally occurring or synthetic flavor compounds combined together to either imitate or enhance a natural flavor. Many flavorants are esters, which can be characterized by a typical flavor, such as diacetyl which gives a buttery flavor, isoamyl acetate that is perceived as banana, cinnamic aldehyde which is the basis for the typical flavor of cinnamon, ethyl propionate is perceived as fruity, limonene is perceived as orange, ethyl-(E, Z)-2,4-decadienoate is perceived as pear, allyl hexanoate is perceived as pineapple, ethyl maltol, is perceived as sugar or cotton candy, methyl salicylate is known as the wintergreen flavor, and benzaldehyde is perceived as bitter almond. Further synthetic flavorant are exemplified by amaretto, cola and ice cream flavors Flavoring agent of a natural source can be, for example, an extract of a fruit, a vegetable, a herb or of any other edible substance, a fruit juice or a vegetable juice, or any combination thereof. Non-limiting examples of fruit flavorants include elder, grape, orange, ginger, red apple, anise, or lemon grass. These additives are added in addition to or instead of those found in the alcoholic beverage, if indeed present therein.
The term "colorant", as used herein, refers to any natural or synthetic coloring substance, and describes any substance that is added to food or drink in order to alter its color. Exemplary usable colorants include, but are not limited to, synthetic colorants such as FD&C Blue No. 1 - Brilliant Blue FCF (E133), FD&C Blue No. 2 ¨ Indigotine (E132), FD&C Green No. 3 - Fast Green FCF (E143), FD&C Red No. 40 - Allura Red AC
(E129), FD&C Red No. 3 ¨ erythrosine (E127), FD&C Yellow No. 5 ¨ tartrazine (E102), and FD&C Yellow No. 6 - Sunset Yellow FCF (E110), and natural food colorants such as carmine (E120), enocianin (E163), black carrot (E163), paprika (E160c), annatto (E160b), beta carotene (E160a), lutein (E161b), riboflavin (E101), curcumin (E100), copper chlorophyllin (E141), chlorophyll (E140), caramel (E150), and extracts of foodstuffs such as elderberry, aronia, grape, beetroot, carrot, turmeric (tumeric) root, spinach, stinging nettle and burnt sugar (caramelized sugar).
The term "preservative", as used herein, describes a synthetic or natural additive substance that is added to edible products in order to prevent or retard chemical and biochemical decomposition of the product by oxygen, moisture and/or microbes.
Exemplary anti-microbial preservatives include, but are not limited to, calcium propionate, sodium nitrate, sodium nitrite, sulfites (sulfur dioxide, sodium bisulfite, potassium hydrogen sulfite, etc.), disodium EDTA, sodium benzoate, potassium sorbate.
Natural substances that retard microorganisms growth include lactic acid, salt, sugar and vinegar.
Exemplary antioxidant preservatives include, but are not limited to, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). Natural antioxidants include, but are not limited to, herbal extracts such as rosemary and oregano, and vitamins such as Vitamin E and Vitamin C (ascorbic acid).
The phrase "foaming agent", as used herein, describes an edible surfactant, which when present in small amounts, facilitates the formation of a foam, or enhances its colloidal stability by inhibiting the coalescence of bubbles. Exemplary foaming agents include, without limitation, sodium laureth/lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES) and ammonium lauryl sulfate (ALS).
The phrase "antifoaming agent", as used herein, describes an edible substance that inhibits the formation of foam and curbs effusion or effervescence in edible products. An exemplary antifoaming agent is polydimethylsiloxane.
The phrases "viscosity modifying agent" or "thickener" as used herein are interchangeable and describe agents that enable to control the viscosity of the enriched alcoholic products described herein. Exemplary thickeners include, but are not limited to, starch-based thickeners such as maltodextrin and gum-based thickeners such as xanthan or cellulose gum.
The enriched alcoholic products described herein may be contained in any of the known containers applied for alcoholic products in general. For example, when the enriched alcoholic product is a beverage, for example a beer, it may be contained and marketed in a 330 ml, 500 ml, 750 ml and 1-liter bottle or tin, or in a barrel. The stability of the enriched alcoholic product obtained according to any of the embodiments described herein is preferably more than 365 days at room temperature, and it may be stored for up to 999 days at 10 C.
In an aspect of some embodiments of the present invention there is provided a process for the preparation of an enriched alcoholic beverage. The process comprises mixing a base liquid as defined herein with an amount of one or more neurotransmitter precursors and/or one or more neurotransmitter precursors as described herein.
In some embodiments, the process further comprises the addition of one or more psychostimulant supplements as described herein. In some embodiments, the base liquid is an alcoholic beverage such as beer, wine, spirit, cider or alcopop.
In some embodiments, the base liquid is a non-alcoholic beverage (e.g, juice, water and the like), and one or more neurotransmitter precursors and/or one or more neurotransmitter precursors and, optionally one or more psychostimulant supplements may be added to the non-alcoholic base beverage together with a desired amount of alcohol.
In some embodiments, the enriched alcoholic beverage, for example beer, is prepared by brewing the beer together with neurotransmitter precursor(s) and the psychostimulant supplement(s). Likewise, wine and spirit may be fermented or distilled, respectively, in processes that are adjusted to includes steps of addition of neurotransmitter precursor(s) and psychostimulant supplement(s), as long as the fermentation, distillation or brewing processes maintain the neurotransmitter precursor(s) and the psychostimulant supplement(s) intact and bioavailable, and further provided that the palatability, texture and appearance of the beverage in not substantially affected by including neurotransmitter precursor(s) and/or the psychostimulant supplement(s) in the process of preparation thereof.
In exemplary embodiments, the process described herein is for the preparation of enriched beers comprising one or more dopamine precursors and, optionally further comprising one or more psychostimulant supplements in the amounts described herein.
In exemplar embodiments, in the process provided herein, tyrosine and caffeine are provided to a base alcoholic beer. In alternative embodiments, an enriched beer is brewed together with tyrosine and caffeine in the brewery.
It is to be understood that the invention as described and discussed in the foregoing and in following sections of the description is not necessarily limited in its application to the details set forth in the present description.
Whenever a numerical range is indicated herein, it is meant to include any cited numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and "ranging/ranges from"
a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as "10 pm"
is intended to mean "about 10 pm".
The term "about" as used herein means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean a range of up to 10%, more preferably up to 5%, and still more preferably up to 1% of a given value.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".
The term "consisting of' means "including and limited to".
The term "consisting essentially of" means that the compositions, for example, enriched alcoholic beverages, may include additional ingredients but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed composition.
As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention.
Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Preparation of beer enriched with tyrosine and caffeine Beer enriched with tyrosine and caffeine was prepared using a protocol comprising the following steps:
(i) grinding barley;
(ii) immersing the grinded barley in water at a temperature of 50-75 C for about an hour;
(iii) adding caffeine;
(iv) transferring the mixture of grinded barley and caffeine to a boiler;
(v) adding hops to the mixture in the boiler, and boiling the mixture for about an hour;
(vi) transferring the boiling mass (herein referred to as the "must") into a fermentation tank via a heat exchanger apparatus that cools the must form 100 C to about 20 C;
(v) adding yeasts to the cooled must;
(vi) fermenting the must for a period of 14 to 16 days so as to obtain a beer;
(vii) transferring the fermented mass into a second tank (herein also termed "intermediate tank");
(viii) adding tyrosine and, optionally, glucose and to the fermented beer; and (ix) transferring the beer to bottles, cans or barrels and storing for a second fermentation for a period of 12-40 days at 18 C.
The enriched beer was unfiltered and contained 5.5% alcohol by volume, and 40 mg tyrosine and 35 mg caffeine, per 100 ml.
Beer enriched with tyrosine and caffeine A further recipe for brewing beer enriched with tyrosine and caffeine comprises the following steps:
(i) milling malted barley;
(ii) mashing: transferring milled malted barley into mash tun, adding water and heating to a temperature of from about 50 C to about 75 C for about 1 - 2 hour;
(iii) lautering: separating the wort (the malty liquid that was extracted during mashing) from the grains;
(iv) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(v) boiling the wort;
(vi) adding hops and boiling the mixture for about 45 - 90 minutes;
(vii) separating hopped wort from solid particles;
(viii) cooling the wort to fermentation temperature (about 4 ¨ 25 C) and aerating it;
(ix) adding brewer's yeasts and fermenting the wort for several weeks;
(x) conditioning/maturing: separating fermented beer from dead yeasts and other debris and transferring it into a conditioning tank for a period of several weeks to several months;
(xi) filtering the beer;
(xii) adding caffeine (from about 10 mg/L to about 700 mg/L);
(xiii) heating the beer to 70 C for pasteurization (elimination of harmful bacteria) and to fully dissolve added tyrosine and caffeine; and (xiv) packaging the enriched beer (i.e., bottling, canning and/or transferring to a barrel), and cooling for storage.
Akopop ("hard lemonade") enriched with tyrosine and caffeine Hard lemonade, an alcopop, enriched with tyrosine and caffeine is prepared according to the following steps:
(i) grinding mint leaves with brown sugar;
(ii) adding boiling water;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L), and stirring the tyrosine-containing mixture;
(iv) adding the following ingredients to the above mixture: water (at room temperature), a spirit with at least 40% alcohol (e.g., vodka), and freshly squeezed lemon juice with pulp, in a ratio mixture:water:vodka:lemon juice of about 1:5:4:2;
(v) adding caffeine (from about 10 mg/L to about 700 mg/L); and (vi) bottling and/or canning the enriched alcopop and cooling for storage.
White wine enriched with tyrosine and caffeine White wine enriched with tyrosine and caffeine is prepared according to the following steps:
(i) crushing, pressing and extracting the grape juice (wort) of white-flesh grapes (so as to separate it from skins, seeds and other solids);
(ii) clearing the wort to remove lees, for example, by settling or by other methods;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(iv) optionally, adding wine yeasts to the wort in addition to the existing natural yeasts;
(v) fermenting the wort in fermentation tanks for several weeks at a temperature of 12 ¨ 37 C;
(vi) eliminating fermentation, if desired.
(vii) clearing and refining: separating the fermented wine from dead yeasts and other debris, for example, by filtration or by other methods;
(viii) adding caffeine (from about 10 mg/L to about 700 mg/L; and (ix) bottling the enriched wine.
Red wine enriched with tyrosine and caffeine Red wine enriched with tyrosine and caffeine is prepared according to the following steps:
(i) destemming and crushing grapes to create a must (i.e., a mixture of grapes, skins, juice and seeds);
(ii) settling the must for pre-fermentation maceration at a temperature of about 10 C for a period of 1 to 4 days;
(iii) adding tyrosine (from about 100 mg/L to about 5000 mg/L);
(iv) optionally, adding wine yeasts to the wort in addition to the existing natural yeasts;
(v) fermenting the must in fermentation tanks for several weeks at a temperature of 12 ¨ 37 C. During fermentation, the contact between skins and liquid phase can be maximized by a desired mixing method;
(vi) extracting the juice from the must by pressing and separating it from remaining solids;
(vii) allowing for malolactic fermentation;
(viii) racking: decanting off lees (dead yeasts and other solids) and providing sulfur dioxide preservative to avoid oxidation and bacterial spoilage;
(ix) aging/maturing the wine for a desired period;
(x) clearing and refining, for example, by filtration or by other methods;
(xi) adding caffeine (from about 10 mg/L to about 750 mg/L; and (xii) bottling the enriched wine.
Cider enriched with tyrosine and caffeine "Hard cider" enriched with tyrosine and caffeine is prepared according to the following steps:
(i) crushing and pressing apples to acquire must (apple juice) from pomace (mixture of solid remains of pressed apples, skins, juice and seeds);
cii) adding tyrosine to concentrations of 100 mg/L ¨ 5 gr/L;
(iii) optionally, adding cider yeasts to the must, in addition to existing natural yeasts;
(iv) fermenting the must in fermentation tanks for several weeks at a temperature of 4 ¨ 16 C;
(v) racking: siphoning the liquor into new vats, separating it from dead yeasts and undesirable materials;
(vi) aging/maturing the cider for a desired period;
(vii) adding caffeine to concentrations of 10 mg/L to about 750 mg/L; and (viii) packaging the enriched cider (i.e., bottling, canning and/or transferring to a barrel), and cooling for storage.
Single Malt whisky enriched with tyrosine and caffeine Single Malt whisky enriched with tyrosine and caffeine is prepared according to the following steps:
(i) milling malted barley;
(ii) mashing: transferring milled malted barley into mash tun, adding hot water in three stages and exceeding temperatures (beginning with approx. 60 C, then approx. 75 C and, finally, approx. 90 C). Wort (the malty liquid that is extracted during mashing) is transferred into a washback;
(iii) cooling the wort to fermentation temperature (about 4-25 C);
(iv) adding whisky yeasts;
(v) fermenting the cooled wort for up to several days to receive the "wash";
(vi) distilling the wash twice using stills: first using wash stills to obtain "low wine", and a second time using spirit stills to obtain the final "new-make" spirit (unaged whisky).
During the second distillation, the more volatile compounds which distil off first (foreshots), and the final stage where more oily compounds are vaporized, are both channeled off so that only the pure center cut is collected;
(vii) optionally, diluting the new-make prior to aging;
(viii) transferring new-make to wooden casks and aging for several years;
(ix) chill filtrating: precipitating and filtering to remove fatty acid esters;
(x) adding tyrosine (final concentration 100 mg/L ¨ 5 gr/L);
(xi) adding caffeine (final concentrations 10 mg/L to about 750 mg/L); and (xii) bottling the enriched whisky.
Vodka enriched with tyrosine and caffeine Vodka enriched with tyrosine and caffeine is prepared according to the following steps:
(i) mashing desired starchy ingredient (potatoes, milled grains, etc.), adding water and boiling;
(ii) cooling the mash to enzyme activity temperatures;
(iii) adding starch-breaking enzymes, such as amylase;
(iv) allowing enzyme activity to break down starch within mash to small sugars;
(v) adding vodka yeasts;
(vi) fermenting the starch-broken mash for several days in yeast-activity temperatures (about 4 ¨ 25 C) to obtain the "wash" (i.e., insipid beverage);
(vii) distilling the wash using standard methods to obtain raw spirit of ¨60%
alcohol by volume (ABV). Separating and discarding products of the first and last distillation stages (i.e., first 5% and final 35% of the whole distillation process);
(viii) rectifying the raw spirit to neutral spirit of ¨96% ABV;
(ix) preparing demineralized water solution containing tyrosine (80 - 585 mg/L) and caffeine (15-670 mg/L), heating to ¨80 C until homogenous, and then cooling to ambient temperature;
(x) adding the demineralized water solution to the neutral spirit to reduce ABV to ¨40%;
(xi) filtering the obtained enriched vodka using standard methods; and (xii) bottling the enriched vodka.
Coffee liqueur enriched with tyrosine and caffeine Coffee liqueur enriched with tyrosine and caffeine is prepared according to the following steps:
(i) combining 3 cups of sugar, 2 cups of water and a tablespoon of vanilla extract in a saucepan;
(ii) boiling and stiffing for approx. 30 minutes until volume is reduced by half;
(iii) adding 100 - 400 mg tyrosine and about 100 gr instant coffee, stiffing until homogenous and allowing the syrup mixture to cool;
(iv) combining the syrup with 750 ml 40% ABV vodka in a closed 1-liter bottle, and shaking well;
(v) optionally, adding up to 180 mg caffeine;
(vi) settling for 10 days in a cool, dark place;
(vii) Straining/filtering the enriched liqueur; and (viii) bottling the enriched liqueur.
Biphasic Alcohol Effects Scale (BAES) study The stimulant and sedative effects caused by consuming a beer enriched with a neurotransmitter precursor such as Tyr and, optionally, a psychostimulant substance such as caffeine, versus the stimulant and sedative effects exerted by a corresponding non-enriched beer was assessed in self-reporting participants using a Biphasic Alcohol Effects Scale (BAES)-based questionnaire. The BAES is a reliable and valid systematic 14-item self-report scale designed to measure stimulant and sedative effects of alcohol as separate and distinct constructs. BAES and a brief version thereof (B-BAES) comprising only 6 items are described, for example, in Rueger and King, 2013 (Alcohol Chn Exp Res. 37(3):
470-476; and references cited therein).
Seven items comprise the stimulant subscale of the BAES (elated, energized, excited, stimulated, talkative, up, vigorous), and another seven items comprise the sedative subscale (difficulty in concentrating, down, heavy head, inactive, sedated, slow thoughts, sluggish). The BAES test demonstrates strong psychometric properties, including high internal consistency, reliability and a four-factor structure reflecting the distinctness of the stimulant and sedative constructs during both the ascending and descending limbs of the breath alcohol concentration (BrAC) curve. With use of a conversion factor, called the blood:breath ratio (BBR), the blood alcohol concentration (BAC) can be estimated from BrAC. This four-factor structure is invariant to dose, drinking history, and sex, and demonstrates robustness to an instructional set that does not disclose the content of the alcoholic beverage (see, for example, Rueger et al., 2009, Alcohol Clin Exp Res. 33:916-924).
The BAES study of alcohol effects in accordance with the disclosed study had multiple assessments in one session. For example, the BAES questionnaire was administered before alcohol was consumed and then the assessment was repeated 3-4 more times after consumption to capture rising and declining BrAC limb effects.
In the BAES questionnaire exemplified herein, each participant was presented with 14 items in alphabetical order, 7 of which describe sensations (feelings, perception) associated with stimulant effects (elevated mood (high spirit), energy, excitement, stimulated, talkativeness, vigorous and vitality), and 7 items describing sensations (feelings, perception) associated with sedative effects (difficulty in concentrating, down feeling, heavy head, heavy body, sedative, slow thinking, sluggishness). Each participant had to assign, next to each of these 14 items, a number in the range from 0 to 10 indicating how closely or how well a certain item expresses, corresponds or describes his/her current feeling/sensation, where "0" indicates "not at all describing" or "irrelevant", and "10"
indicates "exactly (or very much) describing".
The numerical indications of the stimulant and sedative effects were averaged to obtain two numerical values designated STIM and SED, respectively.
Participants Healthy nonalcoholic 198 social drinkers participated in the study.
Participants were recruited from the wider community via advertising placed, for example, in web sites.
Each participant's eligibility was subject to the following criteria: (i) aged 18-60 years; (ii) no history of alcohol addiction; (iii) not taking medication having a stimulative or sedative action; (iv) moderate to low regular consumption of alcohol.
Participants were randomly supplied with either one of: (i) an alcoholic beverage, e.g., beer, enriched with tyrosine and caffeine; or (ii) a corresponding non-enriched alcoholic beverage. The study was double-blind, and the participants did not know whether they were supplied with alcoholic beverage (i) or (ii). The gender split was equal across both groups. All participants were requested to refrain from alcohol consumption at least 24 hours before the study.
Study design The study was a 2-sesssion (2 days) study, wherein the second session (day) was at least a week apart from the first session. Participants were either given an enriched (i.e., comprising Tyr and caffeine) or non-enriched beer having 5.2% alcohol.
In each session, participants first filled a BAES questionnaire to set up a baseline assessment, followed (about 5 minutes later) by the consumption of either enriched beer (i) or non-enriched beer (ii). For each participant, the amount of beer provided was calculated so as to reach blood alcohol level of 0.35 gr per kg body weight.
For example, for a participant weighting 75 kg, 26.25 gr of alcohol are required in order to reach the predetermined blood alcohol concentration, thus this participant was supplied with 504.8 ml beer having 5.2% alcohol.
The total amount of alcohol for a participant was divided into 5 equal portions, and the participant was requested to consume each portion within 2 minutes (overall, 10 min for consuming the whole amount of alcoholic beverage). Immediately after the last portion of beverage was fully consumed, time point zero (T=0) was set. Participant were requested to fill a BAES questionnaire at T= 30 min, T= 60 mm and at T=120 min.
Answers obtained from all BAES questionnaires were gathered, averaged (standard deviation was calculated) to obtain the STIM and SED values, and presented graphically.
The results are shown in Figures 1A-1B and 2A-2B, and presented in Tables 1 and 2.
Table 1. BAES study for non-enriched (regular) beer Regular (non-enriched) Beer STIM SD SED SD
Baseline 3.20 0.76 1.51 0.39 30 min 3.54 0.69 1.90 0.50 60 min 2.49 0.52 2.78 0.53 120 min 2.15 0.45 3.33 0.64 Table 2. BAES study for beer enriched with tyrosine and caffeine Enriched Beer STIM SD SED SD
Baseline 3.08 0.77 1.30 0.40 30 min 5.32 0.83 1.10 0.38 60 min 5.04 0.79 1.07 0.38 120 min 4.05 0.61 1.10 0.35 As seen in Table 1, and Figures 1A and 2A, 30 minutes after the regular (non-enriched beer) was consumed, participants experienced slight stimulant and sedative effects. Sixty minutes (T=60) and 120 minutes after consumption, the sedative effects increase while stimulant effects decreased even below baseline levels.
On the other hand, as seen in Table 2, and Figures 1B and 2B, 30 minutes after the enriched beer was consumed, significant elevation of stimulant effects was demonstrated, along with a slight rise in sedative effects. Sixty minutes (T=60) and 120 minutes after consumption of the enriched beer, the stimulant effects gradually regress or decrease, but they were still higher compared to consumption of non-enriched beer. No significant change was seen in the sedative effects, namely, they remained low even after 120 min.
It is shown herein that the beer enriched with Tyr and caffeine significantly strengthens and prolongs the stimulant and mood elevating effects associated with alcohol consumption as compared to a corresponding non-enriched beer, while significantly reducing, nearly nulling, the sedative effects, and for much longer time compared to non-enriched beer.
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
Claims (29)
1. An alcoholic food product comprising an edible base material, alcohol, and at least one of a neurotransmitter or a neurotransmitter precursor.
2. The alcoholic food product according to claim 1, wherein the edible base material is a liquid, solid or semi-solid edible substance.
3. The alcoholic food product according to claim 1 or 2, wherein the edible base liquid substance is a base beverage.
4. An enriched alcoholic beverage comprising a base beverage, alcohol, and at least one of a neurotransmitter or a neurotransmitter precursor.
5. The alcoholic food product according to any one of claims 1 to 3, or the enriched alcoholic beverage according to claim 4, wherein the base beverage is selected from the group consisting of a natural or artificially flavored fruit juice, vegetable juice, fruit syrup, concentrate or nectar from fruits, plant materials such as agave, jello, carbonated beverages such as cola, optionally with addition of roasted malt beer, caffeinated beverages, specialized flavor formulations emulating the taste of existing beers, wines and spirits, non-alcoholic cocktails ("mocktails"), dealcoholized beer, dealcoholized wine, dealcoholized spirit, malt beer, tonic water and water.
6. The alcoholic food product according to any one of claims 1 to 3, or the enriched alcoholic beverage according to claim 4, wherein the base beverage is an alcoholic base beverage.
7. An enriched alcoholic beverage comprising a base alcoholic liquid, and at least one of a neurotransmitter or a neurotransmitter precursor.
8. The alcoholic food product according or the enriched alcoholic beverage according to claim 6 or 7, wherein the base alcoholic beverage or base alcoholic liquid is selected from the group consisting of beer, wine, spirit, cider, perry and alcopop.
9. The alcoholic food product or the enriched alcoholic beverage according to any one of claims 1 to 8, wherein the alcohol is in amount of from about 0.5%
to about 98%, from about 1% to about 20% or from about 30% to about 50% by volume or by weight.
to about 98%, from about 1% to about 20% or from about 30% to about 50% by volume or by weight.
10. The alcoholic food product or the enriched alcoholic beverage according to any one of claims 1 to 9, wherein the neurotransmitter is selected from the group consisting of norepinephrine, epinephrine, serotonin, dopamine, endorphin, acetylcholine, a gamma-aminobutyric acid (GABA), and the neurotransmitter precursor is selected from the group consisting of a norepinephrine precursor, an epinephrine precursor, a serotonin precursor, a dopamine precursor, an endorphin precursor, an acetylcholine precursor, a gamma-aminobutyric acid (GABA) precursor, and any combination thereof.
11. The alcoholic food product or the enriched alcoholic beverage according to claim 10, wherein the neurotransmitter precursor is a dopamine precursor selected from the group consisting of L-phenylalanine, L-tyrosine, levodopa and any combination thereof.
12. The alcoholic food product or the enriched alcoholic beverage according to any one of claims 1 to 11, wherein the neurotransmitter precursor is tyrosine.
13. The alcoholic food product or the enriched alcoholic beverage according to claim 12, wherein the amount of tyrosine is in the range of from about 100 mg to about 5000 mg per 1 liter.
14. The alcoholic food product or the enriched alcoholic beverage according to claim 13, wherein the amount of tyrosine is about 350 mg/L, about 500 mg/L, about 750 mg/L, or from about 100 mg/L to about 1000 mg/L.
15. The alcoholic food product or the enriched alcoholic beverage according to any one of claims 1 to 14, further comprising one or more psychostimulant substances selected from the group consisting of caffeine, omega-3 fatty acids such as docosahexaenoic acid (DHA), magnesium, soluble fibers, folate, olive oil or monounsaturated fats extracted therefrom, green tea or theanine extracted therefrom, pregnenolone or a derivative thereof, uridine-5w-monophosphate, iron, spices such as turmeric or curcumin extracted therefrom, oregano or an extract thereof, Rhodiola rosea or an extract thereof, vitamin C and vitamin B6, carbidopa and any combination thereof.
16. The alcoholic food product or the enriched alcoholic beverage according to claim 15, wherein the psychostimulant substances is caffeine.
17. The alcoholic food product or the enriched alcoholic beverage according to claim 16, wherein the amount of caffeine is from about 10 mg/L to about 900 mg/L, about 35 mg/L, about 50 mg/L, about 100 mg/L or about 350 mg/L.
18. The alcoholic food product or the enriched alcoholic beverage according to any one of claims 1 to 17, which upon consumption thereof exerts one or more positive psychoactive effects which last from 5 minutes up to 24 hours after consumption and/or one or more positive psychotropic effects which last from 5 minutes up to 48 after consumption.
19. The alcoholic food product or the enriched alcoholic beverage according to claim 18, wherein the positive psychoactive effect is euphoria and the positive psychotropic effect is one or more effects selected from the group consisting of (i) higher motivation, e.g., to work, learn and take part in rewarded activities; (ii) improved concentration and focus; (iii) higher self-confidence; (iv) arousal; (v) wakefulness; (vi) elevated alertness;
(vii) improved creativity and creative thinking (viii) curiosity and openness to new experiences; (ix) sense of self-fulfillment, self-contempt; (x) relaxation;
(xi) improved capacity to switch attention efficiently between tasks; (xii) improved sociability and extroversion behavior (xiii) better cognitive and/or mental function; and (xiv) emotional and physical sense of well-being.
(vii) improved creativity and creative thinking (viii) curiosity and openness to new experiences; (ix) sense of self-fulfillment, self-contempt; (x) relaxation;
(xi) improved capacity to switch attention efficiently between tasks; (xii) improved sociability and extroversion behavior (xiii) better cognitive and/or mental function; and (xiv) emotional and physical sense of well-being.
20. The enriched alcoholic beverage according to any one of claims 4 to 19, selected from the group consisting of an enriched beer, wine, cider, spirit or alcopop.
21. The enriched alcoholic beverage according to claim 20, which is an enriched beer, selected from an enriched ale, stout, porter, or lager.
22. The enriched alcoholic beverage according to claim 20, which is an enriched wine selected from an enrich dry red wine, enrich dry white wine, enrich semi-dry red wine, enrich semi-dry white wine, enrich rose wine, enrich dessert wine, enrich Port wine, enrich Champagne, enrich sparkling wine and enrich vermouth.
23. The enriched alcoholic beverage according to claim 20, which is an enriched spirit selected from enriched brandy, liquor, saki, Ouzo, arrack, rum, vodka, tequila, schnapps, whiskey, gin, cordial, Cachaça or slivovitz.
24. The enriched alcoholic beverage according to claim 20, which is an enriched cider or enriched alcopop selected from an enriched beer cooler, enrich wine cooler and enrich spirit cooler.
25. The enriched alcoholic beverage according to any one of claims 20 to 24, wherein the enriched beer, enriched wine, enriched spirit, enriched alcopop or enriched cider comprises one or more neurotransmitter precursors in an amount that impart to the beverage the ability to exert positive psychoactive and psychotropic effects which exceed the effects exerted by a corresponding non-enriched beer, wine, spirit, alcopop, and cider, respectively, while substantially minimizing intoxication effects.
26. The enriched alcoholic beverage according to any one of claims 20 to 25, comprising tyrosine in an amount from about 0.1 mg/ml to about 1.0 mg/ml or from about 0.1 mg/ml to about 5.0 mg/ml.
27. The enriched alcoholic beverage according to any one of claims 20 to 26, comprising caffeine in an amount of from about 10 mg/L to about 750 mg/L.
28. A process for the preparation of an enriched alcoholic beverage as defined in any one of claims 1 to 27, the process comprising combining a base liquid with alcohol and one or more neurotransmitter precursors, and, optionally, one or more psychostimulant substance.
29. The process according to claim 28, further comprising addition of at least one supplement selected from a flavoring agent, a colorant, an odoriferous agent, CO2, enzymes, a viscosity modifying agent, a foaming agent, an antifoaming agent and a preservative.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762548924P | 2017-08-22 | 2017-08-22 | |
US62/548,924 | 2017-08-22 | ||
PCT/IB2018/056348 WO2019038687A1 (en) | 2017-08-22 | 2018-08-22 | Enriched alcoholic beverages |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3071959A1 true CA3071959A1 (en) | 2019-02-28 |
Family
ID=65438544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3071959A Pending CA3071959A1 (en) | 2017-08-22 | 2018-08-22 | Enriched alcoholic beverages |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP3673037A4 (en) |
JP (1) | JP2020531017A (en) |
KR (1) | KR20200049795A (en) |
CN (1) | CN111065722A (en) |
AU (1) | AU2018320201B2 (en) |
CA (1) | CA3071959A1 (en) |
CL (1) | CL2020000433A1 (en) |
CO (1) | CO2020003137A2 (en) |
EA (1) | EA202090454A1 (en) |
EC (1) | ECSP20019679A (en) |
GE (1) | GEP20217313B (en) |
IL (1) | IL272822B2 (en) |
MX (1) | MX2020001654A (en) |
PE (1) | PE20200702A1 (en) |
PH (1) | PH12020500350A1 (en) |
SG (1) | SG11202001355XA (en) |
WO (1) | WO2019038687A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020039383A1 (en) * | 2018-08-22 | 2020-02-27 | Euphoria Research And Development Ltd. | Methods of enhancing euphoric sensation and improving cognitive abilities |
WO2020226328A1 (en) | 2019-05-03 | 2020-11-12 | 주식회사 엘지화학 | Functional separator, manufacturing method therefor, and lithium secondary battery comprising same |
WO2020248042A1 (en) * | 2019-06-14 | 2020-12-17 | Nhance Neurotechnologies Inc. | Stimulant composition and process for making same |
EP3808832A1 (en) * | 2019-10-14 | 2021-04-21 | Rodriguez Morato, Jose | Beer rich in antioxidants |
KR102684950B1 (en) * | 2020-11-02 | 2024-07-15 | 순천향대학교 산학협력단 | A method of manufacturing beer using shihtake mushroom |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1066084A (en) * | 1963-05-08 | 1967-04-19 | Kyowa Hakko Kogyo Kk | Improved alcoholic beverages |
US20020102345A1 (en) * | 2001-01-26 | 2002-08-01 | International Brewery Business Incorporated | Non-Alcoholic beer composition wih energy enhancing characteristics and method for making the same |
JP4210514B2 (en) * | 2001-12-27 | 2009-01-21 | アサヒビール株式会社 | Method for producing alcoholic beverage containing high GABA |
US20030134007A1 (en) * | 2002-01-16 | 2003-07-17 | Donhowe Erik Thurman | Product and process of making an alcohol containing sport drink |
WO2005006890A2 (en) * | 2003-07-10 | 2005-01-27 | Forest Carl A | Foods, beverages, condiments, spices and salad dressings with specialized supplements |
US20050191386A1 (en) * | 2004-02-26 | 2005-09-01 | Adams Jason P. | Nutritional supplement compositions and methods |
US20080057110A1 (en) * | 2006-08-29 | 2008-03-06 | Alexander Skirpa | Compositions for alcoholic beverages and methods of producing thereof |
US20110065628A1 (en) * | 2007-08-27 | 2011-03-17 | University Of Virginia Patent Foundation | Medication Combinations for the Treatment of Alcoholism and Drug Addiction |
US20090104313A1 (en) * | 2007-10-18 | 2009-04-23 | Brian Lottig | Nutrient-enhanced alcoholic beverage formulations and methods of making the same |
DE202007016949U1 (en) * | 2007-12-05 | 2009-01-08 | Weinhaus Dr. Kling Ag | Wine drink with stimulating substances |
US20090186128A1 (en) * | 2008-01-22 | 2009-07-23 | Banayan Shahram A | Beverage health formulations |
US8202525B2 (en) * | 2009-12-22 | 2012-06-19 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
US20120178799A1 (en) * | 2011-01-07 | 2012-07-12 | O'neil Terence | Energy beverage with creatine and caffeine combination |
WO2013009997A1 (en) * | 2011-07-12 | 2013-01-17 | Burn-Off, Llc | Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication |
US8609162B2 (en) * | 2012-10-04 | 2013-12-17 | Invivo Beverages Llc | Integrated neuromodulation system for mood enhancement of a living human subject |
JP6444658B2 (en) * | 2014-08-29 | 2018-12-26 | キリン株式会社 | Non-fermented beer-taste beverage and method for producing the same |
US11528924B2 (en) * | 2014-12-09 | 2022-12-20 | Clearmind Medicine, Inc. | Alcoholic beverage substitutes |
US20170157075A1 (en) * | 2015-12-07 | 2017-06-08 | James Edward Beecham | Edible Compositions and Methods for Promoting Alpha Brain Waves |
CN106916678A (en) * | 2015-12-27 | 2017-07-04 | 孙良云 | A kind of Woman health beer |
-
2018
- 2018-08-22 MX MX2020001654A patent/MX2020001654A/en unknown
- 2018-08-22 SG SG11202001355XA patent/SG11202001355XA/en unknown
- 2018-08-22 IL IL272822A patent/IL272822B2/en unknown
- 2018-08-22 CA CA3071959A patent/CA3071959A1/en active Pending
- 2018-08-22 EA EA202090454A patent/EA202090454A1/en unknown
- 2018-08-22 GE GEAP201815301A patent/GEP20217313B/en unknown
- 2018-08-22 AU AU2018320201A patent/AU2018320201B2/en active Active
- 2018-08-22 JP JP2020510528A patent/JP2020531017A/en active Pending
- 2018-08-22 CN CN201880054839.XA patent/CN111065722A/en active Pending
- 2018-08-22 PE PE2020000227A patent/PE20200702A1/en unknown
- 2018-08-22 WO PCT/IB2018/056348 patent/WO2019038687A1/en unknown
- 2018-08-22 EP EP18847670.9A patent/EP3673037A4/en active Pending
- 2018-08-22 KR KR1020207008233A patent/KR20200049795A/en not_active Application Discontinuation
-
2020
- 2020-02-17 PH PH12020500350A patent/PH12020500350A1/en unknown
- 2020-02-20 CL CL2020000433A patent/CL2020000433A1/en unknown
- 2020-03-17 CO CONC2020/0003137A patent/CO2020003137A2/en unknown
- 2020-03-20 EC ECSENADI202019679A patent/ECSP20019679A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2020001654A (en) | 2020-07-13 |
SG11202001355XA (en) | 2020-03-30 |
IL272822A (en) | 2020-04-30 |
CN111065722A (en) | 2020-04-24 |
PE20200702A1 (en) | 2020-06-23 |
EA202090454A1 (en) | 2020-07-01 |
KR20200049795A (en) | 2020-05-08 |
WO2019038687A1 (en) | 2019-02-28 |
CO2020003137A2 (en) | 2020-04-24 |
CL2020000433A1 (en) | 2020-06-12 |
IL272822B1 (en) | 2024-02-01 |
JP2020531017A (en) | 2020-11-05 |
ECSP20019679A (en) | 2021-04-29 |
AU2018320201A1 (en) | 2020-04-09 |
BR112020003409A2 (en) | 2020-08-25 |
GEP20217313B (en) | 2021-11-10 |
IL272822B2 (en) | 2024-06-01 |
BR112020003409A8 (en) | 2020-11-03 |
AU2018320201B2 (en) | 2021-08-05 |
PH12020500350A1 (en) | 2021-01-25 |
EP3673037A1 (en) | 2020-07-01 |
EP3673037A4 (en) | 2021-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200190449A1 (en) | Enriched alcoholic beverages | |
AU2018320201B2 (en) | Enriched alcoholic beverages | |
CN101765656A (en) | Fruit-juice-containing alcoholic beverage base, and beverage produced by diluting the base | |
US11528924B2 (en) | Alcoholic beverage substitutes | |
Butnariu et al. | Qualitative and quantitative chemical composition of wine | |
Arora et al. | Nutritional beverages | |
RU2155216C1 (en) | Composition for production of alcoholic beverage | |
BR112020003409B1 (en) | ENRICHED ALCOHOLIC BEVERAGES AND FOOD PRODUCTS | |
FR3118686A1 (en) | Composition for preparing a non-alcoholic beverage, method for extracting flavors in the absence of alcohol and method for preparing a non-alcoholic beverage | |
RU2158292C2 (en) | Alcoholic drink | |
RU2238310C1 (en) | Weak-alcoholic drink "absenter enerdzhi" | |
RU2469082C1 (en) | Wine beverage | |
RU2773322C2 (en) | Special vodka | |
Karki | PREPARATION AND QUALITY ANALYSIS OF YACON (Smallanthus sonchifolius) BASED HERBAL WINE | |
RU2118345C1 (en) | Wine drink "okhotnichy" | |
AU2017286947B2 (en) | An improved spirit drink. | |
RU2424319C1 (en) | Low-alcoholic tonic carbonated drink "zhest energy perezagruzka" | |
RU2160775C1 (en) | Composition of ingredients for wine drink | |
RU2125597C1 (en) | Vodka "strela arbaleta" | |
RU2097417C1 (en) | Wine drink "cheremukha na konyake" | |
Chaudhary et al. | Effect of storage on organoleptic acceptability of red wine prepared from jamun (Syzygium cuminii (L.) Skeels) Fruits | |
RU2143483C1 (en) | Aperitif "ganzeisky" | |
RU2125595C1 (en) | Sweet liquor "nadenka" | |
RU2283343C2 (en) | Weakly alcoholic drink | |
RU2109810C1 (en) | Wine drink "ryabina krasnaya" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20230814 |